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Chapter 1 Introduction and research objective 1
1 Introduction and research objective 
 Immunisation in developing countries is estimated to prevent more than 
three million deaths from measles, neonatal tetanus and pertussis annually as 
well as approximately 490,000 children from being paralysed by poliomyelitis 
(WHO, 1998). This notable achievement is mainly attributed to the improvement 
of transporting and storage conditions of vaccines and better maintenance of 
the cold chain. However, incorrect storage and transportation of vaccines is still 
problematic. Due to thermoinstability of the antigen, almost all current vaccines 
require cold chain conditions from their preparation until administration to 
prevent a loss of the vaccine’s activity (Rexroad et al, 2002). In fact, the 
Expanded Programme on Immunisation (EPI) recommends that all vaccines 
should be stored in the refrigerator or in case of OPV (oral poliovirus vaccine; 
live, trivalent) in the freezer (WHO, 2006). High temperatures or exposure of 
adsorbed vaccines to freezing temperatures are two of the greatest problems 
that often result in substantial drops in vaccine potency (Krugman et al, 1974). 
This leads to enormous costs and is a great source of error especially regarding 
vaccine handling and safety in developing countries (Lala and Lala, 2003).  
 This work’s main focus is the development of an aluminium adjuvanted 
vaccine formulation that will be stable enough not to require cold chain during 
storage and transportation. This would circumvent the numerous problems 
resulting from improper vaccine handling all over the world. The approach is 
lyophilisation of these strongly delicate pharmaceuticals because water removal 
can considerably reduce chemical and physical degradation of vaccines and 
other protein pharmaceuticals (Rexroad et al, 2002). Freeze-drying is the 
separation of liquid water from a frozen solution by vacuum sublimation and is a 
well-established formulation approach used in the pharmaceutical industry for 
the stabilisation of expensive, delicate liquid biologic products.  
 However, there are different challenges to cope with when vaccines or 
proteins are lyophilised. Freezing and subsequent dehydration stresses during 
lyophilisation often lead to stability problems for antigens (usually proteins or 
peptides), as well as for the adjuvant within a vaccine.  
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 On the one hand, the protein suffers from detrimental processes during 
lyophilisation: freezing generates stresses such as the formation of ice crystals, 
increased ionic strength, changed pH, phase separation, concentration effects 
of contained solutes and generation of ice-water interfaces leading to the 
adsorption of the protein and subsequent surface induced denaturation of the 
protein. During dehydration, water is removed that plays an important role in the 
formation of unfolded protein structure. Its removal promotes structural 
alterations of the protein prevalently resulting in physical instabilities often 
manifested as insoluble or soluble protein aggregates.  
 On the other hand, freezing and lyophilisation of an aluminium adjuvant 
contained within a vaccine can accelerate a loss of potency of the adjuvant. The 
physical appearance of unprotected adjuvant alters after freezing inducing 
changes in the structure and morphology of the adsorbent. The latter causes a 
collapse of the suspension resulting in gross aggregation, precipitation and 
formation of agglomerates, floccules or other granular matter increasing 
sedimentation rates.  
 A lot of the described detrimental processes can be circumvented by the 
utilisation of excipients or an alteration of the freezing rate during lyophilisation. 
Much research was conducted on the matter that certain carbohydrates, 
polymers and other glass forming compounds and surfactants and other 
additives can protect proteins as well as aluminium hydroxide adjuvants during 
freezing and dehydration. In preceding studies, trehalose was primarily used to 
stabilise aluminium adjuvants during lyophilisation as well as dextran or 
combinations of disaccharides, amino acids and a colloidal substance (Clausi et 
al, 2008; Csizer et al, 1986; Kyosuke et al, 1989; Maa et al, 2003). However, 
none of these attempts have entirely succeeded. This study intends to develop 
an innovative, stable, lyophilised aluminium hydroxide containing formulation in 
order to find a novel formulation approach capable of efficiently protecting not 
only the protein but also the aluminium hydroxide adjuvant during lyophilisation. 
 Methods currently used for physico-chemical characterisation of 
lyophilised aluminium adjuvanted vaccines include particle size measurements, 
sedimentation behaviour of aggregates, zeta potential measurements and other 
methods determining the point of zero charge, pH and X-ray powder diffraction 
(XRPD) measurements, brightfield microscopy. This work focuses on the 
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implementation of analytics not yet adapted for lyophilised aluminium adjuvant 
containing vaccines. Model vaccines used for this study comprise abagovomab, 
a monoclonal, anti-idiotypic antibody that was developed as an immuno-vaccine 
for the treatment of ovarian cancer. Adsorption isotherms characterising in 
detail the adsorption behaviour of abagovomab to Alhydrogel® after 
formulations were lyophilised and stress tested are an applied method within 
this study. Another method implemented by this work for a detailed 
characterisation of conformational changes of proteins after lyophilisation and 
stress testings is Nile Red fluorescence microscopy.  
 The adsorption behaviour of antigens onto aluminium adjuvants in a 
vaccine formulation has several physiological and technological effects on the 
vaccine's efficacy and a strong influence on its potency. It is important to 
understand the forces controlling the binding of an antigen to the aluminium 
adjuvant, both in the formulation before and in the interstitial fluid immediately 
after administration. The main factors contributing to the adsorption of antigens 
onto aluminium containing adjuvants are electrostatic attractive forces and 
ligand exchange. This work intends to identify the chemical force(s) involved in 
and the influence of the components of interstitial fluid on the adsorption of the 
antigen abagovomab onto an aluminium hydroxide adjuvant.  
 Owing to the fact that each protein has a unique three-dimensional 
structure that is directly connected to its function and that unfolding or 
denaturation of this structure would lead to an inactivation of the protein’s 
function, the characterisation of conformational changes of a protein is of great 
importance. Protein degradation is often studied using standard methods, e.g. 
analysing the protein’s molecular weight with sodium dodecylsulfate 
polyacrylamide gel electrophoresis, size exclusion chromatography or 
determining its isoelectric point with isoelectric focusing.  
 One of this work’s aim is to adapt a method to comprehend protein 
conformational changes using Nile Red fluorescence microscopy for the 
analysis of lyophilised vaccine formulations containing the monoclonal antibody 
abagovomab. 
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2 Theoretical part  
2.1 Proteins 
 Proteins and peptides have advanced to an important class of 
therapeutic drugs. Currently, more than one hundred recombinant proteins are 
in phase 1 clinical trials or beyond and several dozens have received Food and 
Drug Administration (FDA) approval. Recombinant DNA technologies and 
access to monoclonal antibodies are some of the examples for new and highly 
modern approaches to diagnosis, treatment and prevention of poorly controlled 
diseases. The other side of the coin presents unique, unacquainted challenges 
due to a manifold of metabolic properties, limited gastro intestinal absorption, 
diversified tissue penetration attributed to molecule size and toxicity caused by 
stimulation of an immune- or allergic reaction (Jacob et al, 2006). Proteins 
contain rather labile groups and possess fragile three-dimensional structures 
leading to a high susceptibility of the protein to chemical and physical 
degradation processes. To elucidate the relevance of stabilisation and in-depth 
characterisation of protein formulations, it is important to understand structure, 
composition and function of this highly diverse class of modern 
pharmaceuticals. 
2.1.1 Structure 
 A protein’s function is determined by its unique three-dimensional 
structure. It is organised from primary to quaternary structure up to higher level 
structures such as motifs and domains.  
  Primary structure is the linear sequence of amino acids within the protein 
backbone. The backbone atoms consist of the peptide amide units and the 
alpha carbons of the condensed amino acids; the side chains consist of the 
remaining atoms in the molecule. Primary structure is sometimes referred to as 
the "covalent structure" of proteins because except the disulfide bonds 
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(covalent bonds between two cysteine residues), all covalent bonds within 
proteins are defined by the primary structure. 
 Secondary structure constitutes the conformational arrangement of the 
backbone segments of a protein or peptide without regard to the conformation 
of the side chains or the relationship to other segments (IUPAC, 2008). It is 
mainly formed through hydrogen bonds between backbone atoms. Interaction of 
amino acids three or four positions apart in the sequence stabilise secondary 
structure. First conformational arrangements described were alpha helix and the 
beta sheet (Pauling et al, 1951). Their structure saturates all hydrogen bond 
donors and acceptors in the peptide backbone. Amino acids in an alpha helix 
are arranged in a right handed helical structure resembling a spring. Beta 
sheets are extended structures with reduced steric hindrance within the strand. 
Other elements of secondary structure discovered since then are various loops 
and other forms of helices. Random coil is a part of the amino acid backbone 
that is not in a regular secondary structure.  
 Tertiary structure is the entire protein’s spatial organisation including 
conformation consisting of a single chain (IUPAC, 2008). It is largely determined 
by its primary structure. Formation of tertiary structure is mainly driven by the 
burial of hydrophobic residues. Hydrogen bonding, ionic interactions and 
disulfide bonds also stabilise tertiary structure. 
 Quaternary structure is the specific association of two or more 
macromolecules with tertiary structure held together by hydrogen bonds and 
van der Waals and coulombic forces (Banga, 1995). It is basically stabilised by 
the same interactions as tertiary structure. Proteins can function as monomers 
so they do not necessarily possess a quaternary structure. Monomers can 
associate to dimers, trimers and higher orders of oligomers. Oligomers 
consisting of chains with the same sequence are called homodimers; those 
containing different chains are heterodimers. 
 In their natural environment, proteins are usually efficiently and correctly 
folded which is essential for the maintenance of their biological activity. If the 
correct conformational arrangement or folding of the protein’s native state is 
lost, it denatures or unfolds resulting in partial or complete loss of its activity. 
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2.1.2 Instabilities 
 The development of stable vaccines or protein formulations is 
problematic: the active pharmaceutical ingredient of a vaccine is usually a 
protein. Protein pharmaceuticals are much larger (above 5 kDa), contain rather 
labile groups and possess fragile three-dimensional structures compared to 
traditional low molecular weight drugs (Manning et al, 1989). These smaller 
compounds are usually linear or cyclical as their size inhibits extensive 
intramolecular bonding. Ordinary small molecular weight compounds principally 
do not exhibit higher level structures as can be found within proteins (Singh and 
Singh, 2003). Compositional variety and amphiphilic character of proteins are 
the reason for their individual behaviour, particularly folding and unfolding or 
degradation. This individuality of each protein is reflected in a specific function 
that results of its individual three-dimensional structure. Due to this individuality, 
each protein reacts differently to different stresses but also to stabilisation 
attempts trying to inhibit these deterioration processes. Thus, one can never 
speak of the one way to stabilise proteins but must rather focus on the 
characteristic of the specific protein observed. 
 Stability of protein structure can be defined as its tendency to maintain a 
native (biologically active) conformation (Jacob et al, 2006). Degradation of 
these instable biopolymers can be divided into two classes: chemical and 
physical instability.  
 Chemical instability is any process involving protein modification by bond 
formation or cleavage obtaining new chemical entities. This alters primary 
structure of the protein and also has an influence on its higher levels of 
structure. The most common chemical instability is deamidation but oxidation, 
disulfide bond breakage, hydrolysis, succinimidation, non-disulfide cross-linking, 
deglycosylation and maillard reaction also play an important role when talking 
about chemical instability of a protein (Wang et al, 2006).  
 Physical instability includes modifications not involving covalent qualities 
but rather changes in secondary structure and above. Examples are 
denaturation, surface adsorption, aggregation and its macroscopic equivalent 
precipitation (Manning et al, 1989). Aggregation - the most common physical 
instability - may result in reduced to no activity, reduced solubility, and altered 
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immunogenicity (Wang, 1999). Manning et al (1989), Klibanov (1989), Cleland 
et al (1993), Banga (1995) and Wang (1999) have in detail reviewed the protein 
deterioration process elsewhere. Initiation of mentioned instability reactions can 
be a change in pH, solvent, ionic strength or the addition of metal ions or 
denaturing agents. The most prominent denaturants are sodium dodecyl 
sulphate, guanidine hydrochloride and urea. Also, temperature, pressure and 
shear stresses can cause protein denaturation. 
2.1.3 Influence of water on protein stability 
 Especially in aqueous solution, proper folding of a protein in its native 
state is not infinitely stable (Shortle, 1996). Conformational changes that are 
responsible for the unfolding process are caused by intermolecular protein -
solvent interactions prevailing over intramolecular interactions that maintain the 
folded state (Jaenicke, 1990). Protein aggregation and protein folding have in 
common that they are actuated by favourable free energy for the reduction of 
area that is accessible by the solvent, particularly of hydrophobic groups (Dill, 
1990). Proteins expose hydrophobic residues when unfolded. To minimise 
thermodynamically unfavourable interactions of these residues with the solvent, 
they aggregate (Patro and Przybycien, 1996). The perturbation of secondary or 
tertiary structure leading to exposure of previously burried amino acids to the 
solvent is facilitating the protein’s chemical reactivity and leads to loss of its 
native or original characteristics. This process is called denaturation (Jacob et 
al, 2006). Hydrophobic surface area of proteins can be increased (and thus 
aggregation is induced) by many physical factors such as temperature, ionic 
strength, shear stress or surface/interface adsorption (Manning et al, 1989). 
Moreover, water increases molecular motions of a protein and thus increases its 
reactivity, it is a reactant in various destructive reactions and it is the mobile 
phase for the reactants (Constantino Jr. 1995). As a result, many polypeptide 
drugs are formulated as lyophilised products in order to prolong their shelf life 
through water removal (Carpenter et al, 1997). 
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2.1.4 Stabilisation of proteins 
 Due to the high susceptibility of proteins and the need of 
pharmaceutically used proteins to maintain biological activity in all steps of their 
development and distribution, they are usually stabilised. The way of 
stabilisation depends on the stability of each individual protein. Given the 
various pathways that contribute to protein instability, a rational approach for 
their stabilisation can be developed. Generally, proteins can be stabilised either 
by changing their structural characteristics (internally) or by (external) 
modification of its environment (Wang, 1999). Internal stabilisation comprises 
any structural change that increases protein stability without changing the 
essential protein conformation. External protein stabilisation can be 
distinguished into the freeze-dried solid and liquid protein formulation approach. 
Liquid formulation approach is simple in processing and easy applicable but if 
optimisation of liquid formulations does not achieve enough stability, the liquid 
product is converted to the generally more stable solid state by a drying 
technique, usually by lyophilisation (Cleland et al, 1993). 
2.1.4.1 Stabilisation in aqueous solution 
 The most common method for the stabilisation of liquid protein 
pharmaceuticals is the addition of excipients, also referred to as co-solvents or 
co-solutes (Baynes and Trout, 2004). These include sugars, polyols, polymers 
(polyethylene glycol, dextrins etc), surfactants (e.g. polysorbate 80), amino 
acids (predominantly arginine and glycine), methylamines, lyotropic salts and 
others. Often, the mechanism of protection is not fully understood but the most 
accepted mechanism explaining protein stabilisation by excipients in aqueous 
solutions is preferential exclusion. Timasheff (1993) reports that an excipient 
stabilising a protein in aqueous solution is preferentially excluded from a certain 
protein domain so that the amount of solvent/water molecules on the protein 
surface predominates over the amount of excipient molecules (preferential 
hydration). The equilibrium constant of the balance reaction between the native 
(N) and denatured (D) form of the protein can be influenced by certain 
stabilising excipients. If the protein would unfold, the interface between the 
protein and the solution would increase, and with it the area from that the 
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stabilising excipient has to be preferentially excluded. In thermodynamic terms 
this increase in interface and thus hydration of the unfolded protein increases its 
chemical potential and is thermodynamically disadvantageous. Thus, the 
equilibrium between native and unfolded form N↔D is shifted towards the 
thermodynamically favourable native form. Other stabilising excipients such as 
polyvalent alcohols on the other hand are preferentially bound to the protein’s 
surface (preferentially binding) but do not shift the reaction equation towards the 
denatured form (Timasheff, 1998). Solutes that destabilise proteins in solution 
like urea or guanidine HCl are conversely preferentially bound by proteins. This 
theory is further in-depth explained by Timasheff (1993).  
2.1.4.2 Stabilisation during freeze-thawing 
 Stresses during freezing and thawing include low temperature stresses 
and freezing stresses such as formation of dendritic ice crystals, increased ionic 
strength, changed pH, and phase separation (Wang, 2000). Freezing also 
causes a so called concentration effect: it induces a rapid increase of the 
concentration of the solutes in solution due to ice formation. This can change 
ionic strength and the relative composition of solutes because these physical 
properties are related to the solutes’ concentration (Franks, 1990). Ice-water 
interfaces can be generated within protein solutions during freezing that can 
adsorb the protein and result in surface induced denaturation (Strambini and 
Gabelierei, 1996). Additionally, selective crystallisation of buffer salts can lead 
to significant changes in pH. One popular example are phosphate buffered 
formulations: Na2HPO4 crystallises more readily than NaH2PO4 which can 
potentially lead to enormous pH drops. This is often detrimental to protein 
structure as most proteins unfold when exposed to extremely high or low pH 
values (Zippelius, 2002).  
 It is suggested that Timasheff’s preferential exclusion theory that explains 
cryoprotection (protection from cold damages) of proteins in aqueous solutions 
is likewise responsible for the excipients’ protecting properties during freeze-
thawing. There are many solutes that are preferentially excluded from the 
protein’s surface and protect proteins not only in solution but also during 
freezing such as polyols, sugars, amino acids, methylamines and some 
inorganic salts such as (NH4)2SO4 (Carpenter et al, 1990). It is discussed that 
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water surrounding a protein is drawn off into the ice phase which would disrupt 
the hydration shell of the protein. The hydration environment that exists in 
solution is essential for the maintenance of the native structure of a protein and 
would be damaged during freezing. But Prestrelski et al (1993) claim that a 
significant amount of water remains unfrozen when protein formulations are 
frozen and thus Timasheff’s theory can further be valid.  
2.1.4.3 Stabilisation during lyophilisation: mechanism 
 During lyophilisation, proteins are not only exposed to low temperature 
and freezing stresses but also to dehydration stresses. Hydrogen bonding of 
water with polar residues predominately found on the protein’s surface 
significantly contributes to the stabilisation of native protein structure. Thus, 
removal of water also promotes structural alterations of the protein leading to 
physical instabilities often manifested as insoluble or soluble protein aggregates 
(Andya et al, 2003).  
 Thermodynamic arguments that could explain stabilisation of proteins in 
aqueous solution or during freezing and thawing by preferentially excluded 
excipients are not reasonable when water is removed (Carpenter et al, 1990). It 
is assumed that protection of proteins with excipients in the dried state is 
fundamentally different from the mechanisms discussed in aqueous or frozen 
systems. The protein’s hydration shell that is essential for the proteins native 
folding is at least partly removed during freeze-drying and this stress has to be 
overcome. Many excipients stabilising proteins in solution do not have the same 
effect during freeze-drying. There are two main mechanisms described that 
explain protein stabilisation of certain excipients during the freeze-drying 
process. One mechanism is the formation of an amorphous glass and the other 
is the water replacement theory. It could be shown that neither one of the two 
alone can sufficiently explain protein stabilisation during lyophilisation 
(Carpenter and Izutsu, 1999).  
2.1.4.3.1 Amorphous glasses 
 Disaccharides such as trehalose and sucrose along with many other 
polyols including mannitol and sorbitol are the most commonly used excipients 
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in lyophilised protein and peptide formulations (Jacob et al, 2006). When 
aqueous solutions are rapidly cooled in the presence of these dissolved 
carbohydrates or polymers, even below the lowest eutectic point (compare 
section 2.2.1.1), no or incomplete crystallisation takes place. An alteration of the 
solute concentration during lyophilisation eventually changes the solution from a 
viscous liquid to a brittle glass (Hatley, 1997). This phenomenon is often 
described as a transition from the rubbery to the glassy state (Pikal, 1990; 
Hatley, 1997). The temperature of this reversible transition for the maximally 
freeze concentrated solution is termed glass transition temperature, Tg’, 
sometimes also referred to as the temperature of vitreous transformation (Rey, 
1999). Tg’ is used to differentiate this transition from the softening point of a true 
glass transition, Tg of a pure polymer. Glassy materials are formed typically by 
substances containing long chains, networks of linked atoms or excipients with 
complex molecular structure that usually have a high viscosity in the liquid state. 
During rapid cooling their molecular movement is too retarded or the geometry 
too ungainly to take up a crystalline conformation. At the glass transition 
temperature, translatoric movements of the molecules and diffusion come to a 
standstill and the enormously increased viscosity hinders nucleation. Molecules 
are randomly arranged in a way characteristic of the liquid state (Essig and 
Oschmann, 1993). Water is only limitedly accessible for osmosis as its 
translatoric movement is missing. Thus, the glassy state is well applicable for 
the protection of labile substances like proteins (Pikal, 1990). In fact, 
amorphous glasses increase the viscosity of the formulation to as much as 
1012 Pas so conformational relaxation of a protein is decelerated, molecular 
mobility is restricted and thus its native conformation is stabilised (Hagen et al, 
1995). Moreover, the physical separation of the protein molecules inhibits 
protein aggregation (Levin and Slade, 1988).  
 Generally, during lyophilisation (compare section 2.2) the process 
temperature is set below the sub-ambient Tg’ of the formulation during primary 
drying in order to avoid the ‘collapse’ of the product. At temperatures above the 
glass transition temperature or below the lowest eutectic point of the 
corresponding solution, the system is in the rubbery state (Nail and Gatlin, 
1993). This state is still viscous and is characteristic for the conversion from an 
instable amorphous fluid to a metastable amorphous solid. Movement of the 
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polymer chains is enhanced, relaxation and translatoric diffusion takes place 
and macroscopically, viscous fluxion can be observed (Levin and Slade, 1988). 
If the formulation is in this rubbery state for a longer time - during freezing as 
well as during drying - it leads to the irreversible collapse of especially complex 
structures like proteins. Therefore, glass transition temperature is also referred 
to as collapse temperature. Excipients can increase collapse temperature 
leading to the stabilisation of the formulation (Couriel, 1980).  
2.1.4.3.2 Water replacement theory 
 In aqueous solution proteins in their native state are fully hydrated. The 
hydration shell is partly removed during lyophilisation. In the unprotected state 
this could cause dehydration stresses to the protein. Mainly sugars like 
trehalose and sorbitol but also other excipients that can exhibit hydrogen bonds 
to proteins stabilise them by the formation of hydrogen bonds and other weak 
attractive forces to the polar, charged groups of proteins. This replaces the 
water molecules that are withdrawn during lyophilisation preventing dehydration 
induced denaturation of the protein (Carpenter et al, 1990).  
2.1.4.4 Stabilisation during lyophilisation: formulation issues 
 This section discusses the individual classes of excipients useful for the 
stabilisation of proteins during lyophilisation. Different classes and different 
individual excipients can exert their protecting effect by different mechanisms. 
2.1.4.4.1  Sugars and polyols 
 Sugars and polyols are frequently used cryo- and lyoprotectants. The 
stabilisation effect of these excipients depends on their concentration. A 
minimum of 0.3 M is needed for a protective effect during freeze-thawing and 
usually a higher concentration is needed during lyoprotection (Wang, 2000). 
Disaccharides are among the sugars and polyols the most commonly used 
stabilisers for protein protection. Especially trehalose (α-D-glucopyranosyl-
(1→1)-α-D-glucopyranoside) has an impressive and specific protective effect 
against stress treatments of proteins. Trehalose is widespread in nature, 
especially in survival forms of fungi, nematodes, insects, and plants such as 
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spores, cysts, sclerotia or dried desert resurrection plants (Van Dijck et al, 
1995). Its 1→1-α-bonding makes it a non-reducing sugar, very resistant to acid 
hydrolysis and therefore stable in solution at high temperatures even under 
acidic conditions (Bauer et al, 1993, Fiedler 1996). With the discovery that it 
might not only function as a storage compound but also as stress protectant 
during so called anhydrobiosis of some organisms, much attention was drawn 
to it as a protective excipient in pharmaceutical formulations of proteins and 
other biologicals (Van Laere, 1989; Roser 1991). Anhydrobiosis describes a 
mechanism that organisms - with the prominent example of baker’s yeast 
(Saccharomyces cerevisiae) - use to survive in the dry state after losing all their 
body water by producing and accumulating simple, non-reducing sugars such 
as trehalose (Crowe et al, 1996). The protective mechanism of lyoprotectants 
that stabilise proteins during lyophilisation is not entirely understood at the 
molecular level and both hypotheses (amorphous glass and water replacement 
hypothesis) cannot give straightforward explanation for the superiority of 
trehalose in stress protection compared with other molecules of similar structure 
(Van Dijck et al, 1995; Crowe et al, 1990). Other excipients such as dextran that 
exhibit pure glasses during drying cannot provide comparable stabilisation. This 
demonstrates that the glass formation hypothesis alone insufficiently explains 
the stabilisation mechanism of these excipients (Gloger, 2002). 
2.1.4.4.2 Polymers 
 Different polymers have been used for the protection of proteins during 
lyophilisation and there exists a variety of mechanisms explaining the polymers’ 
stabilising properties. Examples are surface activity, preferential exclusion, 
steric hindrance of protein-protein/polymer interactions and limited protein 
structural movement due to increased viscosity (Wang, 1999). Proteins 
themselves (for example BSA) prevent surface adsorption of the protein by 
preferentially adsorbing to surfaces. Less adsorption leads to higher recovery of 
the protein drug. Some polymers can inhibit the pH drop during freezing or 
inhibit the crystallisation of small molecules due to increased, polymer induced 
viscosity such as polyethylene glycols (PEG), dextran, polyvinyl pyrrolidone 
(PVP) and also BSA (Slade et al, 1989). Other prominent polymers used for 
protein protection are hydroxypropyl-β-cyclodextrins (HP-β-CD), hydroxyethyl 
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cellulose (HEC), heparin, gelatine, polyphosphoric acid, poly-L-glutamic acid 
and poly-L-lysine. 
2.1.4.4.3 Surfactants 
 Many surfactants are utilised for protein stabilisation including polymers, 
polyols, nonionic or anionic surfactants. They are believed to be preferentially 
adsorbed at interfaces so that the protein does not adsorb at the interface which 
would lead to unfolding and aggregation. Another mechanism described is the 
binding to the protein and subsequent reduction of the proteins' available 
hydrophobic surface areas. This decreases the proteins' self association and 
thus deleterious interactions with non-specific hydrophobic surfaces (Piatigorsky 
et al, 1977). However, there are studies showing that for example polysorbate 
80 could inhibit protein aggregation during freeze-thawing, but could not protect 
lyophilised proteins during storage or that polysorbate 20 and polysorbate 80 at 
different concentrations inactivated proteins stored at 40ºC and 60ºC (see also 
section 2.3.4.3.1) (Kreilgaard et al, 1998; Adler and Lee, 1999). 
2.1.4.4.4 Others 
 The recovery of labile proteins after lyophilisation was enhanced by 
increasing the initial protein concentration (Anchordoquy and Carpenter, 1996). 
The mechanism of the concentration dependant self protection of proteins is not 
fully understood, but as proteins are polymers, the above mentioned 
mechanisms may explain this phenomenon. 
 On the one hand some metal ions such as Ca2+, Cu2+, Mg2+, Mn2+ and 
Zn2+ can stabilise proteins during lyophilisation. It is discussed that they bind to 
the protein and thus are more rigid, compact and stable (Mozhaev and 
Martinek, 1984; Carpenter et al, 1987). On the other hand, chelating agents can 
be used to stabilise proteins by decreasing the destabilising effects of 
detrimental metal ion contaminations. 
 Many amphiphilic excipients like 3-[(3-cholamidepropyl)-
dimethylammonio]-1-propanesulfate (CHAPS), sodium cholate or sucrose 
monolaurate can increase stability of proteins, usually synergistically with 
sugars like sucrose (Izutsu et al, 1995).  
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 Even though non-aqueous solvents usually destabilise proteins in 
solution, at a low concentration some can have a stabilising effect. Examples 
are polyhydric alcohols such as PEGs, ethylene glycol and glycerol and some 
polar and aprotic solvents such as dimethylsulphoxide (DMSO) and 
dimethylformamide (DMF) (Wang, 2000). 
 Amino acids were used to reduce surface adsorption and inhibit 
aggregation. There are many beneficial effects reported of amino acids used as 
excipients but the stabilising mechanism is not fully understood. Properties of 
the individual amino acids such as an influence on solution pH, reduction of 
buffer salt crystallisation, chelation of metal ions and increase in protein 
solubility are discussed to contribute to their capability to stabilise proteins 
during lyophilisation (Banga, 1995). 
 Various salts and amines such as potassium phosphate, sodium acetate, 
ammonium sulfate, magnesium sulfate, sodium sulphate, trimethylamine N-
oxide or betaine could, for example, stabilise the protein lactate dehydrogenase 
(LDH) during lyophilisation (Carpenter et al, 1990).  
2.2 Lyophilisation 
 As discussed in section 2.1.3, protein instability especially in aqueous 
solutions is a complex subject. Water is either a reactant or a solvent facilitating 
the transfer of other reactants responsible for instability reactions. Therefore it 
participates and enhances many routes of degradation of proteins such as 
hydrolysis and oxidation that lead to protein instability. Thus, water removal can 
considerably reduce chemical and physical degradation of vaccines and other 
protein pharmaceuticals (Rexroad et al, 2002). Lyophilisation is a well-
established formulation approach used in the pharmaceutical industry for the 
stabilisation of expensive, delicate liquid biologic products such as vaccines 
(Adams, 2003). While alternative drying technologies such as spray drying, 
vacuum drying or supercritical fluid technology have been developed to 
decrease the extended processing times and expense involved in large-scale 
manufacturing, lyophilisation is a popular choice as a proven technology. Safety 
and equivalence of alternative processes need to be verified for the 
manufacturing of a protein pharmaceutical. Lyophilised products have many 
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advantages like long-term stability, simple handling during shipment and 
storage, quick reconstitution and an attractive appearance.  
2.2.1 Process 
 The lyophilisation process can be divided into two phases: Freezing and 
a subsequent drying phase. The drying phase can again be distinguished into 
primary drying phase and secondary (terminal) drying phase. 
2.2.1.1 Freezing phase 
 During freezing, the formulation is converted to the solid aggregate state. 
Throughout this phase, it needs to be ensured that the entire product is 
completely frozen prior to proceeding to the primary drying phase. Most 
pharmaceutical solutions prone to be lyophilised are not simple solutions but 
systems containing a variety of additives making the process of freezing more 
complicated than freezing of pure water. Pure water has a freezing point of 0°C 
but it can be supercooled down to -40°C due to aggravated nucleation of ice 
crystals (Essig and Oschmann, 1993). If particles are suspended in an aqueous 
solution, nucleation is facilitated. Adding solutes like NaCl to water lowers the 
freeze point and solutions will exhibit either a eutectic point (for crystalline 
structures) or a glass transition point (for amorphous structures, compare 
section 2.1.4.3.1) far below 0°C. On a phase diagram the eutectic point is the 
temperature and composition coordinate below that only the solid phase exists. 
Solutions containing well crystallising substances like NaCl exhibit eutectic 
freezing properties: water crystallises first in the form of ice and the remaining 
solution is more and more freeze concentrated. Through this freeze 
concentration, the freezing point of the remaining solution is lowered. When the 
eutectic temperature is reached, ice and the dissolved substance crystallise 
next to each other; the system is separated into ice and NaCl crystals. There 
can be more than one eutectic point for a product or none at all, depending on 
the formulation of the solution (Dern, 2005). Cooling rate can also influence 
the structure of the frozen matrix. Quick freezing produces smaller ice crystals 
leading to a finer pore structure in the product. However, as a result water will 
not sublimate quickly during primary drying (Willemer, 1992). Large ice crystals 
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due to a too long and slow freezing phase on the other hand can have 
detrimental properties (Franks and Auffret, 1998). 
2.2.1.2 Annealing 
 Often, prior to the primary drying phase, annealing is included in the 
freeze-drying cycle. This thermal treatment is used for recrystallisation of a 
crystalline component that has not been completely crystallised during freezing. 
However, during annealing an amorphous stabilising excipient can crystallise 
and hydrogen bonding and other interactions with the component that is 
stabilised would be disrupted. This would exhibit an adverse effect on the 
stability of labile components like proteins (Wang, 2000).  
2.2.1.3 Primary drying 
 Primary drying begins with evacuation. Energy input is usually 
accomplished by heat conduction (directly from the shelf by contact to the 
product container) or gas streaming (convection, within the gas filled 
compartment between shelf and container) and rarely by radiation (Essig und 
Oschmann, 1993). Temperature of the product needs to be kept below collapse 
temperature. Water sublimates, is collected at the condenser and is thus 
constantly detracted from the drying chamber. Production of water vapour in the 
vacuum causes the gas volume of 1 g water to increase from 1.2 l at a pressure 
of 1 bar to approximately 1000 l at 1.3 mbar and 10,000 l at 0.13 mbar 
(Barnickel, 1990). The condenser needs to have sufficient surface area in order 
to collect the water contained in the dried batch at a temperature lower than 
product temperature because otherwise (condenser temperature is above 
product temperature), water vapour tends to move back to the product and 
drying cannot take place anymore. Temperature during primary drying needs to 
be low enough so no thawing or sintering can occur (Bauer et al, 1993). 
Subliming of water cools the product and consequently, it will remain colder 
than shelf temperature. The end of primary drying is indicated by an 
asymptotical increase of product temperature towards shelf temperature. At the 
end of primary drying all of the ice should be sublimed and 5-30 % residual 
water remain in the product (Essig und Oschmann, 1993). This residual 
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moisture is either physically or chemically adsorbed as hydration- / swelling 
water or constitutional water. Since no mobile water is left within the product, 
shelf temperature can be increased without causing melting or sintering. 
Moreover, after primary drying the product is already in a rather stable state 
allowing higher temperatures during secondary drying.  
2.2.1.4 Secondary drying 
 During secondary or terminal drying, temperature is increased to desorb 
bound water. It is usually performed at the maximum vacuum the dryer can 
achieve. Equilibrium vapour pressure above the product is determined by the 
way water is adsorbed within the product and thus depends on the composition 
of the formulation. But usually a considerably lower water vapour partial 
pressure is required at accordingly lower condenser temperatures during 
secondary drying (Gölker, 1989). Still, product temperature should not be 
increased too fast and should not exceed the glass transition temperature as 
some products can still collapse if Tg/Tg’ is exceeded at that point of the 
lyophilisation process. Complex products like proteins require residual moisture 
of a few percent to stabilise their structure and others like low molecular, simple 
substances can endure very low water contents of down to 0.1 % so that the 
product itself determines the length of secondary drying. 
2.3 Vaccines 
 Millions of deaths have been prevented every year since the Expanded 
Programme on Immunization (EPI) was launched in 1974. Smallpox was 
eradicated in 1979 and polio, measles, and maternal and neonatal tetanus are 
about to be eradicated nowadays. Smallpox, diphtheria, measles, mumps, 
pertussis, rubella, poliomyelitis, tetanus and hepatitis B were minatory infectious 
diseases in the past but their incidences have declined considerably since the 
beginning of vaccination (WHO, 2003). Common vaccines ought to induce 
immunity to an infectious disease without the patient suffering the pathogenesis 
associated with a natural infection. It can be distinguished between active and 
passive immunisation.  
2.3 Vaccines 
 
19
2.3.1 Active immunisation 
 Active immunisation includes introduction of the whole, part of or a 
modified product of a pathogen to the body initiating the immune system to 
respond defensively. It may be achieved by live attenuated vaccines, 
killed/inactivated vaccines, toxoids, recombinant DNA vaccines, synthetic 
peptides or by DNA vaccines etc. 
 Live attenuated vaccines contain a weakened form of the pathogen that 
causes the disease. This antigen infects the host cells and replicates within 
these cells while it does not initiate the disease. Rather, it triggers an immune 
response and the development of immune memory. Polio, measles, mumps, 
rubella and varicella are some examples for effective attenuated vaccine forms.  
 Whole killed vaccines, also known as whole inactivated vaccines are 
used to prevent a broad range of diseases such as polio, influenza and a 
number of bacterial infections. Inactivation of viruses or bacteria can be 
achieved differently, for example through inactivation with chemicals or 
irradiation.  
2.3.2 Passive immunisation 
 Passive immunisation includes vaccines that contain antibodies obtained 
from actively immunised humans or animals. Passive immunisation provides 
immediate protection but short-term immunisation compared to active 
immunisation that in turn can take a long time to develop.  
2.3.3 Abagovomab 
 Vaccine technology has been enlarging its scope to cover not only 
prophylactic but also therapeutic immunisation against allergies, autoimmune 
and infectious diseases such as bacterial or viral infections and cancer 
(Moingeon et al, 2003). Advanced ovarian cancer is a type of cancer that is 
hardly ever cured and more than 50 % of patients die within five years of their 
initial diagnosis (du Bois et al, 2003). Standard initial treatment of ovarian 
cancer patients includes surgery and chemotherapy. In the vast majority of 
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cases these treatments achieve a preliminary disappearance of ovarian cancer 
lesions. This state is called clinical remission: the patient having no evidence of 
cancer on CT scan or physical examination. However, many patients suffer a 
relapse within one to two years despite an apparently successful treatment with 
surgery and chemotherapy. Cytostatic regimes after failure of first-line therapy 
are limitedly successful so more suitable therapeutic methods are being 
developed (Wagner et al, 2001). Different immunotherapeutic strategies based 
on immunisation with tumor-specific antibody constructs (e.g. bispecific 
antibodies), immunogenic peptides or DNA vaccines have been developed 
(Fernandez et al, 1998; Tighe et al, 1998).  
 One promising strategy is the vaccination with so called anti idiotypic 
(anti-id) antibodies that target tumor associated antigen expressing cells. This 
immunotherapeutic strategy is based on the immune network hypothesis of Nils 
Jerne (1974). According to his theory, variable antigen binding regions of 
antibodies (Ab1) contain ideotypic determinants that are so unique that they 
appear foreign to the immune system and are, therefore, immunogenic and thus 
induce the formation of anti-id antibodies against Ab1 (Ab2). Some of these 
anti-id antibodies (Ab2) can functionally mimic the three-dimensional structure 
of the original antigen recognised by the Ab1 and can cause the production of 
anti-anti-id antibodies (Ab3) that recognise the corresponding original antigen 
identified by Ab1. Thus, immunisation with Ab2 might induce a specific immune 
response directed against the original antigen (Reinartz et al, 2004; Pfisterer et 
al, 2006). Abagovomab is a murine IgG1 monoclonal anti-id antibody that 
contains a variable antigen binding region functionally mimicking the three-
dimensional structure of a specific epitope on the epithelial ovarian cancer 
tumor associated antigen CA 125. CA 125 is a low immunogenic cell surface 
mucin that is expressed in over 80 % of non-mucinous epithelial ovarian 
cancers (Lloyd et al, 1997). Abagovomab is intended to stimulate the host 
immune system to elicit humoral and cellular immune responses against 
CA 125-positive tumor cells. This will eventually result in inhibition of tumor cell 
proliferation. 
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2.3.3.1 Monoclonal antibodies 
 Antibodies in general are Y-shaped proteins that have two identical 
binding sites for their specific antigens (see Figure 1, Alberts et al, 2004). They 
are composed of four polypeptide chains including two identical, glycosylated 
heavy chains of approximately 50 - 70 kDa and two identical smaller light chains 
of approximately 25 kDa that are held together by disulfide bonds (see Figure 
1). The heavy chain variable domain (VH) and the light chain variable domain 
(VL) are the domains with the most diverse sequences and structures in the 
different antibodies. The variable region on the top of the ‘Y’ defines antigen-
binding properties and the constant region constituting the stem of the ‘Y’ is 
interacting with effector cells and molecules (Wang et al, 2006). There are five 
human immuneglobuline (Ig) classes: IgM, IgD, IgG IgE and IgA, depending on 
the constant domain of their heavy chains. IgGs are the most widely used 
antibodies for therapeutic purposes.  
 
Figure 1: Structure of an antibody according to Alberts et al, 2004. 
 Antibodies are defined functionally by the epitope they specifically 
recognise. Monoclonal antibodies (mAb) are homogeneous, well defined, single 
epitope antibodies. In 1984, Georges Köhler and César Milstein were awarded 
with the Nobel Price in Medicine for the development of hybridoma technology 
resulting in the production of monoclonal antibodies (Ambrosial and Keating, 
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1992). Mouse hybridomas were the first reliable source of monoclonal 
antibodies. The hybridoma technology includes immunisation of an animal 
(usually a mouse) obtaining immune cells from its spleen and fusing the cells 
with a cancer cell such as cells from a myeloma to make them immortal so they 
will grow and divide indefinitely. Such a tumor of fused cells is called a 
hybridoma and they secrete mAb (Committee on Methods of Producing 
Monoclonal Antibodies Institute for Laboratory Animal Research National 
Research Council, 1999). In 1986, the first mAb was approved by the Food and 
Drug Administration (FDA) for human use. It was a murine anti-CD3 mAb, 
muromonab (OKT3), used for the treatment of organ transplant rejection (Kunq 
et al, 1979). Rituximab (Rituxan®) was the first mAb approved for the treatment 
of cancer in 1997. In 2007, eight other mAbs have been approved for the 
treatment of cancer and currently hundreds are in preclinical and clinical 
evaluation (Liu et al, 2008).  
 One essential problem with murine antibodies used as pharmaceuticals 
is that in humans, they easily elicit the development of human anti-mouse 
antibodies (HAMA). It would be logical to produce human monoclonal 
antibodies but there are several complex scientific as well as ethical problems 
concerning this endeavour. Thus, humanised and chimeric antibodies are 
produced by homologous recombination: the genes of the mice that code the 
constant domains of the heavy and the light chain are recombined with those of 
humans (Fell et al, 1989). Chimeric mAbs (60-70 % human) contain mouse 
variable regions and human constant regions (Roque et al, 2004). The only 
murine regions in highly humanised mAbs (90-95 % human) are mouse 
complementarity determining regions (CDR). CDRs are short amino acid 
sequences found in the variable domains of the antigen binding site of the 
antibody that complement a specific antigen (Wang et al, 2006). Further 
complete humanisation of the mAb is possible by replacing murine CDRs with 
human CDRs but this process is relatively complicated. Owing to the 
manufacturing technique, completely humanised mAbs cannot be produced in 
hybridomas anymore that are used for large scale production. Moreover, affinity 
of these antibodies is often reduced, the process is very time-consuming and it 
is possible that human anti-humanised antibodies (HAHA) are produced (Little 
et al, 2000; Lüttgau 2004). Adalimumab (Humira®; Abbott, USA) was the first 
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fully human antibody to be approved as a therapeutic antibody. It binds 
specifically to the inflammatory cytokine TNF-α and was approved by the US 
FDA for the treatment of moderate to severe rheumatoid arthritis in December 
2002 (Bain and Brazil, 2003). It is generated through recombinant DNA 
technology in a mammalian cell expression system (DeRuiter and Riley, 2003). 
In 2006, the FDA granted approval to panitumumab (Vectibix®; Amgen Inc., 
USA). It is a human monoclonal antibody for the treatment of patients with 
metastatic colorectal cancer. This antibody was produced by the XenoMouse 
technology: transgenic mice are genetically engineered with a ‘humanized’ 
humoral immune system. This transgenic system recapitulates the human 
antibody response in mice by introducing nearly the entire human 
immunoglobulin loci into the germ line of mice that have an inactivated mouse 
antibody production (Jakobovits et al, 2007). 
2.3.4 Adjuvants 
 Adjuvants are defined as a group of structural heterogenous components 
that are used to elicit or boost an immune response to an antigen (Gupta et al, 
1993). They can also be described as any substance that, when incorporated 
into a vaccine formulation, acts generally to accelerate, prolong or enhance the 
quality of a specific immune response to a vaccine antigen. The word adjuvant 
is derived from the Latin verb adjuvare, meaning to help or aid.  
 The idea of adjuvants arose in the 1920s from observations such as 
those of Ramon and co-workers who showed an increase in the immune 
response against a diphtheria vaccine when it was injected with saponines, 
starch, lecithin, tapioca, oil, breadcrumbs, aleuronic seeds or agar (Thein, 
1988). They discovered that horses developing an abscess at the inoculation 
site of diphtheria toxoid generated higher specific antibody titres and defined 
adjuvants as ‘substances used in combination with a specific antigen that 
produced a more robust immune response than the antigen alone’ (Ramon, 
1925). 
 Mechanism of adjuvantism of this chemically very heterogeneous group 
of compounds is very assorted. Gupta and Siber (1995) classified them into 
three groups: 
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 Substances inducing depot formation on the site of injection (e.g. mineral 
compounds, oil-based adjuvants, liposomes, biodegradable polymer 
microspheres larger than 10 µm etc.). The antigen is bound to an 
indissoluble substance so it is dissolved slowly and the antigen is 
eliminated with delay.  
 Substances acting as delivery vehicles for the antigens helping to target 
the antigens to immune competent cells (e.g. liposomes, oil adjuvants, 
biodegradable polymer microspheres larger than 10 µm, non-ionic block 
polymer surfactants etc.). These adjuvants help to deliver the antigen to 
the spleen and/or lymph nodes where the complex is comprised by the 
dendritic cells and where most of the necessary cell to cell interactions 
take place generating antibody producing plasma cells. 
 Substances acting as immunostimulators (e.g. Freund’s complete 
adjuvant (FCA), muramyl dipeptide (MDP), lipopolysaccharide (LPS), 
lipid A, monophosphoryl lipid A (MPL) pertussis toxin (PT), cytokines 
etc.). They stimulate a local inflammation reaction achieving an 
accumulation of macrophages and moreover leading to a delayed 
release of the antigen.  
 Adjuvants are used to elicit an early, high and persistent immune 
response particularly after primary immunisation. Especially purified, subunit 
and synthetic vaccines are poorly immunogenic and need to be adjuvanted. 
These antigens are expensive in production and by using an adjuvant, less 
antigen can be employed leading to an immense economisation. Traditional 
vaccines contain impurities or other compounds that act as adjuvants such as 
diphtheria-tetanus-pertussis (DTP) that contains two adjuvants from whole cell 
pertussis vaccine (LPS and PT) (Gupta and Siber, 1995).  
 Aluminium salts were introduced for human use in the 1930s. Since then, 
a lot of research was accomplished on new adjuvants in order to gain features 
such as additional antigen-sparing ability, more rapid seroprotection, stimulation 
of T-cell immunity and longer lasting protective immunity (Petrovsky et al, 
2008). New FDA-approved adjuvants currently do not exist at least for the US 
market. One reason may be that safety and tolerability are critical regulatory 
issues and front the greatest barrier to new adjuvant approvals. Usually, 
increased adjuvant potency is associated with increased toxicity. Most modern 
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human adjuvants such as MF59 (Frey et al, 2003), ISCOMS (Smith et al, 1999), 
QS21 (Ronnberg et al, 1995) AS02 (Garcon et al, 2003), and AS04 (Levie et al, 
2002) have considerably higher local reactogenicity and systemic toxicity than 
aluminium adjuvants that already exhibit a number of adverse effects. 
2.3.4.1 Aluminium hydroxide adjuvants 
 Aluminium compounds including aluminium phosphate (AlPO4), 
aluminium hydroxide (Al(OH)3) and alum precipitated vaccines are currently the 
most commonly used adjuvants with human and veterinary vaccines (Gupta 
and Bradford, 2000). Mechanism of adjuvanticity of aluminium adjuvants is not 
yet fully understood but it includes formation of a depot at the site of antigen 
injection, activation of complement, induction of eosinophilia, activation of 
macrophages and uptake of the antigen-adjuvant complex by antigen 
presenting cells (APC) due to their particulate nature and advantageous size 
(Gupta and Siber, 1995). An alternative unifying theory of aluminium adjuvant 
action based on its toxicity was proposed by Petrovsky et al (2007). In their 
model, aluminium particles together with the absorbed antigen are 
phagocytosed by tissue macrophages. They become activated and mobilise 
into the lymph. Aluminium is toxic to cells and when macrophages reach the 
draining lymph node, the majority of those that have ingested aluminium are 
dead or about to die. These macrophages release their cytoplasmic contents 
including the absorbed antigen resulting in macrophage cell debris, antigen and 
co-stimulatory cytokines flowing into the draining lymph node. This is supposed 
to stimulate antigen specific plasma cells and antibody production (Petrovsky et 
al, 2007). 
 There are certain adverse effects of aluminium adjuvants such as 
occasional induction of local reactions at the site of injection, increase in IgE 
antibody responses, ineffectiveness for some antigens and inability to enhance 
cell-mediated immune responses, especially cytotoxic T-cell responses (Gupta 
and Bradford, 2000). But they have a long history of safe use; they are 
comparatively inexpensive and exhibit adjuvanticity with many antigens (Aprile 
and Wardlaw, 1966; Gupta, 1998).  
 Aluminium hydroxide adjuvant is chemically poorly crystalline aluminium 
oxyhydroxide with a structure of the mineral boehmite that is sometimes 
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referred to as pseudoboehmite (Baker and Pearson, 1974). It consists of 
corrugated sheets of octahedral aluminium (see Figure 2). 
 
Figure 2: Structure of aluminium hydroxide as depicted by Vogel and  
Powell, 1995: corrugated sheets of octahedral aluminium. 
 Commercial aluminium hydroxide adjuvants examined by X-ray 
diffraction have bands at 6.46, 3.18, 2.35, 1.86, 1.44, and 1.31 Å indicating 
varying degrees of crystallinity (Shirodkar et al, 1990). The width of the 
diffraction band at half height (WHH) reflects the degree of crystallinity. Poorly 
crystalline boehmite particles show greater line broadening resulting from 
smaller crystallite size (Tettenhorst and Hofmann, 1980). With increasing WHH, 
surface area and chemical reactivity of boehmite increases. Aluminium 
hydroxide adjuvants are composed of fibrous primary particles. Johnston et al 
(2002) could calculate an average primary crystallite size of 4.5 nm x 2.2 nm x 
10 nm that is much smaller than most protein antigens. These primary particles 
form aggregates of 1-10 µm that is comparable to the size of micro organisms 
and thus adequate for uptake by phagocytosis (Hem et al, 2004; Lindblad, 
2004). 
 Preparation of aluminium hydroxide adjuvants is described in numerous 
ways. Generally, they are prepared by adding aqueous solutions of aluminium 
ions (typically sulfates or chlorides) to alkaline conditions or adding a basic 
solution to the aluminium containing solution until the molar ratio of hydroxyl to 
aluminium is reached (Lindblad, 2003; Yau et al, 2006). Already Willstätter and 
Kraut (1923) found that the slightest alterations in preparation formula, 
experimental conditions, temperature, concentration and rate of addition of 
components of the preparation can lead to a variety of aluminium hydroxide 
forms differing with respect to their physico-chemical characteristics, stability 
and protein adsorption. Holt (1950) also found that aluminium precipitated 
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adjuvants can be strongly heterogeneous depending on the anions being 
present at the time of precipitation (from buffers or growth media residues in the 
antigen solution etc.). 
 Vaccines containing aluminium adjuvants can be prepared either by 
mixing a commercially adjuvant with the antigen (“aluminium adsorbed” 
vaccine) or by in situ precipitation of alum [KAl(SO4)2 · 12 H2O] or aluminium 
chloride mixed with the antigen solution (Hem and White, 1995). Resulting 
vaccines are termed “alum precipitated” vaccines. 
 Important parameters for an aluminium adjuvant are stability and high 
surface area for antigen adsorption, particle size distribution, electrical charge 
and the hydrated colloid nature of the precipitate formed with an antigen 
(Lindblad, 2004). Johnston et al (2002) determined surface area of aluminium 
hydroxide through water sorption and X-ray diffraction and yielded values of 
510 m2/g. This is consistent with its high adsorption capacity for various 
proteins. Adsorptive capacity for BSA at pH 7.4 ranges between 1.8 - 2.6 mg 
per mg Al3+ (Hem and White, 1995). Aluminium hydroxide adjuvant has a point 
of zero charge (PZC, for further information see section 2.3.5.2) of 11 and is 
thus positivly charged at pH 7.4 favouring adsorption of negatively charged 
proteins at neutral pH. 
 One problem with aluminium adjuvants is the relative affinity of anions for 
aluminium. Hsu (1989) listed anions based on their affinity for aluminium: 
 Weak affinity:   nitrate, chlorate, chloride 
 Moderate affinity:   sulphate 
 Strong affinity:   phosphate (compare section 2.3.5.3.3) 
 Very strong affinity:  fluoride 
2.3.4.2 Lyophilisation of aluminium hydroxide adjuvants 
 Freezing or lyophilisation of aluminium adjuvant adsorbed vaccines can 
result in a loss of potency of the adjuvant if it is unprotected. The physical 
appearance of the adjuvant alters after freezing. This induces changes in the 
structure and morphology of the adsorbent and causes a collapse of the 
suspension resulting in gross aggregation, precipitation and formation of 
agglomerates, floccules or other granular matter that increases sedimentation 
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rates (WHO, 2006). Menon et al (1974) found that granule size increased on 
repeated freezing and thawing. Zapata et al (1984) propose that water 
crystallises during freezing and the solutes form freeze concentrates. They say 
that within these freeze concentrates, aluminium hydroxide particles are 
compacted in a way they are forced to overcome the repulsive barrier known as 
the primary maximum as described by the modified DLVO Theory. It is 
suggested that particles are forced so close together that the strong attractive 
force present in the primary minimum (also named ‘Energy Trap’) dominates 
and consequently, they coagulate or agglomerate. Clausi et al (2008) argument 
against the assumption that freeze concentration induced approximation of high 
concentrated adjuvant alone is the reason for adjuvant aggregation. They 
assume that it is rather freeze concentration induced phase changes and ion 
exchange reactions on the particles’ surface being responsible for the 
aggregation of the adjuvant during freezing.  
2.3.4.3 Stabilising aluminium hydroxide during lyophilisation 
 There have been many attempts to develop stable lyophilised aluminium 
hydroxide adjuvant containing vaccine formulations. The two main strategies 
applied to improve stability during lyophilisation were the addition of solutes or 
excipients and a more rapid freezing rate. 
2.3.4.3.1 Excipients 
 DLVO theory includes steric repulsive forces that depend on size, 
geometry and conformation of adsorbed molecules to have an influence on 
attractive forces in between the particles. Polymeric solutes that tend to adsorb 
to the aluminium hydroxide particles would minimise aggregation or coagulation 
during freezing by increasing the primary maximum through implementing steric 
repulsive forces. Nakamura and Okada (1977) observed the ability of polyvinyl 
pyrrolidone, polyvinyl alcohol, methyl cellulose, sodium carboxymethyl cellulose, 
pectin, traganth and sodium alginate to reduce the effects of a freeze-thaw 
cycle. Formation of a three-dimensional network by the polymer within the 
aqueous phase was assumed to reduce the growth of ice crystals and 
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immobilise the suspended particles. This reduced the formation of aggregates 
and thus had a protective effect on the suspension.  
 Zapata et al (1984) studied the effect of different surface active agents on 
the freeze stability of aluminium hydroxycarbonate and magnesium hydroxide 
gels. Polysorbate 80 was the most effective surface-active agent to prevent an 
increase in particle size distribution. This is based on the assumption that 
polysorbate 80 is adsorbed with its hydrophobic region while the hydrophilic 
region undergoes little or no adsorption as it is compatible with water. Also, they 
estimated the molecular length of the surface-active agents finding a very high 
one for polysorbate 80. Thus, due to its expected orientation and its large size, 
polysorbate 80 produces the largest steric repulsive region.  
 Another excipient often used to stabilise aluminium adjuvants during 
lyophilisation is trehalose, as well as dextran or combinations of disaccharides, 
amino acids and a colloidal substance (Clausi et al, 2008; Csizer et al, 1986; 
Kyosuke et al, 1989; Maa et al, 2003). For all freeze-dried formulations, 
coagulation remained visible in the optical micrographs implying that these 
former attempts to lyophilise aluminium hydroxide have not succeeded. 
Disaccharides such as trehalose and sucrose along with many other polyols, 
including polysaccharides such as hydroxyethyl starch and dextran have the 
ability to form glasses (compare section 2.1.4.3.1). As empirical knowledge 
shows, this protective mechanism does probably not only protect proteins from 
low temperature-, freezing- and dehydration stresses during lyophilisation but 
also the highly susceptible adjuvant aluminium hydroxide.  
2.3.4.3.2 Freezing rate 
 Clausi et al (2008) could demonstrate that the propensity of Alhydrogel® 
adjuvant particles to aggregate during freeze-thawing and lyophilisation can be 
avoided by faster cooling rates during freezing. Zapata et al (1984) also found 
that large ice crystals formed during freezing cause aluminium particles to 
coagulate more than small ice crystals do. What determines ice crystal size is 
the rate of freezing - the faster the rate, the more nucleation is promoted and 
the greater the number of crystals of smaller size that will result. Smaller ice 
crystals formed during a more rapid freezing rate do not force as many 
aluminium particles into so close proximity that they will coagulate as large ice 
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crystals formed during a slow rate of freezing would. Maa et al (2003) also 
assumed that the faster the cooling rate the greater is the rate of ice nucleation 
and smaller ice crystals are formed causing less aggregation of adjuvant 
particles.  
2.3.5 Adsorption phenomena within vaccines 
 The adsorption behaviour of antigens onto aluminium adjuvants in a 
vaccine formulation is an extensively discussed subject. It has several 
physiological and technological effects on the vaccine's efficacy. Adsorption is 
described as ‘attractive interactions at surfaces without formation of covalent 
chemical bonds. If covalent bonds are formed, the process is called 
chemisorption’ (Matheis et al, 2002). In vaccines, adsorption is referred to as 
the attraction between the colloidal dispersed adsorbent particles and antigens. 
Forces that contribute to the adsorption of antigens by aluminium containing 
adjuvants are mainly electrostatic attractive forces and ligand exchange. 
Responsible for adsorption through ligand exchange are phosphate groups of 
phosphorylated proteins that exchange with surface hydroxyls of the adjuvant 
(Vogel and Hem, 2004; Al-Shakhshir et al, 1995). Van der Waals forces and 
hydrogen bonding are also believed to contribute to adsorption within such 
systems.  
 One crucial step in the fate of an antigen that is adsorbed to an adjuvant 
and subsequently in the way it will induce an immune response is the 
internalisation of the protein by antigen presenting cells (APC) such as dendritic 
cells (DC). Antigens that are desorbed from the adjuvant surface are 
internalised by DCs through macropinocytosis and those remaining adsorbed 
are taken up by phagocytosis. Morefield et al (2005) studied the efficiency of 
each route concluding that both mechanisms of internalisation of an antigen by 
DCs occur rapidly but adsorbed antigens were found to be internalised more 
efficiently. They claim that the relative contribution of macropinocytosis and 
phagocytosis to antigen internalisation by APCs is likely to depend on the rate 
of desorption of the antigen from the adjuvant after administration. This finding 
endorses results obtained by Chang et al (2001) who manifest the importance 
of the degree of adsorption in interstitial fluid (IF) rather than in the vaccine 
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formulation for its efficiency in eliciting an immune response. These results 
show that adsorption of antigens by aluminium containing adjuvants seems to 
have a great influence on the potency of a vaccine.  
2.3.5.1 Antigen adsorption by aluminium containing adjuvants through 
electrostatic attraction or ligand exchange? 
 Jiang et al (2006) conducted a study to evaluate the relationship between 
the exposure of an adsorbed antigen to IF (compare section 2.3.5.3) and the 
adsorption mechanism. They used the effect of ionic strength on the adsorptive 
capacity to determine whether the mechanism is electrostatic attraction or 
ligand exchange and could show that adsorptive capacity through electrostatic 
attraction is inversely related to ionic strength. Adsorption by ligand exchange 
on the other hand is not affected by ionic strength (Stumm, 1992); it can actually 
increase with increasing ionic strength. They studied four antigens (lactalbumin, 
bovine serum albumin (BSA), lysozyme and myoglobin) that do not contain any 
phosphate groups presuming that they would not adsorb to aluminium 
adjuvants by ligand exchange. This assumption was confirmed by the results: 
they could show that the adsorptive capacity of those four antigens decreased 
with increasing sodium chloride concentrations. The other four antigens (alpha 
casein, dephosphorylated alpha casein, phosphorylated BSA (PBSA) and 
hepatitis B surface antigen, HBsAg) contained phosphate groups. The 
adsorptive capacities of alpha casein, dephosphorylated alpha casein and 
PBSA increased with rising sodium chloride concentration due to charge 
shielding that allows closer packaging on the adjuvant surface. The complex 
structure of HBsAg was assumed to be the reason for no change in its 
adsorptive capacity with changing sodium chloride concentration. They 
concluded that latter four proteins were adsorbed through ligand exchange. 
They also exposed the different antigens to sheep lymph imitating IF and could 
show that most of the antigens being adsorbed by electrostatic attraction were 
eluted completely and quickly just as most of the antigens being adsorbed by 
ligand exchange showed almost no desorption during exposure to IF for up to 
24 hours because ligand exchange is a stronger adsorption force than 
electrostatic attraction.  
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2.3.5.2 Adsorption as a function of pH surface charge 
 Because most antigens as well as aluminium containing adjuvants are 
amphoteric, the pH of the vaccine consisting of both determines their net 
surface charge (Seeber, 1991a). Is the pH above the point of zero charge (PZC, 
the pH value at which net surface charge of the aluminium adjuvant is zero) or 
the isoelectric point (pI), net surface charge will be negative and the other way 
around. Generally, adsorption of an antigen to an aluminium adjuvant should 
best be performed in the pH interval between the pI of the antigen and the PZC 
of the aluminium adjuvant (Lindblad, 2004). In this pH range, electrostatic 
attraction and adsorption can best take place, due to opposite charge. The 
alkaline PZC (11.1 at pH 7.4) of Al(OH)3 makes it suitable for adsorption of 
acidic pI proteins with respect to advantageous electrostatic attractive forces at 
physiological pH of 7.4. Seeber et al (1991a) adsorbed albumin with a pI of 4.8 
(exhibiting a net negative surface charge at pH 7.4) to Al(OH)3. They found that 
adsorption between albumin and aluminium hydroxide was stronger than that 
between antigens and adjuvants of alike charges that show only little 
adsorption. The acidic PZC of AlPO4 makes it suitable for adsorption of alkaline 
pI proteins, as Seeber et al (1991a) exemplified with hen egg lysozyme that has 
a pI of 11.0 exhibiting a net positive charge at physiological pH of 7.4. Rinella et 
al (1998) analysed the effect of pH on the elution of model antigens from 
aluminium containing adjuvants. They prepared vaccines containing ovalbumin 
(pI = 4.7, Righetti and Caravaggio, 1976) and aluminium hydroxide, adjusted 
the pH to values ranging from 3 to 11 and found varying concentrations of not 
adsorbed protein depending on the pH of the test solution. At pH 4.3, 5.3 and 
6.2, small amounts of ovalbumin were found in solution and thus more 
ovalbumin was adsorbed to the adjuvant whereas at pH values below 4.3 or 
above 7.4, an increase of ovalbumin in solution was observed inferring that 
adsorption power decreased. The elution of ovalbumin from the aluminium 
hydroxide in samples adjusted to pH values above 7.4 cannot be explained by 
electrostatic repulsive forces because within this pH range, antigen and 
adjuvant are oppositely charged. Thus, they explain ovalbumin elution with the 
solubility of aluminium hydroxide at certain pH values. Its dissolution increases 
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sharply when pH is below 5.0 or above 9.0 with a minimum of dissolution at pH 
5. This is assumed to be the reason for protein elution at pH values above 7.4. 
2.3.5.3 Adsorption phenomena of vaccines in interstitial fluid 
 In various papers (Chang et al, 2001; Jiang et al, 2006; Seeber et al, 
1991a) it is claimed that after subcutaneous (s.c.) or intramuscular (i.m.) 
administration of vaccines containing antigens adsorbed to aluminium 
adjuvants, they are exposed to two different environments resulting in an 
altering degree of adsorption. The two environments are the components of the 
vaccine prior to administration and IF after i.m./s.c. administration. Mainly 
phosphate anions, citrate anions, interstitial proteins but also some other 
components of the IF are liable for this phenomenon (Seeber, 1991a). On the 
one hand, the different degrees of adsorption in different environments depend 
on the nature of the aluminium (pre-treated with phosphate) and on the other 
hand they are due to the properties of the protein itself. Chang et al (2001) 
showed that the immune response induced by an aluminium adjuvant 
containing vaccine formulation correlates primarily with the degree of antigen 
adsorption in IF rather than with the degree of adsorption of the antigen to the 
adjuvant in the vaccine formulation. Iyer et al (2003) found that aluminium 
hydroxide potentiated the immune response to antigens being eluted by IF as 
well as to antigens that do not elute when exposed to IF for 24 hours. Still, 
Morefield et al (2005) could show within an in vitro study of model vaccines that 
antigen uptake by dendritic cells is enhanced when the antigen remains 
adsorbed to the adjuvant. The disparities in the results obtained by the various 
studies are probably due to the different antigens used in combination with 
varying adjuvants: Chang et al (2001) used lysozyme with aluminum hydroxide. 
The surface charge of the adjuvant was modified by pre-treatment with 
phosphate resulting in five vaccines having degrees of adsorption ranging from 
3 to 90%. Iyer et al (2003) used ovalbumin, alpha casein or dephosphorylated 
alpha casein with aluminium hydroxide and Morefield et al (2005) used alpha 
casein and aluminium hydroxide. 
 Information about the composition of IF is rather limited and there are 
differences in the reported concentrations of proteins and anions. Generally, it is 
agreed that IF is identical to lymph (Tortora and Anagnostakos, 1990). 
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Therefore, in preceeding studies (Chang et al, 2001; Jiang et al, 2006), sheep 
lymph has been used to simulate IF and declarations concerning the 
concentrations for proteins and other components in IF are based on their 
concentrations in lymph.  
2.3.5.3.1 Interstitial proteins 
 It is commonly known and manifoldly investigated that regarding 
adsorption, proteins compete on surfaces and that one protein in solution is 
liable to displace a previously adsorbed protein from surfaces such as those of 
aluminium hydroxide adjuvants. Heimlich et al (1999) found that previously 
adsorbed model antigens like lysozyme or myoglobin are extensively displaced 
when exposed to interstitial proteins as for example albumin or fibrinogen.  
 Different concentrations have been reported for albumin (the main 
protein in IF) in lymph at different sites of the body (Heimlich et al, 1999). 
Examples of this are 25.5 mg/ml found in intestinal lymph or an assumed total 
protein content in IF of 20.6 mg/ml reported by Fogh-Anderson et al (1995). 
2.3.5.3.2 α-Hydroxy carbonic acids 
 Citrate and other α-hydroxy corboxlate anions in the IF can solubilise 
aluminium adjuvants. That results in a more rapid release of the antigen 
following administration of a vaccine (Seeber et al, 1991b). Citric acid in 
particular is commonly well known to have a solubilising effect on aluminium 
materials. α-Hydroxy carbonic acids in general are good chelators of metal ions 
since they form stable five or six membered rings (Puhlman and McColl, 1986). 
Organic acids contained within IF are acetoacetic, citric, α-ketoglutaric, lactic, 
malic, pyruvic and succinic acids but, however, only citric, lactic and malic acid 
are α-hydroxy carbonic acids and therefore only these three of the seven are 
responsible for altering the degree of adsorption of the antigen to an aluminium 
adjuvant. The total organic anion concentration within IF has been documented 
to range from 3.4 to 7.0 mEq/l (Frisell, 1982; Bell et al, 1976; Selkurt, 1967) with 
a mean concentration of 6.3 mEq/l. Seeber et al (1991b) used this value to 
represent the total organic anion concentration of IF and - assuming that each 
of the seven organic anions’ concentration is equal within IF - they took the 
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concentration of organic anions capable of chelating aluminium as 3/7 of 
6.3 mEq/l (= 2.7 mEq/l) and chose citrate anion to represent these complexing 
anions.  
2.3.5.3.3 Phosphate 
 IF contains 5 mM phosphate and sulphate anions combined (McSweeny, 
1988). Phosphate anions adsorb specifically onto the surface of aluminium 
hydroxide through ligand exchange with the surface water, even more than 
sulfate anions (Liu et al, 1984; Serna et al, 1977). Corresponding to their 
relative strong coordination to aluminium, they have a great impact on 
aluminium adsorption power (Nishida et al, 1992). When adding increasing 
amounts of phosphate anions to an ovalbumin-adjuvant complex, 45 % of 
ovalbumin desorbed when 4 mM phosphate anions were added (Rinella et al, 
1995). It was also observed that less ovalbumin was desorbed by phosphate 
anions as the protein-adjuvant complex aged. This phenomenon can be 
explained by Norde et al (1986) who suggested that proteins may undergo 
conformational changes upon adsorption in order to optimise surface 
interactions. Bleam et al (1991) used 31P solid-state NMR to study phosphate 
adsorption at the surface of boehmite finding a formation of inner-sphere 
surface complexes between phosphate and the surface aluminium atoms. 
Phosphates in these complexes hydrolyse with varying pH. Moreover, 
substituting surface hydroxyl groups with phosphate anions at neutral pH can 
decrease the PZC of aluminium hydroxide from 11 to 4.1 (Iyer et al, 2003). This 
changes the initially positive surface charge of the adjuvant at neutral pH to a 
negative charge and is part of the reason why adsorptive manner of charged 
proteins changes following addition of phosphate anions.  
2.3.5.3.4 Chloride  
 Chloride anions are non-specifically adsorbed and held loosely situated 
in the diffuse layer region of the electrical double layer of the aluminium 
hydroxide particles (Serna et al, 1977). Rinella et al (1995) showed that an 
increase in ionic strength up to 200 mM with potassium chloride caused 
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approximately 2.5 % of 2.59 mg ovalbumin adsorbed to 1 mg aluminium 
hydroxide adjuvant to be desorbed.  
2.3.5.3.5 Hydrophobic interactions 
 Other attraction forces involved in protein-adjuvant adsorption are 
hydrophobic interactions. Ethylene glycol is often used to reduce hydrophobic 
interactions between the protein and the sorbent in hydrophobic interaction 
chromatography by stabilising the hydration layer of the protein making 
hydrophobic interactions thermodynamically unfavourable (Srinivasan and 
Ruckenstein, 1980). Thus, it can be used to determine whether or not 
hydrophobic interactions play a role in the adsorption of an antigen to an 
aluminium adjuvant (Al-Shakhshir et al, 1995). 
2.3.6 Nile Red fluorescence microscopy 
 For the determination of changes in antigen or protein structure like 
aggregation or other conformational changes, fluorescence microscopy is a 
well-established method. Nile red (9-diethylamino-5H-benzo[α] phenoxazine-5-
one) is a photochemically stable fluorescence dye with a fluorescence strongly 
dependent on its environment that has been well characterised (Sackett and 
Wolff, 1987; Greenspan and Fowler, 1985). It has a low fluorescence quantum 
yield in a polar environment. In a more hydrophobic surrounding its quantum 
yield increases and its emission maximum is blue shifted (shifted to shorter 
wavelengths, Hendriks et al, 2002). As a hydrophobic dye, Nile Red binds to 
hydrophobic sites of proteins. Generally, hydrophobic residues within proteins 
are located in the interior of the molecule and are excluded from the solvent. 
They are usually exposed to the protein’s surface as a result of biologically 
significant conformational changes due to destruction of the native state of the 
protein through (partial) denaturation. This results in an alteration of the 
environment of the dye and a subsequent shift in the emission wavelength. The 
colour of the light that is visible under the microscope changes. Therefore, 
fluorescence microscopy of samples stained with Nile Red has effectively been 
used to monitor conformational changes within proteins (Sackett and Wolff, 
1987; Demeule et al, 2007). 
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3 Practical part  
3.1 Materials 
 Table 1 lists the proteins, the adjuvant and the excipients used for this 
work. All chemicals were of reagent grade or higher quality. Chemicals included 
within special application kits and antibodies for the ELISA are mentioned in the 
respective sections. Water, pre-treated by reverse osmosis, was further purified 
by a Millipore system (Millipore Corporation, USA). 
Table 1: Proteins, adjuvant and excipients. 
Item Manufacturer 
Proteins  
Abagovomab drug substance solution Goodwin Biotechnology Inc., USA 
Bovine serum albumin Sigma-Aldrich Chemie GmbH, Germany 
Adjuvant  
Alhydrogel® Brenntag Biosector, Denmark 
Excipients  
Ammonium acetate Merck, Germany 
L-Arginine Ajinomoto OmniChem, Belgium 
Bromine Merck, Germany 
Copper sulphate solution 0.1 M Merck, Germany 
Dextran MW 35,000 - 45,000 Sigma-Aldrich Chemie GmbH, Germany 
Ethanol absolute Merck, Germany 
Ethylene glycol Riedel-de Haën, Germany 
Glacial acetic acid 100 % Merck, Germany 
Glucose Roquette Frères GmbH, France 
Glycine Ajinomoto OmniChem, Belgium 
Hexamethylene tetramine Fluka, Germany 
Hydrochloric acid fuming 37 % Merck, Germany 
Hydroxyethyl starch (HES) 200/0.5 Laevosan Pharma GmbH, Austria 
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Item Manufacturer 
HES 450/0.7 Laevosan Pharma GmbH, Austria 
Hydroxypropyl-beta-cyclodextrin,  
(HP-β-CD) 97 % 
 
Acros Organics, USA 
KCl, KH2PO4, NaCl, Na2HPO4 · 7H2O Merck, Germany 
D (-) Mannitol Roquette Frères GmbH, France 
Methyl orange  Merck, Germany 
NaOH pellets GR for analysis Merck, Germany 
Nile Red  Fluka, Germany 
Nitric acid 65 % J.T. Baker, The Netherlands 
Polyethylene glycol (PEG) 1000 Clariang GmbH, Germany 
PEG 3000 Clariang GmbH, Germany 
PEG 8000 Sigma-Aldrich Chemie GmbH, Germany 
Polysorbate 80 S. Black GmbH, Germany 
Polysorbate 20 Calbiochem, USA 
Polyvinyl pyrrolidone (PVP/Povidon)  
K 12, K 17 and K 25 
 
BASF AG, Germany 
Pyridylazonaphthol J.T. Baker, The Netherlands 
Sodium acetate, anhydrous Merck, Germany 
Sodium citrate dihydrate J.T. Baker, The Netherlands 
Sodium EDTA: Titrisol Triplex III Merck, Germany 
Sorbitol Merck, Germany 
Sulphuric acid 95-98 % Merck, Germany 
Saccharose Merck, Germany 
D (+)Trehalose dihydrate  Sigma-Aldrich Chemie GmbH, Germany 
Xylenol orange tetra sodium salt Merck, Germany 
Zinc volumetric standard  Merck, Germany 
Continuation of Table 1 
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3.2 Methods 
3.2.1 Formulation development 
3.2.1.1 Preparation of the formulations 
3.2.1.1.1 First batch 
 To gain an insight into the quality assuring effects of different stabilising 
agents on the stability of aluminium hydroxide adjuvant during freeze-drying, 
suspensions containing only the aluminium adjuvant, buffer, surfactant and 
stabilising excipient were prepared (see Table 2). Excipients were dissolved in 
PBS pH 7.4 at a concentration twice as high as the final amount using a VMS-
C10 magnetic stirrer (VWR International GmbH, Darmstadt, Germany) and 
0.2 % polysorbate 80 were added. Subsequently, 2.5 ml aluminium hydroxide 
gel and 2.5 ml of the corresponding excipient solution were mixed resulting in a 
suspension containing 0.1 % polysorbate 80, 5-20 % excipient (see Table 2) 
and 10 mg/ml aluminium hydroxide. This model concentration was chosen to 
see whether or not it is possible to protect formulations containing this much 
aluminium hydroxide adjuvant. The pH of the suspensions was determined (see 
section 3.2.1.5) and adjusted to 7.4 with 1 N HCl or 0.1 N NaOH respectively. 
The suspensions were aliquoted into 2 ml borosilicate vials for lyophilisation 
(Wheaton, USA) at volumes of 1.0 ml. To compare the influence of molecular 
weights of the used polymers, several types of PVP (K 12, 17 and 25) were 
employed as well as different HES (200/0.5 and 450/0.7) and PEG (1000, 3000 
and 8000) types. Trehalose formulations were produced at four different 
concentrations, namely 5, 10, 15 and 20 % trehalose (w/v). 
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Table 2: Aluminium hydroxide adjuvant formulations containing 10 mg/ml 
aluminium hydroxide, stabilising excipient, 0.1 % polysorbate 80 and PBS pH 
7.4 (for abbreviations see section 3.1). 
Excipient Amount    
% (m/V) 
 Excipient Amount 
% (m/V) 
 Excipient Amount 
% (m/V) 
Trehalose 5, 10, 15, 20  PVP K 12 5, 10  HES 200/0.5 5, 10 
Saccharose 5, 10  PVP K 17 5, 10  HES 450/0.7 5, 10 
Sorbitol 5, 10  PVP K 25 5, 10  Arginine 5, 10 
Mannitol 5, 10  PEG 1000 5, 10  Glycine 5, 10 
Dextran 5, 10  PEG 3000 5, 10    
HP-β-CD 5, 10  PEG 8000 5, 10    
3.2.1.1.2 Stability batch 
 Based on data obtained from the screening of formulations described in 
section 3.2.1.1.1, a sterile stability batch was produced using abagovomab as a 
vaccine antigen. Formulations were prepared comprising aluminium hydroxide, 
abagovomab, polysorbate 80 and PBS pH 7.0 in every formulation with varying 
stabilising excipients as listed in Table 3. 
Table 3: Formulations containing 10 mg/ml aluminium hydroxide, stabilising 
excipient, 2 mg/ml abagovomab, 0.1 % polysorbate 80 and PBS pH 7.0 
(abbreviations see section 3.1). 
Excipient Amount % (m/v) 
Trehalose 15 
Dextran 10 
PVP K 25 10 
HES 450/0.7 10 
Saccharose 10 
Sorbitol 10 
 Sterile abagovomab solutions containing polysorbate 80, PBS pH 7.0 
and stabilising excipients were prepared initially without the adjuvant as in 
contrast to Alhydrogel® that is a suspension, the solution can be sterile filtered. 
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The required amount polysorbate 80 was dissolved in PBS pH 7.0. Stabilising 
agents were added and stirred on a magnetic stirrer at 400 rpm for 1 h using a 
VMS-C10 magnetic stirrer (VWR International GmbH, Germany). Abagovomab 
drug substance solution (5.4 mg abagovomab/ml) was added and filled up with 
PBS pH 7.0. The solution was mixed carefully at 200 rpm for 1 h with a 
magnetic stirrer (for formulation composition see Table 3) and pH was adjusted 
with 0.1 N NaOH/ HCl, respectively. The solutions were filtered through 
vacuum-driven 250 ml cup Stericup®-GV Filter Units (units with very low protein 
binding, 0.22 µm Durapore® (PVDF) membrane, Millipore Corporation, USA) 
using a Divac 2.4 l vacuum pump (Leybold AG, Germany). 0.5 ml Alhydrogel® 
were aliquoted into 2 ml borosilicate glass vials for lyophilisation, sealed with 2-
leg lyophilisation stoppers (Wheaton, USA), crimped with aluminium seals 
(Wheaton, USA) and autoclaved using a Fedegari Autoclavi S.p.a. type FOF/1-
Z2 (Fedegari S.p.a., Italy). Under a laminar airflow bench, 0.5 ml of the sterile 
abagovomab solution were added and mixed carefully for 1 h on a plate shaker 
yielding a final aluminium hydroxide concentration of 10 mg/ml and an 
abagovomab concentration of 2 mg/ml.  
3.2.1.2 Freeze-thaw cycle 
 Prior to lyophilisation, freeze-thaw cycles were conducted. 1 ml samples 
were frozen on dry ice (-78.5°C) for 3 h and afterwards thawed at room 
temperature for 1 h. 
3.2.1.3 Lyophilisation 
 Clausi et al (2008) could show that the propensity of Alhydrogel® 
adjuvant particles to aggregate during freeze-thawing and lyophilisation can be 
avoided by faster cooling rates during freezing. Thus, chosen formulations were 
frozen on dry ice (3 h) that has a temperature of -78.5°C and therefore causes a 
rapid freezing rate. The vials were transferred into the pre-cooled (-30°C) ice 
condenser chamber of a Christ ALPHA 1-4 LSC freeze-dryer (Christ, Germany). 
The heatable shelves were pre-cooled on dry ice overnight. Freeze-drying 
conditions were set as followed: -30°C reaching -5°C within 12 h and an 
increase from -5°C to 20°C within 6h with a vacuum pressure of 0.1 mbar. 
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Secondary drying took place for 4 h at 20°C with a vacuum pressure of 
0.05 mbar. According to data obtained by DSC (compare section 3.2.1.8), 
primary drying was set below -25°C in the first part of the freeze-drying process. 
After lyophilisation, samples were sealed with 2-leg lyophilisation stoppers 
(Wheaton, USA) and crimped with aluminium seals (Wheaton, USA). 
3.2.1.4 Stability testing 
 To provide information on how the quality of freeze-dried formulations 
varied with time under the influence of different temperatures, samples were 
stored at the conditions listed in Table 4. Tests conducted with stress tested 
samples are listed in Table 5.  
Table 4: Storage conditions of lyophilised samples. 
Study Storage condition 
Testing Frequency 
[months] 
Refrigerator 5°C ± 3°C 0, 3, 6 
Accelerateda 25°C ± 2°C/60% RH ± 5% RH 0, 3, 6 
Intermediate 30°C ± 2°C/65% RH ± 5% RH 0, 3, 6 
Acceleratedb 40°C ± 2°C/75% RH ± 5% RH 0, 3, 6 
aAccording to ICH (2003): Stress tests for drug products intended for storage in a refrigerator  
bAccording to ICH: Stress tests for drug product, general case (intermediate conditions) 
3.2 Methods 
 
43
Table 5: Stability test program for samples stored at 5°C, 25°C, 30°C and 40°C. 
For abbreviations see sections below.  
Test parameter Testing time [months] 
 0 3 6 
General characterisation of the formulations    
Sedimentation assay x x x 
Particle size analysis x x x 
WAXD x x x 
SDS-PAGE x x x 
ELISA x x x 
In-depth characterisation of the formulations    
Nile Red fluorescence microscopy x x  
Adsorption studies x x  
3.2.1.5 pH value measurement 
 pH value measurements were conducted at a temperature of 20 - 25°C 
using pH 211 Microprocessor pH Meter (HANNA instruments, USA). 
3.2.1.6 Water determination - Karl Fischer titration 
 Karl Fischer water content measurements were conducted using the 
Titrando modular system Titrando 835 (basic unit, Metrohm AG, Switzerland), 
operating via an 840 Touch Control. Dosing was carried out with the 806 
Exchange Unit and an 803 KF Titration Stand was used for stirring and 
manually exchanging the spent titration vessel contents. A double platinum 
electrode (Metrohm AG, Switzerland) was used for endpoint detection. 
 For sample analysis, a mixture of two parts Hydranal Solvent® (Riedel-de 
Haën, Germany) and one part Hydranal Formamid dry® (solubiliser, Riedel-de 
Haën, Germany) was added to the titration vessel and the solvent was pre-
titrated with the titrating solution Hydranal Titrant® 5 (Riedel-de Haën, Germany) 
until a stable endpoint was obtained. The volume of the reagent used was 
ignored because this operation was intended to remove any moisture from the 
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reaction vessel. At least 20 mg sample were added to the vessel removing the 
stopper of the delivery port only for a short time, samples were stirred until they 
dissolved and were then titrated with the titrating solution. Samples were 
measured in triplicate. Calculation of the water content in % was accomplished 
automatically by the instrument. 
 The titre of the titrating solution was determined by five times titrating 
30 µl water. The mean volume of titrant used (in mg/ml) was calculated 
automatically by the instrument, saved and considered as titre for the next 
measurements.  
 The instrument was calibrated using Hydranal Standard® (sodium tartrate 
dihydrate, Riedel-de Haën, Germany) with a theoretical water content of 
15.7 %. Approximately 200 mg Hydranal Standard® were transferred to the 
titration vessel. Water content of the standard was determined three times and 
the mean value was allowed to range within  0.2 % of the theoretical water 
content.  
3.2.1.7 Optical microscopy 
 Visual analysis of the aluminium hydroxide particles was performed using 
an optical microscope (CX 41, Olympus, Germany) with 10 x and 40 x objective 
lenses. The system was equipped with a digital camera system (Colour view I, 
Olympus, Germany) and a Cell-A imaging software (Olympus Soft Imaging 
System, Germany) for image output. 
3.2.1.8 Differential scanning calorimetry 
 A Differential Scanning Calorimeter DSC 220C with a disk station SSC 
5200H (Seiko, Japan) was used. Approximately 5 mg of the formulations 
(before lyophilisation) were put into an aluminium crucible SSC000C008 (C3 
Analysis Technique, Germany) and the crucible was welded. An empty crucible 
was used for comparison. For Tg’, the samples were cooled from +25°C down 
to -40°C with a cooling rate of 5°C/min and simultaneously, the corresponding 
enthalpies were measured. The instrument was calibrated with indium and tin 
before use. Thermal transition onset temperatures were determined as the point 
at that the thermogram first deviated from the baseline. 
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3.2.1.9 Particle size analysis 
 Particle size distribution was measured by laser diffraction with PIDS 
(Beckman Coulter LD 13 320 Laser diffraction particle size analyser, Beckman 
Coulter GmbH, Germany) in triplicate and then averaged for calculations. This 
method calculates particle size by measuring the diffraction angle of particles 
passed through a laser beam. Measurements were conducted 50 seconds after 
sample suspensions were mixed with a Vortex Genie mixer (VWR Scientific 
Products, USA) for 10 seconds. Data was evaluated with the Beckman Coulter 
LD 13 320 software (Beckman Coulter GmbH, Germany) and reported in 
volume %.  
3.2.1.10 Wide angle X-ray diffraction 
 Wide angle X-ray measurements of the lyophilisates were accomplished 
with a sample stage Spinner PW3064/00 on a generator PW3040/60 X’Pert Pro 
connected to the tube PW3373/00 (copper anode) that delivered X-ray of the 
wavelength λ = 0.1542 nm at a high voltage of 40 kV and an anode current of 
40 mA resulting in a power of 1600 W. The goniometer PW3050/60 MPD 
System measured from 3.0° to 45.0° in a step-size of 0.015° (1 s/step) using a 
PreFIX X’Celerator detector. An X’Pert Data Collector was used and data was 
evaluated with the software X’Pert High Score (all Panalytical B.V., 
Netherlands). The interlayer spacing d can be determined by calculation of the 
diffraction peaks with the Bragg equation (nλ = 2dsinθ), while n is the order of 
the diffraction peak and θ is the scattering angle.  
3.2.1.11 Transmission electron microscopy 
 The samples were shock frozen between two gold platelets in melting 
nitrogen at -210°C. This system was first freeze cleaved in a Balzers freeze-
etch apparatus BAF 400 (Balzers, Germany) at -100°C and 5·10-6 bar and then 
shadowed with platinum-carbon in a 45° angle and subsequently stabilised with 
pure carbon in a 90° angle. The platinum-carbon replicas were cleaned with 
water and concentrated sulphuric acid, picked up on electron microscope grids 
and examined with a transmission electron microscope EM 300 (Philips, 
Germany).  
Chapter 3 Practical part 
 
46
3.2.1.12 Aluminium hydroxide as aluminium 
 The test was carried out according to the current version of the 
Ph. Eur. 2.5.13 using standardised 0.02 M sodium edetate solution and 
standardised 0.02 M copper sulphate solution. Copper sulphate solution was 
standardised by adding sodium acetate and pyridylazonaphthol solution and 
subsequently titrating the solution with 0.02 M sodium edetate solution. Sodium 
edetate solution was standardised as followed: zinc volumetric standard was 
dissolved in hydrochloric acid R1, bromine water was added, bromine excess 
was driven off by boiling and subsequently, the sample solution was diluted with 
water. Xylenol orange triturate and hexamethylenetetramine were added until 
the solution became violet-pink, then 2 g of hexamethylenetetramine were 
added. The sample solution was titrated with the sodium edetate solution until 
the violet-pink colour changed to yellow. For the determination of aluminium 
hydroxide as aluminium, sulphuric acid R, nitric acid R and glass beads were 
added, the solution was heated until thick, white fumes evolved and then 
allowed to cool. Water was added and boiled until a clear solution was obtained, 
the solution was cooled and then methyl orange solution was added and 
neutralised with strong sodium hydroxide solution R. Any occurring precipitates 
were dissolved by adding dilute sulphuric acid R. Water, sodium edetate 
solution, acetate buffer solution pH 4.4 and glass beads were added and boiled 
gently for not less than 3 minutes. Pyridylazonaphthol solution was added and 
the hot solution was titrated with the copper sulphate solution until the colour 
changed to blue. A blank titration was conducted omitting the sample. 
Aluminium hydroxide content was calculated. 
3.2.1.13 Sedimentation assay 
 For the data obtained from the first batch produced and the respective 
freeze-thaw experiments, a different procedure was accomplished for 
sedimentation studies as for the stability data. For the former method, 1 ml of 
the formulations before lyophilisation or before freezing on dry ice which served 
as fresh wet control and 1 ml of the reconstituted lyophilisates/ frozen and 
thawed samples were allowed to sediment in a 1 ml syringe. In order to obtain a 
distinguished differentiation between the different formulations, the height of the 
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sediment column was measured at various time intervals up to 24 h and 
expressed in percent of that of the respective fresh control. The height was 
expressed as volume because identical syringes were used and height of the 
column is equal to the volume of the sediment that can be read of the syringe 
scaling. The average value of duplicate measurements was used as the results 
were close to similar.  
 For the stability data, a different assay method was used. 1 ml of the 
freshly produced, reconstituted lyophilised formulations which served as fresh 
wet control and 1 ml of the reconstituted, stress tested lyophilisates was allowed 
to sediment in a 1 ml syringe. The height of the sediment column was measured 
at various time intervals up to 24 h and expressed in percent of that of the 
respective fresh control. The average value of duplicate measurements was 
used as the results were close to similar.  
3.2.1.14 Adsorption phenomena in the stability batch samples 
 1 ml of the sample suspensions (before lyophilisation and after 
reconstitution of the lyophilisates/after stress testing) was mixed in Eppendorf 
cups (Eppendorf AG, Germany) with additional abagovomab drug substance 
solution and water (final volume: 2 ml) obtaining suspensions with 
concentrations of abagovomab ranging from 1.0 mg/ml (no additional drug 
substance added) to 4.0 mg/ml and an Al3+ concentration of 1.7 mg/ml (0.5 % 
aluminium hydroxide, aluminium content determined as mentioned in section 
3.2.1.12). Suspensions were mixed on a plate shaker at room temperature 
(25°C) for 1 h and centrifuged in an Eppendorf centrifuge 5804R (Eppendorf 
AG, Germany) at 6000 rpm for 10 min until a clear supernatant was obtained. 
The concentration of abagovomab in the supernatant was determined using the 
bicinchoninic acid protein assay (see section 3.2.1.15). The amount of 
abagovomab adsorbed was calculated by the difference between the amount 
added to that found in solution. 
3.2.1.15 Bicinchoninic acid assay 
 The bicinchoninic acid (BCA) assay relies on the formation of a Cu2+-
protein complex under alkaline conditions (“Biuret reaction”) followed by 
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reduction of the Cu2+ to Cu1+. The reduction is proportional to the amount of 
protein present in solution. Cysteine, tryptophan, tyrosine and the peptide bond 
are able to reduce Cu2+ to Cu1+. BCA forms a purple-blue complex with Cu1+ in 
alkaline solutions. This complex is highly chromogenic with an absorbance 
maximum at 562 nm. The colour obtained by this reaction is stable and 
increases proportionally over a broad range of increasing protein concentration 
(20-2,000 µg/ml, Smith et al, 1985). Results obtained by the BCA method 
provide a greater tolerance of the bicinchoninate reagent toward interferences 
such as nonionic detergents and buffer salts when compared to the Lowry 
assay - another method for protein quantification.  
 The test is carried out by the BCA assay method according to Ph. 
Eur. 2.5.33, method 4, using the BCA Protein Assay Kit from Pierce, USA 
containing Reagent A, B and Albumin Standard. Reagent A contains sodium 
carbonate, sodium bicarbonate, bicinchoninic acid and sodium tartrate in 0.1 M 
sodium hydroxide and Reagent B contains 4 % cupric sulphate. Albumin 
Standard ampoules contain 2 mg/ml bovine serum albumin in 0.9 % saline and 
0.05 % sodium azide. The sample procedure was conducted according to the 
manufacturer’s instructions except when explained differently (see below). 
 Some substances can interfere with the BCA protein assay, for example 
the presence of glucose results in artifactually high values but can be 
compensated with a reaction blank (Sapan et al, 1999). As some utilised 
stabilising excipients had an influence on the test results, protein standards 
were treated identically to the samples (recommended in the manufacturers 
instructions). An equal amount of excipient as contained within the formulations 
was added to each standard. 
3.2.1.16 Isoelectric focusing 
 Isoelectric focusing (IEF) was carried out using PhastGel Dry IEF gels 
(GE-Healthcare, UK). The dry, frozen gels were rehydrated in PhastGel Dry IEF 
re-hydrating solution in a PhastGel cassette (GE-Healthcare, UK). The re-
hydrating solution consists of Pharmalyte pH 5-8 (GE-Healthcare, UK), 
Pharmalyte pH 8-10.5 (GE-Healthcare, UK) and water. Samples were diluted 
with BIO-RAD IEF sample buffer (BIO-RAD, USA) and applied to the gels using 
the sample applicator 8x1 µl (GE-Healthcare, UK). Gels were separated and 
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silver stained with an automated electrophoresis PhastSystem (GE-Healthcare, 
UK) and a PlusOne Silver Staining Kit (GE-Healthcare). Bands were evaluated 
by calculation of the pIs of the highest and the lowest band based on a 
calibration curve generated from the IEF calibration kit broad pI (pH 3-10, GE-
Healthcare, UK). 
3.2.1.17 Sodium dodecylsulfate polyacrylamide gel electrophoresis 
 The molecular weight of abagovomab was determined with sodium 
dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) using a 
PhastSystem automated electrophoresis and gel-staining system. Laemmli 
sample buffer (BIO-RAD, USA) was used containing 62.5 mM Tris-HCl, pH 6.8, 
25 % glycerol, 2 % SDS and 0.01 % bromphenol blue. Samples were diluted 
with sample buffer before application onto the PhastGel gradient 4 - 15 gels 
(GE-Healthcare, UK). 5 µl molecular weight marker (broad range from BIO-
RAD, USA) were diluted with 195 µl buffer solution. For the detection limit 
marker (0.1 mg/ml) the corresponding amount of reference solution was diluted 
with water. Gels were applied to the separation beds together with PhastGel 
SDS buffer strips (GE-Healthcare, UK) and were then separated and silver 
stained using an automated electrophoresis system.  
3.2.1.18 Enzyme-linked immunosorbent assay 
 To determine the abagovomab amounts, an enzyme-linked 
immunosorbent assay (ELISA) was performed. At room temperature, Immuno 
96 MicroWell® plates (type: flat bottom MaxiSorp® surface, Nunc A/S, Denmark) 
were coated with 50 µl of a monoclonal mouse anti-human CA125, clone 
OC125 (Calbiochem, USA) solution per well with a final concentration of 1 µg/ml 
in a carbonate buffer pH 9.6. Plates were incubated for 1 h on a plate shaker 
IKA HS 260 (IKA, Germany) and then blocked with BSA in a phosphate 
buffered saline (PBS) / 0.025 % polysorbate 20 solution (PBST) for 30 min at 
room temperature (200 µl / well). They were then washed three times with wash 
buffer (100 µl/well) containing 0.9 % sodium chloride and 0.1 % polysorbate 20 
in water. After washing, 50 µl of affinipure sheep anti-mouse IgG, Fc gamma 
fragment specific antibody solution (mAb OC125 Fc, Jackson Immuno 
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Research Laboratories, Inc., USA) with a final concentration of 10 µg/ml was 
added; the plates were incubated at room temperature on a plate shaker and 
then washed three times with the wash buffer. The diluted samples and the 
abagovomab reference solution were added and diluted further on the plate. 
Then the plates were incubated for 1 h at room temperature on a plate shaker 
and washed three times with PBST (100 µl/well). 50 µl of conjugated secondary 
antibody (peroxidase conjugated affinipure fragment goat anti-mouse IgG, 
Jackson Immuno Research Laboratories Inc., USA) were added to each well 
and incubated on a plate shaker for 1 h at room temperature. The plates were 
washed three times with wash buffer, and 50 µl of a 1:1 mixture of TMB-
peroxidase substrate and peroxidase-substrate Solution B (KPL, USA) were 
added. The plates were incubated at room temperature for 10 min after that 
50 µl of 1 M HCl were added to each well. The absorbance of each well was 
measured by a microplate reader at 450 nm (Bio Tek Instruments, Inc., USA). 
The absorbance readings for each standard, sample, and blank were averaged 
and the blank reading subtracted from each averaged standard and sample 
value. A standard curve was created using KC4 software (BioTek Instruments, 
Inc., USA) capable of generating a four parameter logistic (4-PL) curve-fit. The 
concentration of each diluted sample was calculated with this software and the 
signal in the calibrated range; the results were averaged. A curve normalisation 
was performed and the following system suitability test was applied for 
statistical evaluation: Dilutions with a normalised OD within 30 and 75 % of the 
maximum OD value were selected quantifiable. The relative standard deviation 
(srel) of the potency from each quantifiable dilution was calculated. Valid 
dilutions with srel  15 % were then selected and the mean potency of the valid 
dilution(s) was calculated. 
3.2.1.19 Nile Red fluorescence microscopy 
 Staining of the samples was achieved according to Demeule et al (2007) 
by dissolving Nile Red in ethanol producing a 100 µM stock solution. 0.5 µl of 
this stock solution were added to 50 µl of the sample solution obtaining a final 
Nile Red concentration of approximately 1 µM and an abagovomab 
concentration of approx. 2 mg/ml in the final sample. Immediately after staining, 
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samples were transferred onto a Neubauer haemocytometer (Feinoptik, 
Germany) and analysed by fluorescence microscopy using an Olympus CX 41 
microscope (Olympus, Germany) with 10 x and 40 x objective lenses. The 
system was equipped with a 100W U-LH100HG mercury lamp as a source of 
excitation radiation (Olympus, Japan) and an Olympus filter cube green DMG 
(EX BP 545, DM 570, EM LP 590, Olympus, Germany). A digital camera 
system and a Cell-A imaging software was used for image output (compare 
section 3.2.1.7). Fluorescing particles were counted within 5 x 4 squares of the 
Neubauer haemocytometer. The grids outlining the displayed squares had a 
mesh size of 250 µm corresponding to a volume of 6.25 nl at a depth of 0.1 mm. 
A mean number of particles per microlitre was calculated from the 5 counts. 
3.2.2 Adsorption phenomena 
3.2.2.1 Preparation of sample suspensions 
3.2.2.1.1 Samples containing phosphate, sodium chloride, citrate or 
ethylene glycol 
 A stock suspension of aluminium hydroxide was prepared by diluting the 
commercially available aluminium hydroxide adjuvant with water; the pH was 
adjusted to 7.4 with 0.1 M NaOH. A 4 M NaCl stock solution and a 1 M 
phosphate solution were prepared; the pH of the latter was adjusted to 7.4. A 
citrate stock solution was prepared according to the method described by 
Seeber et al. (1991b, compare section 2.3.5.3.2) obtaining final sample 
solutions with citrate concentrations of 2.7 (simulated IF), 27 and 270 mEq/l. 
The pH of the citrate stock solution was adjusted to 7.4. Samples containing an 
Al3+ concentration of 1.7 mg/ml were prepared by diluting the aluminium 
hydroxide stock suspension with the required volumes of the stock solution 
(sodium chloride, phosphate or citrate) or ethylene glycol (EG) plus sodium 
chloride to obtain the final concentrations given in Table 6. 
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Table 6: Final concentrations of the different additives in the sample 
suspensions. 
Additive Concentration of additive  
NaCl [M] 0.05 0.154 0.25 0.75 1.00 
Phosphate [mM] 5 10 15 50 100 
Citrate [mEq/l] 2.7 27 270 - - 
Ethylene glycol [%] 10 20 30 - - 
 
 The ethylene glycol samples were adjusted to pH 7.4 with 0.06 M NaOH 
or HCl, as these samples also contained 0.06 M NaCl. Suspensions were mixed 
on a plate shaker for 16 h at room temperature to allow for the exchange of the 
salts or ethylene glycol with the adjuvant.  
 The abagovomab stock solutions had an abagovomab concentration of 
6.0 mg/ml and a pH of 7.4. Final abagovomab concentrations between 0.2 and 
3.0 mg/ml were obtained by adding the required volume of the abagovomab 
stock solution to the required volume of sodium chloride, phosphate, citrate or 
ethylene glycol stock solution and finally diluting each aliquot to a volume of 
2 ml with water (final Al3+ concentration: 1.7 mg/ml). Samples were mixed on a 
plate shaker at 450 rpm for 1 h and then centrifuged at 6000 rpm for 10 min 
until a clear supernatant was obtained. The abagovomab concentration in the 
supernatant was determined using the BCA protein assay (see section 
3.2.1.15). The amount of abagovomab adsorbed was calculated by the 
difference between that added to that found in solution. 
3.2.2.1.2 Samples containing simulated interstitial fluid 
 In previous studies (Chang et al, 2001; Jiang et al, 2006), sheep lymph 
was used to simulate IF as it was considered equivalent to IF. Here, IF was 
simulated using components responsible for the desorption effects of IF. As 
mentioned before and in the literature, phosphate, citrate, sodium chloride and 
proteins are mainly responsible for the degree of antigen adsorption onto an 
adjuvant (Seeber et al, 1991a; Seeber et al, 1991b; Rinella et al, 1995). 
Therefore, to investigate how adsorption behaviour of abagovomab and 
aluminium hydroxide changes with the environment of the vaccine, two IF-
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simulating protein solutions with phosphate, citrate and sodium chloride were 
prepared and are referred to as Solution 1 and Solution 2 here (Table 7). 
Solution 1 contained these components with a low BSA concentration (20 
mg/ml) and no sodium chloride; Solution 2 also contained sodium chloride in 
addition to protein, phosphate, and citrate and simulated an environment closer 
to the in vivo situation with a higher BSA concentration (25 mg/ml) and a 
physiological sodium chloride concentration (0.154 M). Stock solutions of BSA, 
citrate, phosphate and sodium chloride and the aluminium hydroxide stock 
suspension were prepared; their pH values were adjusted to 7.4. Required 
volumes of the adjuvant stock suspension and the citrate, phosphate and BSA 
stock solutions were filled to 2 ml Eppendorf cups and diluted accordingly to 
obtain citrate and phosphate concentrations of 2.7 mEq/l and 5 mM, 
respectively (Table 7). Samples were mixed on a plate shaker at 450 rpm for 
16 h at temperatures of 5°C, room temperature (25°C) and 37°C. The required 
volume of the abagovomab stock solution was added to the aliquots to obtain 
final abagovomab concentrations between 0.2 and 3.0 mg/ml; each sample was 
diluted to 2 ml with water. Samples were mixed on a plate shaker at 450 rpm for 
1 h at the temperatures mentioned above and then centrifuged at 6000 rpm for 
10 min until a clear supernatant was obtained. The protein concentration in the 
supernatant was determined with ELISA (see section 3.2.1.18). The amount of 
abagovomab adsorbed was calculated by the difference between that added to 
that found in solution. 
Table 7: Concentrations of the components in the simulated IFs. 
Component Solution 1 Solution 2 
BSA 20 mg/ml 25 mg/ml 
Citrate 2.7 mEq/l 2.7 mEq/l 
Phosphate 5 mM 5 mM 
Sodium chloride - 154 mM 
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4 Results and discussion 
4.1 Formulation development 
 First of all, DSC data was evaluated to set up an appropriate 
lyophilisation cycle for the given formulations. For characterisation of frozen and 
thawed and lyophilised samples, a sedimentation assay was created as well as 
an evaluation/ranking system for the results. Particle size of samples after a 
freeze-thaw cycle and particle size after lyophilisation was scanned to observe 
changes in aluminium hydroxide gel quality. The crystalline character of the 
lyophilisates was examined by WAXD as it has an influence on the overall 
stability of the final product. Finally, optical micrographs of the chosen 
formulations were evaluated to see whether or not aluminium gel texture of 
chosen formulations has changed after freezing and thawing or lyophilisation 
respectively.  
4.1.1 Differential scanning calorimetry 
 Generally, during freeze-drying the process temperature is set below the 
sub-ambient glass transition of the maximally freeze-concentrated solution (Tg') 
of the formulation during primary drying in order to avoid the ‘collapse’ of the 
product during lyophilisation. Due to energy utilisation considerations, it is 
desirable to know the maximum acceptable temperature to that the frozen 
sample can be adjusted before a vacuum is applied. The formulation containing 
aluminium hydroxide, buffer, polysorbate 80 and 10 % glycine shows the lowest 
peak onset temperature with -23.8°C (for further DSC results see Table 8). 
Therefore, temperature during the first phase of primary drying is set below 
-23.8°C at -30°C to avoid collapse of the lyophilisation cake due to a too high 
drying temperature at the beginning. 
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Table 8: Results obtained by DSC with a cooling rate of 5ºC/min for 
formulations containing 10 % of the respective stabilising excipient.  
Formulation Tg’ [°C] Peak onset [°C] 
Aluminium hydroxide -11.9 -18.2 
Trehalose 10 % -8.1 -10.4 
Mannitol 10 % -15.6 -20.2 
Dextran 10 % -10.0 -14.9 
HP-β-CD 10 % -13.8 -18.8 
PVP K 25 10 % -13.1 -18.1 
Arginine 10 % -14.5 -18.9 
PEG 8000 10 % -11.2 -15.3 
HES 450 10 % -14.5 -19.8 
Saccharose 10 % -12.2 -15.6 
Glycine 10 % -19.5 -23.8 
Sorbitol 10 % -15.1 -19.8 
4.1.2 Sedimentation assay 
 Physico-chemical properties of aluminium hydroxide formulation frozen 
and thawed (FT) or freeze-dried (FD) in presence of the protecting material 
mentioned above can well be characterised by the sedimentation rate after a 
freeze-thaw cycle or reconstitution following lyophilisation. Aluminium hydroxide 
adjuvant that was frozen or dried with no stabilising agent and thawed or 
rehydrated aggregated into large clumps. They sedimented immediately and 
yielded a gel column below zero millilitres within the syringe so it was not 
detectable. Pure aluminium hydroxide gel that was neither frozen and thawed 
nor freeze-dried had a constant gel column throughout the 24 h period. 
Therefore, frozen and thawed or lyophilised aluminium adjuvant respectively 
had a degree of sedimentation of 0 % referring to the gel column of the fresh 
control. A ranking system was created rating the remaining results as depicted 
in Table 9 a). It was created referring to Gribbon et al (1996) who have dried 
aluminium hydroxide gel in the presence of trehalose and for the reconstituted, 
dried gel they could show a volume after sedimentation slightly below 90 % 
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concluding that the adjuvant exhibits no significant loss of gel structure. Hence, 
it can be reasoned that such sedimentation patterns (with a sedimentation rate 
≥ 85 % that are rated ‘good’ or ‘very good’ within this ranking system) indicate 
that the hydrated, non-aggregated molecules have a hydration shell volume 
separating one from another causing them to sediment slowly.  
Table 9: a) Ranking system rating the results of the sedimentation assay 
according to the height of their gel columns of the freeze-thawed and freeze-
dried samples in % of their fresh control after 24 h of sedimentation; b) Ranking 
system rating the particle size reported in volume % and expressed as the 
mean diameter in µm of aluminium hydroxide particles after a freeze-thaw cycle. 
a) ‘Very good’ ≥ 95 % ++ b) ‘Very good’ ≤ 25µm ++ 
 ‘Good’ ≥ 85 % +  ‘Good’ ≤ 30µm + 
 ‘Medium’ ≥ 60 % Ø  ‘Medium’ ≤ 50µm Ø 
 ‘Poor’ < 60 % -  ‘Poor’ > 50µm - 
 
 First of all, it is important to note that the majority of the lyophilised 
samples have a lower gel volume percentage compared to the samples that 
underwent a freeze-thaw cycle. This phenomenon demonstrates that 
dehydration stresses during lyophilisation have an additional negative influence 
on the adjuvant. Also, most of the formulations show anticipated results: the 
5 % formulation is less protective resulting in smaller gel columns than the 10 % 
formulation. It is also noticeable that within the 5 % formulations, half of the FD 
samples reached slightly better results than the FT samples whereas amongst 
the 10 % formulations only the lyophilised dextran formulation yielded a better 
result than the frozen and thawed sample; all other FD samples yielded 
considerably lower gel columns than the FT samples.  
 FT samples 
 No formulation containing 10 % protecting excipient was ranked inferior 
to ‘medium’; some even achieved ‘very good’ results (the 20 % trehalose 
formulation, PVP 12 and 25, saccharose, glycine, sorbitol). Only five 
formulations containing 5 % excipient reached a ‘medium’ (arginine PEG 8000, 
HES 450 and 200, sorbitol) and two formulations were rated ‘good’ (saccharose 
and glycine).  
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 FD samples 
 Freeze-dried dextran, PVP 25, arginine, and HES 450 and 200 
formulations were rated ‘medium’ at a concentration of 5 %, the only 5 % 
formulation achieving a ‘good’ was HES 200. The lyophilised 10 % dextran 
formulation was the only FD sample that obtained a ‘very good’ amongst the FD 
samples, PVP 25, HES 450 and 200, saccharose, and sorbitol were rated 
‘medium’. Figure 3 (a-d) displays the sedimentation assays for the saccharose, 
sorbitol, glycine and arginine formulations; the other results are displayed below 
where the respective type or concentration of excipient is discussed. All values 
are expressed as height of the gel columns in % of their corresponding fresh 
control. Deviations of three measurements have been left out because they 
were so marginal that error bars were hardly recognised as such and rather 
disturbed the visual perception and understanding of the graphics. 
 
Figure 3: Sedimentation assay of freeze-dried formulations (FD) and samples 
after a freeze-thaw cycle (FT) containing different concentrations of the 
stabilising excipients. Top: saccharose/sorbitol (a) FD and (b) FT, 
 saccharose 5 %,  saccharose 10 %,  sorbitol 5 %,  sorbitol 10 %. 
Bottom: glycine/arginine (c) FD and (d) FT,  glycine 5 %,  glycine 10 %, 
 arginine 5 %,  arginine 10 %.  
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 Some exceptions are depicted in Figure 4 (a, b): the 5 % HP-β-CD 
formulation reaches 49.2 % after 24 h when freeze-dried but only 38.5 % when 
frozen and thawed. Figure 4 (a, b) also shows that dextran is well protecting the 
aluminium adjuvant both during FD and FT at a concentration of 10 % whereas 
the 5 % formulation is another one of the few examples that protects the 
adjuvant better during FD resulting in a column of 75.8 % referring to the fresh 
control after 24 h in contrast to the FT sample yielding 42.4 % after 24 h. 
 
Figure 4: Sedimentation assay of freeze-dried formulations (FD) and samples 
after a freeze-thaw cycle (FT) containing different concentrations of the 
stabilising excipients mannitol, dextran or HP-β-CD: (a) FD and (b) FT, 
 mannitol 5 %,  mannitol 10 %,  HP-β-CD 5 %,  HP-β-CD 10 %, 
 dextran 5 % and  dextran 10 %. 
 Comparing the differently concentrated trehalose formulations 
 Figure 5 (a, b) displays that the more trehalose is contained within the 
formulation, the higher is the gel column after a freeze-thaw cycle or after 
lyophilisation. The 20 % formulation can even circumvent any deviation from 
sedimentation compared to fresh control within 24 h after a FT cycle whereas 
after FD there was a gel column of only 39.4 % of the fresh control after 24 h. 
These results demonstrate that within all trehalose formulations, a notable 
degree of aggregation takes place during freeze-drying leading to a quicker 
sedimentation of the aluminium hydroxide adjuvant. Still, trehalose at 
concentrations between 15 and 20 % can well protect damages through 
freezing and thawing reaching gel columns of more than 85 % of the fresh 
control after 24 h which corresponds to the findings of Roser et al (2005) who 
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demonstrated that at least 15 % trehalose must be comprised to prevent 
aggregation of aluminium hydroxide gel during lyophilisation.  
 
Figure 5: Sedimentation assay of freeze-dried formulations (FD) and samples 
after a freeze-thaw cycle (FT) containing different concentrations of trehalose. 
(a) FD and (b) FT,  trehalose 5 %,  trehalose 10 %,  trehalose 15 % and 
 trehalose 20 %. 
 Comparison of the different types of polymers 
 Another point of interest was how different types of the same polymer 
would behave during a freeze-thaw cycle or lyophilisation respectively to find 
out the most eligible one for the protection of aluminium adjuvants during 
freezing and freeze-drying. Three different types of PVP (K 12, K 17 and K 25), 
PEG (1000, 3000 and 8000) and HES 450 and HES 200 were used. 
 As seen in Figure 6 (a, b), during lyophilisation the three different types of 
PVP are more protective the higher their K-value. The K-value of such polymers 
represents a viscosity index and is related to its molecular weight by the 
Fikentscher equation (1932). During the freeze-thaw cycle there is no 
considerable difference between the different types of PVP but here it is 
noticeable that the 10 % formulations have much higher gel columns than the 
5 % formulations.  
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Figure 6: Sedimentation assay of freeze-dried formulations (FD) and samples 
after a freeze-thaw cycle (FT) containing different concentrations of the different 
types of PVP. (a) FD and (b) FT,  PVP 12 - 5 %,  PVP 12 - 10 %, 
 PVP 17 - 5 %,  PVP 17 - 10 %,  PVP 25 - 5 % and  PVP 25 - 10 %. 
 Sedimentation behaviour of aluminium hydroxide particles within the 
different PEG formulations is shown in Figure 7 (a, b). Higher molecular PEG 
8000 only just reaches a ‘medium’ ranking at a concentration of 5 % when 
frozen and thawed; the FD samples at that concentration all reach ‘poor’ results. 
Of the 10 % concentrated formulations, similarily none of the FD samples obtain 
better than ‘poor’ results. Of the FT samples, the PEG 8000 and 3000 
formulations reach ‘medium’ rated gel columns and the formulation containing 
10 % PEG 1000 has a gel column of 92.7 % of the fresh control after 24 h so it 
is rated ‘good’. These results display that PEG 1000 as well as PEG 3000 and 
8000 do not protect aluminium hydroxide gel sufficiently during freeze-drying to 
prevent aggregation leading to low gel columns of the adjuvant after 24 h of 
sedimentation. 
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Figure 7: Sedimentation assay of freeze-dried formulations (FD) and samples 
after a freeze-thaw cycle (FT) containing different concentrations of the different 
types of PEG. (a) FD and (b) FT,  PEG 1000 - 5 %,  PEG 1000 - 10 %, 
 PEG 3000 - 5 %,  PEG 3000 - 10 %,  PEG 8000 - 5 %,  and 
 PEG 8000 - 10 %. 
 There is no remarkable difference between the HES 450 and 200 
formulations. It is noticeable that within the 5 % concentrated formulations of 
both types; the FD samples reach better results than the FT samples. Both 
during a freeze-thaw cycle and during lyophilisation, HES 450 and 200 are 
‘medium’ to ‘good’ protective excipients as depicted in Figure 8 (a, b).  
 
Figure 8: Sedimentation assay of freeze-dried formulations (FD) and samples 
after a freeze-thaw cycle (FT) containing different concentrations of the two 
types of HES. (a) FD and (b) FT,  HES 450 5 %,  HES 450 10 %,  HES 
200 5 % and  HES 200 10 %. 
4.1.3 Particle size analysis 
 Pure aluminium hydroxide adjuvant is characterised by a multimodal 
particle size distribution indicating the existence of several populations between 
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10 % (d10) and 90 % (d90) of d10 = 0.68 µm, d50 = 1.52 µm and d90 = 25.70 µm 
and a mean particle diameter of 6.84 µm. As seen in Figure 9, the PSD curve of 
particles within pure aluminium hydroxide has four maxima and is dominated by 
a population centred at 1.5 µm (maximum at 5.5 % Vol.) followed by a second 
coarser population centred at 7 µm (0.8 % Vol.) and two other populations at 
22 µm (1.2 % Vol.) and 44 µm (1.3 % Vol.). This shows that even when the 
adjuvant is not frozen or freeze-dried, aluminium hydroxide gels exhibit particle 
aggregates that cannot be determined as discrete particles but as aggregates of 
the smaller particles with higher particle sizes. Aluminium hydroxide gel after 
freeze-drying without any protection displays a monomodal PSD with 
d10 = 11.2 µm, d50 = 53.3 µm and d90 = 125.0 µm and a mean particle diameter 
of 61.3 µm. This great increase in particle size indicates that most particles 
have undergone aggregation during lyophilisation.  
 
Figure 9: Particle size distribution of aluminium hydroxide particles before 
lyophilisation (a) and after reconstitution of the lyophilisate (b), three 
measurements. Results are reported as volume %. 
 Still, the less increase in particle size is caused through lyophilisation, the 
closer are the particles to their initial character. Nygaard et al (2004) showed 
that the particle diameters as well as number of particles of polystyrene 
particles injected in mice were the crucial factors determinating the strength of 
an immune response. Morefield et al (2005) emphasised these findings by 
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demonstrating that antigen internalisation of adjuvant particles was higher the 
smaller the particle size of the adjuvant aggregates was. Therefore, a ranking 
system was created rating a low increase in particle size as good and a higher 
increase as poor. Also considering that 90 % of the particles within aluminium 
hydroxide gel are smaller than 25.7 µm, within the created system, all particles 
being smaller than 25 µm were rated as ‘very good’. Particles between 25 and 
30 µm were ranked as ‘good’ and particles with a mean diameter between 30 
and 50 µm were ranked as ‘medium’ as the largest particle population that is 
existent within aluminium hydroxide gel has a size of 44 µm. Every formulation 
that contains particles with a mean diameter above 50 µm was rated with ‘poor’ 
as seen in Table 9 b). 
 Initially, formulations were frozen and thawed and then particle size was 
determined and summarised in Table 10. Comparing the results based on the 
evaluation of the particle size analysis of the samples that underwent a freeze-
thaw cycle and the results from the sedimentation assay, it can be concluded 
that for the majority of excipient better results are achieved when using a 
formulation containing 10 % of the respective protective agent. Exceptions 
regarding the mean diameter of the frozen and thawed samples are observed 
for the samples containing PVP K 17, PEG 3000 and HES 450/0.7. In these 
cases the mean particle diameter determined for the samples containing 10 % 
of the stabilising excipient was higher than the one determined for the samples 
containing 5 % of the stabilising excipient, in the case of HES 450/0.7 only 
marginally but still higher. 
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Table 10: Summary of the particle population between 10 % and 90 % of the 
formulations with different stabilising excipients at different concentrations after 
a freeze-thaw cycle (all containing 0.1 % polysorbate 80, 10 mg/ml aluminium 
hydroxide and PBS). MD = mean diameter. For comparison, the ranking further 
contains the results of the sedimentation assay of the freeze-dried samples 
(FD) and the frozen and thawed samples (FT). Results are derived from a 
particle distribution reported in volume %. 
    d10 
[µm] 
d50 
[µm] 
d90 
[µm] 
MD 
[µm] 
Ranking 
 MD  FD  FT 
Trehalose 20 % 7.21 48.67 110.67 55.57 - - ++ 
 15 % 10.39 32.40 70.03 37.50 Ø - + 
 10 % 14.13 39.57 98.00 49.10 Ø - Ø 
  5 % 16.63 46.20 114.00 57.17 - - - 
Mannitol 10 % 6.68 32.20 76.17 38.73 Ø - + 
 5 % 12.90 35.07 77.70 41.70 Ø - - 
Dextran 10 % 1.50 20.87 57.43 26.13 + ++ + 
  5 % 10.87 31.77 74.60 38.90 Ø Ø - 
HP-β-CD 10 % 12.80 36.03 88.97 44.67 Ø - Ø 
 5 % 23.33 72.00 154.67 81.60 - - - 
PVP K 12 10 % 2.43 25.73 84.10 35.70 Ø - ++ 
  5 % 15.77 42.17 93.60 53.73 - - - 
PVP K 17 10 % 9.26 56.40 138.33 67.87 - - + 
 5 % 17.43 47.67 101.93 54.57 - - - 
PVP K 25 10 % 1.53 32.50 93.63 43.83 Ø Ø ++ 
  5 % 18.33 49.80 104.53 56.43 - Ø - 
Arginine 10 % 1.11 18.33 47.13 21.03 ++ + + 
 5 % 11.80 44.50 113.67 54.83 - Ø Ø 
PEG 8000 10 % 2.08 34.80 84.43 40.33 Ø - Ø 
  5 % 16.60 47.00 97.73 52.87 - - Ø 
PEG 3000 10 % 6.24 52.07 124.33 60.53 - - Ø 
 5 % 15.10 42.77 95.73 50.33 - - - 
PEG 1000 10 % 4.66 31.30 63.77 33.63 Ø - + 
  5 % 15.70 44.63 102.10 53.10 - - - 
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    d10 
[µm] 
d50 
[µm] 
d90 
[µm] 
MD 
[µm] 
Ranking 
 MD  FD  FT 
HES 450/0.7 10 % 0.82 1.70 23.40 54.97 - Ø + 
 5 % 16.43 45.07 102.73 53.53 - Ø Ø 
HES 200/0.5 10 % 6.79 32.00 68.90 36.23 Ø Ø Ø 
  5 % 13.20 36.93 79.30 42.70 Ø + - 
Saccharose 10 % 2.34 28.73 86.57 41.27 Ø Ø ++ 
 5 % 14.77 42.50 107.00 53.10 - - + 
Glycine 10 % 6.49 28.97 81.00 37.90 Ø - ++ 
  5 % 9.65 31.23 75.10 38.47 Ø - + 
Sorbitol 10 % 1.48 7.74 62.60 23.03 ++ Ø ++ 
  5 % 8.72 28.87 70.77 35.53 Ø - Ø 
Continuation of Table 10. 
 Preceding sedimentation assays of the freeze-dried and freeze-thawed 
samples as well as particle size analysis of the freeze-thawed samples could 
demonstrate that a concentration of 10 % excipient could protect aluminium 
hydroxide better from coagulation/aggregation so in proceeding experiments 
this concentration was decided to be used. The 10 % formulations were 
lyophilised and Table 11 summarises the PSD measured for the different 
formulations. Except for the formulation containing 10 % trehalose, the mean 
particle diameter is never higher than the largest particle population (44 µm) 
found in aluminium hydroxide gel before freeze-drying. It is rather surprising that 
the mean particle diameter decreased compared to the samples that underwent 
a freeze-thaw cycle. This is contrastive to former results indicating that the 
aluminium adjuvant is less influenced by a freeze-thaw cycle than by freeze-
drying. In this case though, the particle diameter measured of the freeze-dried 
samples is closer to the one of pure aluminium hydroxide gel. 
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Table 11: Summary of the particle population between 10 % (d10) and 90 % 
(d90) of the different formulations at a concentration of 10 % of the respective 
stabilising excipient after reconstitution of the lyophilisate. Results are derived 
from a particle distribution reported in volume %. FD = freeze-drying. 
 
d10 
[µm] 
d50 
[µm] 
d90 
[µm] 
Mean 
diameter [µm] 
Number of 
maxima 
Trehalose (10 %) after FD 18.90 55.50 108.00 60.10 1 
Mannitol (10 %) after FD 4.20 12.20 26.80 14.00 1 
Dextran (10 %) after FD 4.40 10.70 26.60 13.40 1 
HP-β-CD (10 %) after FD 11.10 25.50 49.00 28.20 1 
PVP K 25 (10 %) after FD 0.99 2.58 41.40 12.90 1-2 
Arginine (10 %) after FD 4.05 14.60 32.60 16.50 1 
PEG 8000 (10 %) after FD 1.61 7.86 28.80 11.90 2 
HES 450 (10 %) after FD 3.19 5.95 22.60 9.93 3 
Saccharose (10 %) after 
FD 
9.61 23.30 44.20 25.30 1 
Glycine (10 %) after FD 2.67 5.47 19.60 8.75 3 
Sorbitol (10 %) after FD 8.94 23.10 43.50 25.00 1 
 However, the size distribution curves of most of the formulations have 
changed in so far as after freeze-drying there were monomodal curves with a 
maximum at higher particle sizes as the dominating maximum within the 
formulations before freeze-drying as exemplified in Figure 10 for formulations 
containing dextran and sorbitol. 
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Figure 10: Particle size distribution of the formulation containing 10 % dextran 
before lyophilisation (a) and after reconstitution of the lyophilisates (b), and 
10 % sorbitol before lyophilisation (c) and after reconstitution of the 
lyophilisates (d), three measurements each. Results are reported as volume %. 
 This displays that aggregation of the particles must have occurred to 
some degree since there were less small particles found in the freeze-dried 
samples and more large ones. But except for the 10 % trehalose formulation, 
none of the aggregates were larger than the largest ones that could be found 
within the samples before lyophilisation. That indicates that the extent of 
aggregation should not be a sign of destruction of the particles’ properties since 
aggregates of that size could be found – albeit a minor percentage – in the non-
freeze-dried formulations as well. Against this background, the shift of PSD from 
a multimodal curve distribution to a monomodal one has pharmaceutical 
advantages as well: 
 Aluminium hydroxide gel is a pharmaceutical suspension and ideally, the 
particles in a pharmaceutical suspension should not sediment. Therefore, it is 
desirable that particles settle slowly or the formulation should allow easy 
redispersion of sedimented particles in a suspension for the uniformity of dose 
(Voigt, 1993). According to the Stoke's equation the velocity of sedimentation of 
particles in a suspension is depending, inter alia, on the size of the particles 
(Bauer et al, 1993). Most lyophilised and resuspended samples show a 
monomodal PSD curve (compare Table 11: number of maxima) compared to 
samples before lyophilisation with multimodal PSD curves. Regarding 
Chapter 4 Results and discussion 
 
68
redispersion of the sedimented suspension this could be an advantage when 
comparing it to flocculated/deflocculated systems: in so called deflocculated 
systems, small particles sediment more slowly than the larger ones which in 
turn will form a close packed arrangement with the smaller particles filling the 
voids in between the larger ones. The lower particles are more and more 
compacted by the upper ones and eventually the energy barrier causing 
repulsion is overcome, the particles reach close proximity and this close packed 
deflocculated sediment eventually forms a solid hard cake that cannot be 
redispersed easily. A flocculated suspension with larger particles is more 
desirable than a deflocculated suspension because flocculated particles (loose 
aggregates) settle faster than the smaller deflocculated particles but in contrast 
to deflocculated particles this sediment does not form solid cakes but is loose 
and easy to redisperse by minor agitation (List, 1985). Regarding the 
mechanism of flocculation, it could be assumed that the absence of a 
multimodal PSD containing particles of various sizes, reconstituted freeze-dried 
suspensions can be considered advantageous in this respect as they comprise 
homogenous particles with favourable sedimentation and redispersion 
properties.  
 Adjuvanticity of mineral adjuvants is said to result - inter alia - from their 
ability to convert soluble antigens to particulate forms, which in turn facilitates 
antigen targeting, as for example preferential uptake by APCs (Lindblad, 2004). 
The particle size of commercially available aluminium adjuvant gels is supposed 
to be less than 10 µm, the average size for aluminium hydroxide, Alhydrogel® 
was 3.07µm (Gupta et al, 1995). But when discussing particle size distribution 
(PSD) of any suspension it is important to note that there are different ways of 
evaluating data gained with laser diffraction measurements resulting in different 
mean particle diameters and d10, d50 and d90 values. Samples can for example 
be reported as number %, volume %, relative volume and surface area %. 
Number % and volume % are the most common ways to do so and these 
methods often provide very different results as exemplified for the non-
lyophilised HES sample in Figure 12. The dissimilar results obtained for the 
same sample reported in three different manners are listed Table 12. 
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Figure 11: Particle size distribution measured with laser diffraction exemplarily 
represented by an untreated (and non-freeze-dried) sample containing 
Alhydrogel®, HES, abagovomab, polysorbate 80 and PBS. Top: reported as 
volume %; bottom: reported as surface area %. 
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Figure 12: Particle size distribution measured with laser diffraction exemplarily 
represented by an untreated (and non-freeze-dried) sample containing 
Alhydrogel®, HES, abagovomab, polysorbate 80 and PBS reported as 
number %. 
Table 12: Particle sizes obtained with the different particle size reporting 
methods exemplarily for particles in the formulation containing HES. 
Method of 
evaluation 
Mean 
[µm] 
Median 
[µm] 
d10 
[µm] 
d50 
[µm] 
d90 
[µm] 
Volume % 6.3 2.6 1.1 2.6 19.1 
Surface area % 2.2 1.7 0.8 1.7 3.6 
Number % 1.0 0.9 0.9 0.9 1.8 
 Number % size distribution curves report the percentage of the particle 
populations in different size categories whereas volume % size distribution 
curves report the percentage of the particle volume in different size categories. 
Therefore, within volume % size distribution curves, larger particles have the 
most volume displacement and the graph will be shifted towards larger sizes 
(Lobeiras, 2002).  
 Particle size data from the literature are frequently inconsistent and thus 
comparisons are impossible because of the different evaluation procedures 
(Lindblad, 2004; Clausi et al, 2008). The method of reporting PSD curves of 
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analysed aluminium hydroxide adjuvants is sometimes claimed as “%” 
(Lindblad, 2004) or surface area % (Clausi et al, 2008). Comparing the “%”-
reported results to PSD curves obtained within this work leads to the conclusion 
that number % was used as reporting method leading to a smaller mean particle 
diameter than when reported with volume %. Others have reported PSDs as 
surface area resulting in aluminium hydroxide particles reported with a median 
diameter of 1.01 ± 0.01 µm and a surface area weighted mean diameter of 2.25 
± 0.37 µm. Within this work the particle size is reported in volume % as changes 
at higher particle sizes are easier to detect this way. This explains why PSD 
reported in this study might differ from those found for aluminium hydroxide 
adjuvants reported in literature.  
 Moreover, PSD of aluminium hydroxide adjuvant is very sensitive to 
shearing and strongly dependent on the method used for its characterisation as 
well as on the way samples are treated before the measurements. Depending 
on the treatment of the suspension before particle size measurements, size 
distribution differs enormously. Therefore, it is necessary to treat the samples in 
a uniform manner before the measurements are conducted. 
4.1.4 Wide angle X-ray diffraction 
 An important criterion for the quality of the stabilisation by excipients is 
the amorphous character of the resulting lyophilisates. Within amorphous 
glasses that can result from the drying process, molecules are oriented rather 
randomly. This state is also referred to as the amorphous state. The water 
replacement theory states that these glass forming excipients have multiple 
external hydrogen bonds that are able to replace the essential structural water 
molecules that are hydrogen bonded to biomolecules like proteins and thus 
maintain their molecular structure (Willmann, 2003; compare section 2.1.4.3.1). 
This bonding is facilitated through the random orientation of the stabilising 
molecules. Crystallisation of the protective material would lead to loss of its 
protective action. During crystallisation, phase separation between the stabiliser 
and the material to be protected occurs and interactions between these two are 
broken. The process of phase separation itself can also destroy the material to 
be protected (Hinrichs and Frijlink, 2002). Freeze-dried amorphous insulin is far 
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more stable than crystalline insulin (Pikal and Rigsbee, 1997) and Izutsu et al 
(1995) found that only those amphiphilic excipients that remain amorphous in 
the solid state protected the enzyme LDH during freeze-drying. Accordingly, 
amorphous lyophilisates are preferred and crystalline lyophilisates are excluded 
from further investigation. Table 13 summarises the formulations that showed 
amorphous or crystalline X-ray diffraction patterns of the lyophilised samples. 
Table 13: Wide angle X-ray diffraction (WAXD) results of the lyophilisates of the 
chosen formulations. 
Formulation WAXD results   Formulation WAXD results 
Trehalose (15 %) amorphous  Arginine (10 %) crystalline 
Trehalose (20 %) amorphous  PEG 1000 (10 %) crystalline 
Mannitol (10 %) crystalline  PEG 3000 (10 %) crystalline 
Dextran (10 %) amorphous  PEG 8000 (10 %) crystalline 
HP-β-CD (10 %) amorphous  HES 200 (10 %) amorphous 
PVP 12 (10 %) amorphous  HES 450 (10 %) amorphous 
PVP 17 (10 %) amorphous  Saccharose (10 %) amorphous 
PVP 25 (10 %) amorphous  Glycine (10 %) crystalline 
Arginine (10 %) crystalline  Sorbitol (10 %) amorphous 
 As crystallisation of the protective material would lead to loss of its 
protective action, the formulations resulting in crystalline lyophilisates are less 
eligible than those resulting in amorphous lyophilisates. Therefore, the mannitol, 
arginine, glycine and PEG containing formulations are considered as less 
appropriate excipient candidates for successfully protecting vaccine 
formulations containing aluminium hydroxide adjuvant during lyophilisation.  
4.1.5 Optical microscopy 
 After the preliminary examinations, the favourable 10 % concentrated 
formulations were examined under the optical microscope. Untreated aluminium 
hydroxide adjuvant shows smooth and sandy texture without any perceptible 
particles (Figure 13 a). When aluminium hydroxide adjuvant was frozen on dry 
ice for 3h and reconstituted at room temperature (Figure 13b), large particles 
4.1 Formulation development 
 
73
were visible indicating that significant coagulation took place. The same large 
particles are visible after pure aluminium gel has been freeze-dried and 
reconstituted (Figure 13 c) portending that the adjuvant coagulates during this 
process as well. Exemplarily, optical micrographs of the 10 % trehalose 
containing formulation after freezing on dry ice (Figure 13 f), after lyophilisation 
and reconstitution with water (Figure 13 d) and the untreated sample (Figure 
13 e) are displayed. 
 All formulations show nearly the same optical micrographs: non-freeze-
dried formulations containing one of the protective excipients show the same 
smooth and sandy texture as pure aluminium hydroxide adjuvant does. Both 
after freezing on dry ice and after lyophilisation and subsequent reconstitution 
with water, the smooth and sandy structure found in untreated aluminium 
hydroxide adjuvant can be maintained. These observations suggest that given 
excipients at a concentration of 10 % are able to prevent aluminium hydroxide 
adjuvant from aggregating and circumvent coagulation. 
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Figure 13: (a) Optical micrograph of aluminium hydroxide adjuvant and (b) 
aluminium hydroxide adjuvant after freezing on dry ice and thawing at room 
temperature (freeze-thaw cycle). (c) Optical micrograph of reconstituted, 
lyophilised aluminium hydroxide adjuvant and (d) reconstituted, lyophilised 10 % 
trehalose formulation. (e) Optical micrographs of 10 % trehalose formulation 
and (f) 10 % trehalose formulation after freezing on dry ice and thawing at room 
temperature (freeze-thaw cycle). 
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4.1.6 Concluding discussion: formulation development 
 In preceding studies, mainly trehalose was used to stabilise aluminium 
adjuvants during lyophilisation, as well as dextran or combinations of 
disaccharides, amino acids and a colloidal substance (Clausi et al, 2008; Csizer 
et al, 1986; Kyosuke et al, 1989; Maa et al, 2003). For all freeze-dried 
formulations, significant coagulation remained visible in the optical micrographs 
implying that these former attempts to lyophilise aluminium hydroxide have not 
succeeded. This study could demonstrate that there are other excipient 
formulations promising to be able to stabilise aluminium adjuvanted vaccines 
during lyophilisation. Sedimentation assay and particle size analysis could show 
that not all chosen excipients were able to maintain characteristics of aluminium 
hydroxide adjuvant. Still, many yielded promising results. It could be 
demonstrated that 5 % (w/V) excipient were generally not able to maintain the 
adjuvants characteristics sufficiently whereas many of the analysed 
formulations containing 10 % excipient yielded good to very good results within 
the created ranking system. In every case except HES 200, better results were 
obtained for the 10 % formulations than for the 5 % ones. Based on these 
results, 10 % formulations were further analysed regarding the excipients’ ability 
to protect the adjuvant and its characteristics while being exposed to freezing 
stresses. Wide angle X-ray diffractograms of the resulting lyophilisates 
generated knowledge of their amorphous character leading to the exclusion of 
those samples with crystalline character (mannitol, arginine, PEG, and glycine) 
as the amorphous state is preferred. Finally, optical micrographs could depict 
that the chosen formulations maintained the texture of aluminium hydroxide 
adjuvant before exposure to coldness stresses. 
 Based on given results, the formulations containing the protective 
excipients trehalose at a concentration of 15 or 20 % as well as dextran, PVP K 
25, HES 450 and 200, saccharose and sorbitol at a concentration of 10 % 
promise to be good candidates for the protection of aluminium adjuvanted 
vaccines during the process of freezing or lyophilisation. Not only do they have 
properties to protect a given protein within the vaccine from lyophilisation 
stresses, but also do the results gained from X-ray diffraction patterns, 
sedimentation assay, optical microscopy and particle size analysis conducted 
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within this study reveal auspicious results for the protection of aluminium 
hydroxide adjuvant within a vaccine formulation during freezing and the process 
of lyophilisation. 
4.2 Stability testings 
 Previous work of chapter 4.1 could show that adjuvant formulations 
containing trehalose at a concentration of 15 or 20 %, as well as a 10 % 
concentrated formulation of dextran, PVP K 25, HES 450 and 200, saccharose 
and sorbitol promise to be well-protective for aluminium adjuvanted vaccines 
during the process of freezing or lyophilisation. Based on these results, a sterile 
stability batch was prepared with abagovomab as a vaccine antigen utilising the 
most promising protective excipients of the preceding studies. For the stability 
testings, HES 450 was used and HES 200 was omitted. Samples were stored 
and stress tested (compare section 3.2.1.1.2). 
4.2.1 Sedimentation assay 
 Sedimentation data shown in Figure 14 - Figure 16 demonstrate that time 
and temperature had an influence on the volume of the gel column within the 
stress tested samples. As expected, the volume of the gel columns tendentially 
decreased the higher the storage temperature was.  
 
Figure 14: Sedimentation assay of lyophilised samples containing 15 % 
trehalose. Left after 3 months and right after 6 months relative to a freshly 
prepared sample (= time point 0, fresh control):  5°C,  25°C,  30°C and 
 40°C. 
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a) 
 
b) 
 
c)  
 
d)
 
Figure 15: Sedimentation assay of lyophilised samples containing: a) 10 % 
dextran, b) 10% HES, c) 10% PVP and d) 10% saccharose. Left after 3 months 
and right after 6 months relative to a freshly prepared sample (= time point 0, 
fresh control):  5°C,  25°C,  30°C and  40°C. 
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Figure 16: Sedimentation assay of lyophilised samples containing 10 % 
sorbitol. Left after 3 months and right after 6 months relative to a freshly 
prepared sample (= time point 0, fresh control):  5°C,  25°C,  30°C and 
 40°C. 
 Except for the HES (Figure 15 b) and sorbitol (Figure 16) samples, the 
gel columns of the samples stored at 5°C were noticeably higher than those of 
samples stored at aggravated conditions. Time did not influence the volume of 
the gel columns as much as storage temperature did. For example, the volume 
of the gel columns within the 3 months (M) samples containing trehalose 
(Figure 14) started decreasing after 10 min. After 24 h the samples stored at 
5°C had lost gel column volume down to 55.8 % whereas the samples stored at 
40°C showed a decrease in gel column volume down to 44.2 %. The samples 
stored for 6 months showed similar behaviour concerning temperature influence 
(a considerable decrease with elevated temperature) but no obvious tendency 
to decrease due to a longer storage period. Samples containing saccharose 
(Figure 15 d) or sorbitol also achieved dissatisfactory results with a decrease of 
gel column volume down to 12.5 % (3 M, 25°C) after 24 h for the saccharose 
samples and 20.0 % after 24 h (6 M, 40°C) for the sorbitol samples. Better/good 
results were achieved for the samples containing dextran (Figure 15 a), PVP 
(Figure 15 c) or HES. Samples containing dextran did not sediment within the 
first hour and after 3 h, volume of the gel columns of all samples decreased no 
more than 4 %. After 24 h the lowest column had a volume of 67.3 % of fresh 
control. PVP containing samples did not sediment for the first ten minutes and 
not more than 5.0 % within the first 30 min. After 24 h, the samples stored at 
5°C had a volume of 75.0 % after 3 months as well as after 6 months whereas 
the samples stored at 40°C showed a lower sedimentation level with a volume 
of 55.8 %, also for both samples, stored for 3 and for 6 months. None of the 
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samples containing HES decreased for the first 3 h and after 24 h the samples 
stored at 5°C surprisingly showed the lowest gel column with 84.2 % for the 
samples tested after 3 months and 70.0 % for the samples tested after 
6 months. Samples stored at higher temperatures yielded gel columns of 
89.5 % relative to their respective fresh control and higher; the highest with 
96.5 % after 6 months storage at 25°C. These results indicate that HES, 
dextran and to a less extent PVP and trehalose are most adequate for 
protecting aluminium hydroxide adjuvant within vaccine formulations against 
changes in its sedimentation character during lyophilisation. 
4.2.2 Particle size analysis 
Table 14 displays the results of the particle size measurements of the samples 
at time point zero before freeze-drying, after reconstitution of the lyophilisates 
with water and freeze-dried stress tested samples stored at different 
temperatures after three and six months, respectively. 
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Table 14: Results of particle size measurements of the stability study samples. 
Results are derived from a particle distribution reported in volume %. 
M = months, FD = freeze-dried and reconstituted, non-FD = non-freeze-dried. 
 d10  
[µm] 
d50  
[µm] 
d90  
[µm] 
Mean diameter 
[µm] 
Trehalose 15 %     
0 M non-FD 1.5 3.3 7.4 6.2 
0 M FD 13.9 40.6 96.3 49.1 
3 M 5°C FD 13.4 35.8 77.0 41.7 
3 M 25°C FD 14.2 37.3 83.9 44.5 
3 M 30°C FD 12.9 38.5 83.9 44.4 
3 M 40°C FD 10.5 31.5 67.9 36.5 
6 M 5°C FD 13.7 37.3 79.6 43.0 
6 M 25°C FD 11.1 35.1 76.4 40.7 
6 M 30°C FD 10.7 34.0 72.5 38.8 
6 M 40°C FD 14.2 41.4 92.0 48.4 
Dextran 10 %     
0 M non-FD 1.3 2.9 19.9 7.1 
0 M FD 2.2 6.5 28.3 13.1 
3 M 5°C FD 2.7 14.2 35.3 17.3 
3 M 25°C FD 4.3 17.2 40.1 21.1 
3 M 30°C FD 2.1 5.7 23.8 10.8 
3 M 40°C FD 9.9 25.4 52.6 29.6 
6 M 5°C FD 3.5 17.1 43.5 20.9 
6 M 25°C FD 2.1 13.0 34.6 17.1 
6 M 30°C FD 3.6 15.2 35.9 18.0 
6 M 40°C FD 4.9 16.8 40.1 20.1 
HES 10 %     
0 M non-FD 1.1 2.5 19.1 6.3 
0 M FD 6.5 17.7 38.2 20.9 
3 M 5°C FD 8.0 20.9 44.9 24.9 
3 M 25°C FD 9.9 24.7 52.3 29.1 
3 M 30°C FD 3.6 15.8 35.5 18.9 
3 M 40°C FD 9.0 23.2 49.8 27.4 
6 M 5°C FD 11.2 30.1 63.3 35.1 
6 M 25°C FD 9.8 27.6 61.8 32.9 
6 M 30°C FD 9.5 26.7 59.4 31.7 
6 M 40°C FD 11.4 35.5 80.5 42.0 
PVP 10 %     
0 M non-FD 1.5 3.3 24.5 8.5 
0 M FD 1.9 4.8 24.6 10.0 
3 M 5°C FD 2.2 6.9 29.1 13.2 
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 d10  
[µm] 
d50  
[µm] 
d90  
[µm] 
Mean diameter 
[µm] 
3 M 25°C FD 2.3 7.2 27.6 13.2 
3 M 30°C FD 2.1 6.4 25.7 11.8 
3 M 40°C FD 2.0 15.6 36.2 17.7 
6 M 5°C FD 1.1 3.3 35.7 11.9 
6 M 25°C FD 1.6 16.3 41.8 19.6 
6 M 30°C FD 1.4 13.2 35.3 16.5 
6 M 40°C FD 1.6 12.5 32.3 15.2 
Saccharose 10 %     
0 M non-FD 1.7 4.1 36.8 12.2 
0 M FD 10.4 27.3 55.6 31.3 
3 M 5°C FD 9.9 26.4 53.7 29.5 
3 M 25°C FD 9.2 23.8 48.0 27.3 
3 M 30°C FD 11.1 34.7 75.6 40.3 
3 M 40°C FD 12.4 36.7 90.4 45.3 
6 M 5°C FD 8.7 25.3 54.8 29.6 
6 M 25°C FD 8.6 23.9 49.1 27.3 
6 M 30°C FD 1.5 15.5 45.9 20.3 
6 M 40°C FD 12.7 50.6 134.0 70.2 
Sorbitol 10 %     
0 M non-FD 1.1 2.5 6.8 4.9 
0 M FD 10.6 26.0 50.2 29.2 
3 M 5°C FD 11.6 27.9 54.2 31.3 
3 M 25°C FD 11.0 28.2 56.4 32.0 
3 M 30°C FD 10.4 28.2 61.4 33.3 
3 M 40°C FD 4.3 16.1 36.0 18.7 
6 M 5°C FD 12.7 36.7 74.4 41.1 
6 M 25°C FD 11.1 35.1 76.4 40.7 
6 M 30°C FD 10.8 33.3 69.5 37.7 
6 M 40°C FD 8.7 34.2 112.0 49.1 
     
Continuation of Table 14 
 The samples containing trehalose reveal a slight decrease in mean 
particle diameter over the time at different storage temperatures in comparison 
to the 0 M value for the FD formulation. The mean diameter of samples 
containing dextran showed a tendency to increase compared to 0 M FD values 
except for the 3 M 30°C value which showed a surprising decrease in mean 
particle diameter from 13.1 µm for the 0 M FD value to 10.8 µm for the 3 M 
30°C value. Samples containing PVP and sorbitol showed a similar behaviour: 
the particles’ mean diameter revealed a tendency to increase with some 
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irregularities. For example the 3 M 40°C value for the sorbitol samples 
decreased from a mean particle diameter of 29.2 µm for the 0 M FD value to 
18.7 µm for the regarded sample (compare Table 14). HES samples showed a 
tendency of the particles’ diameter to increase with increasing time and 
temperature compared to the 0 M FD samples with the exception of the 3 M 
30°C value. No obvious tendency could be observed for the saccharose 
samples. The mean particle diameter was lower than or close to the 0 M FD 
samples for the 3 M 5 and 25°C samples as well as for the 6 M 5, 25 and 30°C 
whereas there was an increase in mean particle diameter detectable compared 
to the initial 0 M FD for the 3 M 30 and 40°C samples and even clearer for the 
6 M 40°C samples. Altogether, compared with the results obtained by the 
sedimentation assay, these results are rather surprising as a decrease in the 
volume of the gel column that can be observed with increasing time and 
temperature for most of the samples would lead to the conclusion that particle 
diameter had increased over the storage period which in turn would result in a 
quicker sedimentation.  
 However, mean diameter of the particles has never reached more than 
50 µm except once for the 6 months, 40°C sample containing saccharose with a 
mean particle diameter of 70.2 µm. Storage thus has caused the adjuvant 
particles to aggregate to some extent. But PSD curves of particles within non-
freeze-dried formulations have three to four maxima with the population of 
maximum particle diameter around 50 µm (dextran, HES, sorbitol) and 80 µm 
(saccharose, see Figure 17) depending on the formulation. 
 Therefore, none of the particles within the stressed samples were larger 
than the largest aggregates found within the initial formulations (see Figure 9). 
Even untreated formulations contained particle aggregates of that size 
indicating that presence of particles of that size does not necessarily have to be 
a sign of destruction of the adjuvants’ physico-chemical character by an 
increase in particle diameter. 
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Figure 17: Particle size distribution measured with PIDS expressed in 
volume % of the six formulations before freeze-drying.  
 Compared to the results obtained within the first batch for freeze-dried 
vaccine formulations containing only Alhydrogel®, stabilising excipients, 
polysorbate 80 and buffer (and no abagovomab/antigen), it is noticeable that for 
abagovomab containing samples analysed within this study except the ones 
prepared with HES as protective excipient, particles after lyophilisation have a 
smaller mean diameter. This is probably due to abagovomab being present 
within these samples. To understand why abagovomab as a protein is 
potentially accountable for protecting the aluminium hydroxide adjuvant during 
freeze-drying, it is important to recall how freezing influences the adjuvant 
particles: initially, it was hypothesised that solutes form freeze concentrates as 
water crystallises during freezing pushing adjuvant particles together so close 
that they overcome repulsive forces and exhibit attractive forces (Zapata et al, 
1984; Maa et al, 2003; compare section 2.3.4.2). Clausi et al (2008) claim that 
not only physical proximity causes the adjuvant particles to aggregate but rather 
charge-charge interactions on the adjuvants’ surface due to freeze-
concentration-induced phase changes and ion exchange reactions on the 
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particle surface. Abagovomab as a protein is a polymer and thus can exhibit a 
variety of properties potentially protecting the adjuvant from detrimental 
processes (compare section 2.1.4.4.2). Thus, these properties of abagovomab 
as a protein/polymer probably contributed to the protection of the adjuvant and 
caused the particle size to increase less during lyophilisation than when freeze-
dried without abagovomab. Adsorption of abagovomab to the adjuvant’s surface 
probably hindered the particles sterically from close proximity preventing 
aggregation to some extent. It is assumed that it also shielded the particles from 
charge depending interactions that are supposed to be responsible for 
aggregation. 
4.2.3 Wide angle X-ray diffraction 
 The X-ray diffraction patterns of the six formulations stored for 3 and 6 
months at different conditions are shown in Figure 18 - Figure 23. For all 
formulations, the patterns of the samples stored at 5°C resemble patterns for 
initial samples (data not shown) and except the sorbitol sample the typical ‘halo’ 
pattern can be seen, demonstrating that the lyophilisates are amorphous initially 
or after storage at 5°C, respectively.  
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Figure 18: The X-ray diffraction patterns of the formulation containing 15 % 
trehalose stored for 3 months (top) and 6 months (bottom) at temperatures 
between 5°C and 40°C. M = months. 
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Figure 19: The X-ray diffraction patterns of the formulation containing 10 % 
dextran stored for 3 months (top) and 6 months (bottom) at temperatures 
between 5°C and 40°C. M = months. 
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Figure 20: The X-ray diffraction patterns of the formulation containing 10 % 
HES stored for 3 months (top) and 6 months (bottom) at temperatures between 
5°C and 40°C. M = months. 
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Figure 21: The X-ray diffraction patterns of the formulation containing 10 % 
PVP stored for 3 months (top) and 6 months (bottom) at temperatures between 
5°C and 40°C. M = months. 
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Figure 22: The X-ray diffraction patterns of the formulation containing 10 % 
saccharose stored for 3 months (top) and 6 months (bottom) at temperatures 
between 5°C and 40°C. M = months. 
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Figure 23: The X-ray diffraction patterns of the formulation containing 10 % 
sorbitol stored for 3 months (top) and 6 months (bottom) at temperatures 
between 5°C and 40°C. M = months. 
 The X-ray diffraction patterns of freeze-dried solids containing sorbitol 
(Figure 23) showed an increased level of crystallinity but not as crystalline as 
pure sorbitol (data not shown) indicating that the mixture with the other 
formulation components and freeze-drying influenced the degree of crystallinity 
of sorbitol. Lyophilised samples containing dextran (Figure 19) showed close to 
no increase in crystallinity over time and aggravated storage conditions. X-ray 
diffraction patterns of PVP samples (Figure 21) and to a less extent the HES 
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samples (Figure 20) reveal that over the time with increasing temperature one 
peak appears and increases in intensity at 31°2θ. Compared to diffraction 
patterns of salts contained within PBS (compare Figure 24) this was probably a 
buffer salt that recrystallised under aggravated temperature conditions.  
 
 
Figure 24: The X-ray diffraction patterns of salts contained within PBS. Top: 
KCl (left) and NaCl (right). Bottom: KH2PO4 (left) and Na2HPO4 (right). 
 X-ray patterns of the trehalose samples (Figure 18) show that after three 
months storage, samples recrystallised when stored at 40°C. After six months 
storage, recrystallisation of the lyophilisates was even enhanced at 40°C. 
Saccharose samples (Figure 22) also show recrystallisation after 3 months 
when stored at 30° and 40°C. When stored for 6 months, even the samples 
stored at 25°C show increasing levels of crystallinity. Although it is possible to 
change crystalline character of formulations by variations in formulation or 
lyophilisation cycle parameters, this study intends to evaluate the quality of 
these formulations freeze-dried under given circumstances. Therefore, 
formulations containing trehalose or saccharose that recrystallised to a great 
extent after six months storage at aggravated temperature conditions are rated 
detrimental as crystallisation of the protective material leads to a loss in its 
protective action. The same applies to sorbitol samples as they revealed an 
increased level of crystallinity slightly increasing with time and temperature over 
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the storage period. Higher residual moisture content in the samples compared 
to each other did not correlate with a higher degree of recrystallisation. For 
example the dextran formulation contained 3.72 % residual moisture after 
lyophilisation but did not recrystallise during stress testing whereas for example 
the PVP samples contained less water (2.09 %) after lyophilisation and showed 
a higher degree of crystallinity with increased temperature over the time 
(compare Table 15).  
Table 15: Residual moisture of the different freeze-dried samples after 
lyophilisation. 
Trehalose 
15 % 
Dextran 
10 % 
HES    
10 % 
PVP    
10 % 
Saccha-
rose 10 % 
Sorbitol    
10 % 
1.76 % 3.72 % 1.53 % 2.09 % 3.05 % 2.95 % 
4.2.4 Sodium dodecylsulfate polyacrylamide gel electrophoresis 
 Figure 25 depicts results of SDS-PAGE analysis of the initial samples 
and the results obtained from the samples of the stability tests after 3 and 6 
months storage at 5°C and 40°C, respectively. SDS-PAGE of the initial samples 
before lyophilisation and after reconstitution of the lyophilisates immediately 
after production of the samples revealed the same general pattern indicating 
that no detectable degradation products have formed during lyophilisation. Also, 
storage for up to 6 months at 40°C did not generate additional bands as could 
be detected for unprotected drug substance stored for 3 months at 30°C or 
40°C, respectively (Figure 26, gel b, lane 3 and 4).  
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Figure 25: SDS-PAGE gels of the stability samples that were silver stained 
using a PlusOne Silver Staining Kit (GE Healthcare, UK). Gels are 
representative for 3 replicates. Lane occupancy is listed in Table 16.  
 It can be concluded that no detectable degradation of abagovomab 
occurred during storage of the samples because no bands at higher molecular 
weight appeared for lyophilised samples stored up to 6 months at 40°C. Again, 
this is an improvement compared to unprotected samples that revealed 
additional bands when stored for three months at temperatures up to 40°C. 
There were no clear bands visible for samples containing PVP. This is probably 
due to a reaction of the PVP during electrophoresis hindering the protein from 
migrating. Therefore, no PVP sample was applied to the polyacrylamide gels 
when the six months samples were tested but rather a detection limit marker 
containing 0.1 mg/ml abagovomab (compare Figure 25, 6 M gels and Figure 26 
a). Evaluation of these gels could show that degradation products of such low 
concentration were still detectable with this method. 
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Table 16: Lane occupancy of SDS-PAGE gels depicted in Figure 25 and  
Figure 26. M = months, DS = drug substance, aba = abagovomab.  
Gel Lane Sample 
1 DS as reference 
2 15 % Trehalose formulation 
 
3 10 % Dextran formulation 
4 10 % PVP formulation  
5 10 % HES formulation 
6 10 % Saccharose formulation 
Gels of 0 M and 
3 M samples 
7 10 % Sorbitol formulation 
1 DS as reference 
2 15 % Trehalose formulation 
3 10 % Dextran formulation 
4 10 % HES formulation 
5 10 % Saccharose formulation 
6 10 % Sorbitol formulation 
Gels of 6 M 
samples 
7 Detection limit marker (0.1 mg/ml aba) 
1 DS as reference 
2 DS 3 M 40° + 15 % Trehalose 
3 DS 3 M 40° + 10 % Saccharose 
4 DS 3 M 40°  
5 DS 6 M 40° + 10 % Saccharose 
6 DS 6 M 40° 
a 
7 Detection limit marker (0.1 mg/ml aba) 
b 
1 
2 
3 
4 
DS 3 M 5°C 
DS 3 M 25°C 
DS 3 M 30°C 
DS 3 M 40°C 
   
4.2 Stability testings 
 
95
 
Figure 26: SDS-PAGE gels of the stability samples stained with silver staining. 
(a) SDS-PAGE analysing the influence of two exemplary sugars on the visibility 
of bands, (b) SDS-PAGE analysis of pure abagovomab drug substance after 
three months storage at different temperatures. Gels are representative for 
three replicates. Lane occupancy is listed in Table 16.  Bands for 
abagovomab degradation products;  common bands for non-degraded 
abagovomab. 
 To test if sugars/protective excipients added to the formulation might 
disturb visualisation of the lower concentrated degradation products, the 
respective amounts of excipients (as contained within the formulations) were 
added to unprotected abagovomab drug substance that was stored for three 
and six months at 40°C and analysed with SDS-PAGE. As exemplarily depicted 
in Figure 26, gel a for trehalose and saccharose added, samples with sugars 
added after storage (lanes 2, 3 and 5) revealed the same band for degradation 
products as samples without an additive (lanes 4 and 6). This proves that the 
added excipients (apart from PVP) did not disturb visualisation of additional 
lower concentrated degradation products in SDS-PAGE analysis. 
4.2.5 Enzyme-linked immunosorbent assay 
 Quantification of abagovomab within initial samples (0 M non-FD and 0 M 
FD) and samples that underwent the stability testing revealed no explicit 
changes of abagovomab concentration (estimated from sample potency data 
after a standard curve was generated) after freeze-drying or storage of the 
samples over six months at temperatures up to 40°C compared to samples 
before lyophilisation. Results are summarised in  
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Table 17. These results are consistent with those obtained by SDS-PAGE 
demonstrating that abagovomab remains stable throughout lyophilisation and 
ensuing stability testings. 
Table 17: Quantification of abagovomab (ABA) within initial samples (freeze-
dried and after reconstitution of the lyophilisates) and within stability tested 
samples that were lyophilised and reconstituted with water using ELISA. 
M = months, FD = freeze-dried and reconstituted with water, non-FD = non-
freeze-dried. 
Sample ABA 
[mg/ml] 
 Sample ABA 
[mg/ml] 
 Sample ABA 
[mg/ml] 
Trehalose   Dextran    HES  
0 M non-FD 2.02  0 M non-FD 2.08  0 M non-FD 2.07 
0 M FD 2.03  0 M FD 2.01  0 M FD 2.03 
3 M 5°C FD 2.01  3 M 5°C FD 1.98  3 M 5°C FD 2.04 
3 M 25°C FD 2.02  3 M 25°C FD 1.99  3 M 25°C FD 2.01 
3 M 30°C FD 2.01  3 M 30°C FD 2.01  3 M 30°C FD 1.98 
3 M 40°C FD 2.04  3 M 40°C FD 2.00  3 M 40°C FD 2.01 
6 M 5°C FD 2.04  6 M 58°C FD 1.99  6 M 5°C FD 1.99 
6 M 25°C FD 2.01  6 M 25°C FD 2.01  6 M 25°C FD 1.97 
6 M 30°C FD 2.03  6 M 30°C FD 2.00  6 M 30°C FD 1.96 
6 M 40°C FD 1.97  6 M 40°C FD 1.98  6 M 40°C FD 1.99 
PVP   Saccharose   Sorbitol  
0 M non-FD 2.06  0 M non-FD 2.03  0 M non-FD 1.98 
0 M FD 2.01  0 M FD 2.02  0 M FD 1.95 
3 M 5°C FD 2.01  3 M 5°C FD 2.01  3 M 5°C FD 1.99 
3 M 25°C FD 2.00  3 M 25°C FD 1.98  3 M 25°C FD 2.00 
3 M 30°C FD 1.98  3 M 30°C FD 2.01  3 M 30°C FD 2.01 
3 M 40°C FD 2.01  3 M 40°C FD 1.97  3 M 40°C FD 2.00 
6 M 5°C FD 1.98  6 M 58°C FD 2.01  6 M 5°C FD 1.97 
6 M 25°C FD 1.94  6 M 25°C FD 1.98  6 M 25°C FD 1.98 
6 M 30°C FD 1.98  6 M 30°C FD 1.97  6 M 30°C FD 1.99 
6 M 40°C FD 1.96  6 M 40°C FD 2.01  6 M 40°C FD 1.97 
        
4.2.6 Adsorption studies 
 The Langmuir equation is a mathematical description of adsorption that 
can be used to determine adsorption capacity (amount of protein adsorbed at 
monolayer coverage) and the adsorption coefficient (measure of affinity of the 
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protein towards the surface) of protein/adsorbent systems (Iyer et al, 2004). If a 
straight line is obtained when adsorption isotherms are plotted according to the 
linear form of the Langmuir equation (data not shown), it can be assumed that 
adsorption isotherms are described by the Langmuir equation.  
Table 18: Effect of lyophilisation on the adsorption of abagovomab to aluminium 
hydroxide adjuvant: adsorption capacities and coefficients of determination (R2) 
of the linear form of the Langmuir equation obtained for initial samples and 
samples after lyophilisation. M = months, FD = freeze-dried and reconstituted, 
non-FD = non-freeze-dried. 
Sample Adsorption 
capacity 
[mg/mg Al3+] 
R2  Sample Adsorption 
capacity 
[mg/mg Al3+] 
R2 
Trehalose     Dextran    
0 M non-FD 1.33 >0.99  0 M non-FD 1.38 >0.99 
0 M FD 1.04 >0.99  0 M FD 1.32 >0.99 
HES    PVP   
0 M non-FD 1.35 >0.99  0 M non-FD 1.37 >0.99 
0 M FD 1.25 >0.99  0 M FD 1.20 >0.99 
Saccharose    Sorbitol   
0 M non-FD 1.44 >0.99  0 M non-FD 1.29 >0.99 
0 M FD 0.98 >0.99  0 M FD 1.08 >0.99 
 
 Adsorption capacities and coefficients of determination of the isotherms 
plotted according to the linear Langmuir equation are given in Table 18. The 
results demonstrate that adsorption of abagovomab to the aluminium hydroxide 
adjuvant followed the Langmuir equation as could be confirmed by a coefficient 
of determination (R2) value of >0.99 for the linear form of the Langmuir equation 
for samples before lyophilisation and after reconstitution of freeze-dried 
samples. Adsorption capacities of different systems (aluminium hydroxide, 
abagovomab and different additives) were determined from the plateau of the 
isotherms as proposed in the literature (see Figure 27; Al-Shakhshir et al, 
1995).  
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Figure 27: Effect of freeze-drying on the adsorption isotherms of abagovomab 
adsorbed to aluminium hydroxide adjuvant. Top: before lyophilisation, bottom: 
after lyophilisation. Formulations containing: (■) 15 % trehalose, (▲) 10 % 
dextran, (●) 10 % HES, (□) 10 % PVP, (Δ) 10 % saccharose, (○) 10 % sorbitol; 
n = 3; mean ± SD. 
 Figure 27 depicts that adsorption of abagovomab to the aluminium 
hydroxide adjuvant depends on the excipient added. Adsorption of proteins to 
adjuvants generally depends on numerous factors such as pH, ionic strength, 
salt concentration etc. of the solution. Addition of different polymers/sugars 
alters the conditions within the sample suspensions. Even though pH was 
adjusted, other changes of the samples’ characteristics due to the addition of 
the different excipients were certainly somewhat attributed to the protective 
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excipient added. When lyophilised, adsorption capacity of the individual 
samples tendentially decreased. Saccharose samples prior to lyophilisation 
showed a comparatively high adsorption capacity for abagovomab adsorbed by 
the adjuvant of 1.44 mg/mg Al3+ that decreased down to 0.98 mg/mg Al3+ after 
lyophilisation. Adsorption capacity within the trehalose formulations decreased 
from 1.33 down to 1.04 mg/mg Al3+ and within the sorbitol formulations from 
1.29 down to 1.08 mg/mg Al3+. Adsorption capacity within the dextran 
formulations decreased only by 0.06 mg/mg Al3+ from 1.38 to 1.32 mg/mg Al3+, 
in the HES formulations from 1.35 to 1.25 mg/mg Al3+ and within the PVP 
formulations from 1.37 Al3+ to 1.20 mg/mg Al3+. Samples containing the 
stabilising excipients dextran, HES and PVP revealed slightly higher adsorptive 
capacities than those containing trehalose, saccharose and sorbitol. This 
indicates that former excipients could better protect the adjuvants adsorption 
capacity for abagovomab during lyophilisation than the other three did. 
4.2.7 Concluding discussion: stability testings 
 Results obtained by the present stability study demonstrated that all 
excipients successfully inhibited abagovomab from denaturation or loss in 
potency to the extent that could be analysed with methods applied so far within 
this study (SDS-PAGE and ELISA). Dextran, HES and to a less extent PVP 
were most effectively protecting the adjuvant from lyophilisation stresses as 
physico-chemical characteristics of the adjuvant analysed during the stress 
testing could be best maintained. 
4.3 Methods first-time used for the characterisation of lyophilised 
aluminium adjuvanted vaccine formulations 
 Dextran, HES and to a less extent PVP formulations yielded good 
stability results so that these promising formulations were used to further 
implement methods used to characterise freeze-dried aluminium hydroxide 
adjuvanted vaccines: fluorescence microscopy and adsorption isotherms 
characterising adsorption behaviour of the antigen to the adjuvant. Also, it was 
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analysed if adsorption studies are applicable for the revelation of changes in 
formulation characteristics throughout a stability study. 
4.3.1 Adsorption studies 
 Results obtained for adsorption isotherms of stability tested samples after 
three months are summarised in Table 19 (for results at time point zero 
compare Table 18). The samples containing PVP stored at 40°C achieved a 
coefficient of determination (R2) of >0.98 when plotted according to the linear 
form of the Langmuir equation but this can still be regarded as sufficiently 
demonstrating the validity of the Langmuir equation for these samples.  
Table 19: Effect of storage over three months at elevated temperatures on the 
adsorption of abagovomab adsorbed to aluminium hydroxide: adsorption 
capacities and coefficients of determination (R2) for the linear form of the 
Langmuir equation. M = months, FD = freeze-dried and reconstituted. 
Adsorption 
solution 
Adsorption 
capacity 
[mg/mg Al3+] 
R2  Adsorption 
solution 
Adsorption 
capacity 
[mg/mg Al3+] 
R2  
Dextran    HES   
3 M 5°C FD 1.33 >0.99  3 M 5°C FD 1.24 >0.99 
3 M 25°C FD 1.32 >0.99  3 M 25°C FD 1.25 >0.99 
3 M 30°C FD 1.30 >0.99  3 M 30°C FD 1.22 >0.99 
3 M 40°C FD 1.31 >0.99  3 M 40°C FD 1.22 >0.99 
PVP   
3 M 5°C FD 1.19 >0.99 
3 M 25°C FD 1.20 >0.99 
3 M 30°C FD 1.16 >0.99 
3 M 40°C FD 1.13 >0.98 
 
 The data show that adsorption capacity decreased marginally when 
dextran/HES samples were stored for three months up to 40°C. PVP containing 
samples reveal a greater decrease in adsorption capacity when exposed to 
higher storage temperature with an adsorption capacity of only 1.13 mg/mg Al3+ 
after three months storage at 40°C. This is consistent with data obtained by 
sedimentation assay. Adjuvant particles within PVP samples were sedimenting 
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faster over the time when stored at higher temperatures compared to samples 
containing dextran or HES. This faster sedimentation of the particles indicates 
that PVP was not as efficient in protecting the adjuvant from detrimental 
modification as the other two excipients were. Results obtained by WAXD 
analysis might explain why the adjuvant particles that were protected with PVP 
were influenced more negatively during stress testings than those protected by 
the other excipients: when storage temperature increases, the X-ray diffraction 
patterns of the PVP containing samples showed an increasing peak at 31°2θ 
implying recrystallisation of the PBS buffer salts. This might cause a loss in 
protective action of the excipients. Recrystallisation of the buffer salts exerts 
additional interfacial tension and shear on the adjuvant on the one hand and on 
the other can lead to a pH shift due to selective crystallisation of a buffer 
component (for example disodium phosphate prior to monosodium phosphate, 
Chang et al, 1996) and thus might cause enhanced aggregation of the adjuvant.  
4.3.2 Nile Red fluorescence microscopy 
 This staining technique is especially beneficial for the characterisation of 
differences between freeze-dried and non-freeze-dried vaccine formulations 
containing aluminium hydroxide adjuvant. The adjuvant has a sandy texture 
providing a background in brightfield microscopy that makes it impossible to 
differentiate protein aggregates when the samples are observed visually. 
Comparing the brightfield micrograph depicted in Figure 28 with the same 
image detail of the same sample obtained with fluorescence microscopy after 
staining with Nile Red (Figure 29, top), it can be demonstrated that visualisation 
of the abagovomab aggregates with Nile Red under the fluorescence 
microscope is much more efficient in comparison to brightfield microscopy. 
Aggregates seen in Figure 29, top (see arrows) for samples before 
lyophilisation at time point zero detected with fluorescence microscopy cannot 
at all be detected within the brightfield micrograph.  
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Figure 28: Brightfield microscopy exemplified with pictures obtained with PVP 
formulations before lyophilisation after Nile Red staining at time point zero. The 
picture was taken immediately after fluorescence microscopy.  
 To ensure that the dye itself does not promote or inhibit aggregation or 
fibrillation when it interacts with the abagovomab molecules, Nile Red was 
added to an abagovomab drug substance sample (without the adjuvant) that 
was placed under a brightfield microscope. Presence of approximately 1 µM 
Nile Red and approximately 1 % ethanol did neither induce immediate 
aggregation nor did it modify size or shape of any existing aggregates (data not 
shown). ELISA performed with samples containing corresponding amounts of 
Nile Red and ethanol showed that abagovomab did not loose potency through 
the addition of the dye dissolved in ethanol. Table 20 summarises the number 
of aggregates calculated based on the counted fluorescence micrographs of 
stained samples (compare Figure 29). It can be demonstrated that lyophilisation 
has no considerable influence on protein conformation as the number of 
aggregates counted and calculated per µl did not increase after lyophilisation 
(compare Table 20). 
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Table 20: Nile Red stained particles visualised with fluorescence microscopy 
were counted and calculated per µl within the different formulations before and 
after lyophilisation. Results are the mean of 5 counts. M = months, FD = freeze-
dried and reconstituted, non-FD = non-freeze-dried. 
Adsorption 
solution 
Particles 
per µl 
< 5 µm 
Particles 
per µl 
> 5 µm 
 Adsorption 
solution 
Particles 
per µl 
< 5 µm 
Particles 
per µl 
> 5 µm 
Dextran    HES   
0 M non-FD 58 0  0 M non-FD 53 0 
0 M FD 53 0  0 M FD 53 0 
3 M 5°C FD 60 0  3 M 5°C FD 59 0 
3 M 25°C FD 69 9  3 M 25°C FD 69 0 
3 M 30°C FD 70 12  3 M 30°C FD 70 8 
3 M 40°C FD 71 20  3 M 40°C FD 69 23 
PVP   
0 M non-FD 57 0 
0 M FD 53 0 
3 M 5°C FD 45 0 
3 M 25°C FD 49 2 
3 M 30°C FD 61 8 
3 M 40°C FD 62 18 
   
 All samples (containing dextran, HES or PVP) show an increasing 
number of detected aggregate particles with increasing temperature after three 
months storage. Also, the diameter of the particles detected increased with 
increasing temperature. Within all samples before lyophilisation and in the 
reconstituted suspensions (lyophilisates with water) as well as within the 
reconstituted samples stored for three months at 5°C, no particles with a 
diameter above 5 µm could be detected. HES samples stored at 25°C for three 
months did not contain any particles above 5 µm either, whereas there could be 
some aggregates detected with a mean diameter above 5 µm within samples 
containing dextran and PVP when stored at 25°C. All samples revealed - albeit 
a small number - particles of 5 µm or greater when stored for three months at 
30 or 40°C. Generally, the higher the storage temperature was the more 
particles could be found within the samples that had a particle diameter of 
above 5 µm. When pure aluminium hydroxide adjuvant was analysed under the 
fluorescence microscope, no aggregates were observed as it was expected. 
The number of Nile Red stained particles counted and calculated per µl within 
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pure drug substance diluted to 2 mg abagovomab/ml (same concentration as in 
the lyophilised samples) was in the same range as could be counted and 
calculated for 0 M non FD samples containing dextran, HES or PVP (55 
particles per µl < 5 µm and none > 5 µm).These results show that Nile Red 
staining and subsequent analysis of the samples with fluorescence microscopy 
is well applicable for the determination of changes within stress tested vaccine 
formulations. 
 
 
 
Figure 29: Fluorescence microscopy exemplified with pictures obtained with 
PVP formulations after Nile Red staining before lyophilisation at time point zero 
(top). Fluorescence microscopy with the original PVP formulations after Nile 
Red staining before lyophilisation after 3 months storage at 40°C (bottom). 
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 Demeule et al (2007) could detect early calcitonin aggregates with Nile 
Red fluorescence microscopy that were not detected by UV absorbance or 
other analytical methods used in their study. These aggregates had no further 
impact on the average properties of the solution. They propose that the 
aggregates were “seeds” leading to further aggregation which were not 
detectable by other methods as they represent a small proportion of the protein 
molecules and had no further impact on the solution. For abagovomab samples, 
it can be concluded that this method spotlights a slight increase in aggregation 
taking place over storage for three months at temperatures up to 40°C. An 
increase in counted and calculated aggregates as well as an increase in particle 
diameter was visibly detectable throughout the stability testing when 
fluorescence microscopy was utilised. But it had no further influence on the 
potency of the vaccine as ELISA and SDS-PAGE revealed no changes after 
storage for three or six months at temperatures up to 40°C.  
4.3.3 Concluding discussion: stability testings and methods used for the 
characterisation of lyophilised vaccine formulations 
 The present stability study could on the one hand clearly demonstrate the 
superiority of formulations containing 10 % dextran and 10 % HES when 
considering the enhancement of stability of the adjuvant aluminium hydroxide 
within a vaccine formulation under accelerated conditions (stress testing) in 
comparison to the other excipients tested. Particle size analysis and 
sedimentation assay revealed that characteristics of the adjuvanted suspension 
could be maintained sufficiently for formulations containing these two excipients 
compared to other excipients tested. WAXD analysis showed that the 
amorphous character of the lyophilisates of the two eminent formulations could 
be maintained. WAXD analysis of the PVP formulation revealed that the PBS 
buffer salts recrystallised with accelerated storage conditions. Amorphous 
‘glass’ character of the lyophilisates is advantageous for the excipients’ 
stabilising effect. Formulations containing trehalose, saccharose or sorbitol 
showed enormous recrystallisation over time and accelerated storage 
temperatures. Abagovomab on the other hand could be protected from 
denaturation or loss in potency over the storage period of six months with 
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aggravated temperature up to 40°C by all excipients tested as could be 
demonstrated by ELISA and SDS-PAGE. This is an improvement compared to 
pure, unprotected drug substance that revealed changes in SDS-PAGE 
patterns during the stability testings. Nile Red fluorescence microscopy and 
adsorption studies - two methods used within this work for the characterisation 
of freeze-dried vaccine formulations containing an aluminium hydroxide 
adjuvant - proved to be efficient methods for in-depth characterisation of the 
formulations’ attributes. Nile Red fluorescence microscopy proved to be a well-
applicable method for the early detection of abagovomab aggregation ‘seeds’ in 
the samples when exposed to accelerated storage conditions. Adsorption 
studies showed a slight decrease in adsorptive capacity of the 
abagovomab/adjuvant system when lyophilised and slight changes depending 
on the excipient contained. This was probably due to an alteration in 
suspension attributes by the different sugars/polymers. However, it could be 
demonstrated that adsorption capacity of abagovomab adsorbed to aluminium 
hydroxide adjuvant could principally be maintained during storage due to the 
use of the presented vaccine formulation excipients protecting the adjuvant from 
freezing- and drying stresses. 
4.4 In-depth characterisation of the vaccine formulations 
4.4.1 Transmission electron microscopy 
 Figure 30 (left) is representative of TEM micrographs of an exemplary 
vaccine formulation containing abagovomab, the adjuvant aluminium hydroxide 
(Alhydrogel®) and phosphate buffer at 16000-fold magnification compared to a 
micrograph taken of pure Alhydrogel® (Figure 30, right). Hem and White (1995) 
present a transmission electron micrograph of aluminium hydroxide adjuvant 
depicting fibrous primary particle morphology. This morphology is also 
perceptible in present micrographs of pure Alhydrogel® and the formulation 
containing abagovomab but not as clear as they depict it. It is more apparent in 
Figure 31, left: a micrograph of the vaccine formulation with a lower 
magnification.  
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Figure 30: Left: TEM-micrograph of a vaccine formulation containing 
abagovomab 2 mg/ml, Alhydrogel® and phosphate buffer at 16000 fold 
magnification; right: TEM-micrograph of pure Alhydrogel® at 25000 fold 
magnification. 
 
Figure 31: TEM-micrographs of a vaccine formulation containing abagovomab 
2 mg/ml, Alhydrogel® and phosphate buffer. Magnification left: x 5500; right: 
x 25000. 
 Spherical particles were also detectable with sizes between 50 and 
500 nm for both, pure Alhydrogel® and the vaccine formulation. This indicates 
that no alteration was detectable with TEM concerning structure of the adjuvant 
when abagovomab and phosphate buffer were added to Alhydrogel®.  
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Figure 32: TEM-micrographs of abagovomab reference standard (5.4 mg/ml). 
Magnification left: x 63000; right: x 63000. The white arrows mark structures 
resembling the typical triangular shape of a monoclonal antibody. 
 Figure 32 depicts TEM micrographs of pure, non-diluted abagovomab 
drug substance solution (5.4 mg/ml) at a 63000-fold magnification. The white 
arrows point out some of the triangular shaped structures typical for a 
monoclonal antibody that can be found within samples with this method 
(Murphy et al, 1988). 
4.4.2 Adsorption of abagovomab onto the aluminium hydroxide adjuvant 
as a function of pH surface charge 
 The determination of the isoelectric point of the antibody abagovomab 
evaluated by calculation of the pI of the highest and the lowest band based on a 
calibration curve from the pI calibration kit (broad pI, pH 3-10) yielded a range of 
peaks between a minimum pI of 7.6 and a maximum pI of 8.5. This indicates 
that the net surface charge of abagovomab is positive at a physiological pH of 
7.4. For adsorption of an antigen onto an aluminium adjuvant that is based on 
electrostatic attraction, it is best performed at a pH between the pI of the protein 
antigen and the PZC of the aluminium adjuvant (Lindblad, 2004; compare 
section 2.3.5.2). The following study will show that the adsorption mechanism of 
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abagovomab is mainly based on ligand exchange and is therefore only 
marginally due to electrostatic attraction. 
4.4.3 Influence of ionic strength on the adsorption of abagovomab onto 
the aluminium hydroxide adjuvant 
 The influence of the change in the vaccine's ionic strength on adsorption 
was analysed by adding different sodium chloride concentrations and 
measuring the resulting adsorption of abagovomab onto aluminium hydroxide 
adjuvant. A similar approach was used by Jiang et al (2006) to evaluate the 
relationship between the exposure of an adsorbed antigen to interstitial fluid and 
its adsorption. The effect of ionic strength on the adsorption capacity was used 
to determine whether adsorption was driven by electrostatic attraction or ligand 
exchange. The effect of ionic strength on the adsorption of aluminium hydroxide 
adjuvanted abagovomab was characterised by the 3-fold measurement of the 
adsorption isotherms at pH 7.4 and 25 °C with a blank and samples of 0.05 M, 
0.154 M (physiological salt concentration), 0.25 M, 0.75 M and 1.0 M NaCl 
(Figure 33). 
 
Figure 33: Isotherms of the adsorption of abagovomab onto the aluminium 
hydroxide adjuvant at pH 7.4 and 25 °C with ionic strengths between 0 and 1 M 
NaCl. Water is used as the blank. Error bars indicate the standard deviation of 
three measurements. (○) 1.0 M NaCl, (□) 0.75 M NaCl, (x) 0.25 M NaCl, (▲) 
0.154 M NaCl, (■) 0.05 M NaCl, (●) water; n = 3; mean ± SD. 
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 The rate of increase in abagovomab adsorbed reflected by the steep 
slope of the isotherms at very low abagovomab concentrations is related to the 
strength of the adsorption force and characterised by the adsorption coefficient 
(Jendrek et al, 2003). As the concentration of abagovomab increases, the 
amount of abagovomab adsorbed reaches a plateau; this indicates that the 
protein forms a monolayer on the adjuvant’s surface with additional protein 
amounts remaining in solution. The amount of protein adsorbed as a complete 
monolayer is calculated as the adsorption capacity. The adsorption of additional 
protein molecules would cause a multilayer to form and is not the case for the 
analysed samples. 
 The Langmuir equation has frequently been used to determine the 
adsorption capacity and the adsorption coefficient of protein/adsorbent systems 
(Seeber et al, 1991a; Heimlich et al, 1999; Vogel and Hem, 2003; Chang et al, 
1997; Iyer et al, 2004). The adsorption isotherms were plotted according to the 
linear form of the Langmuir equation and analysed (Jendrek et al, 2003). The 
coefficient of determination R2 of the linear Langmuir equation and the 
adsorption capacities are given in Table 21, page 120, summarising adsorption 
data collected within this study. That the adsorption of abagovomab by the 
aluminium hydroxide adjuvant at pH 7.4 follows the Langmuir equation at ionic 
strengths of 0.05 M, 0.154 M, 0.25 M, 0.75 M and 1.0 M is confirmed by a R2 
value of >0.99 for the linear form of the Langmuir equation. Adsorption 
capacities of different systems (aluminium hydroxide, abagovomab and 
additive) were determined from the plateau of the isotherms. The adsorption 
capacity of abagovomab decreased with increasing salt concentration from 
1.50 mg/mg Al3+ for the blank (no NaCl added) to 1.0 mg/mg Al3+ with 1 M NaCl. 
This indicates that electrostatic forces contribute to the adsorption of 
abagovomab. Furthermore, it is demonstrated that at the physiological salt 
concentration and at a final total abagovomab concentration of 2.0 mg/ml, only 
1.9 %  of abagovomab is not adsorbed (value is calculated by evaluating the 
percentage share of the desorbed abagovomab in relation to the complete 
amount of abagovomab added to the sample). 
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4.4.4 Influence of components of interstitial fluid (IF) and simulated IF 
4.4.4.1 Phosphate 
 As mentioned before, adsorption of antigens to aluminium hydroxide is 
influenced by phosphate anions, citrate anions, interstitial proteins and other 
components of the IF. Therefore, the influence of the phosphate anions, citrate 
anions and simulated IF on the adsorption of abagovomab onto aluminium 
hydroxide adjuvant was examined here. The effect of the phosphate anions on 
the adsorption of abagovomab onto aluminium hydroxide adjuvant was 
analysed and the isotherms shown in Figure 34 were generated.  
 
Figure 34: Isotherms of the adsorption of abagovomab onto the aluminium 
hydroxide adjuvant at pH 7.4 and 25 °C with phosphate concentrations between 
0 and 100 mM. Formulations containing different amounts of abagovomab were 
used. Water was used as the blank. Error bars indicate the standard deviation 
of the three measurements. (○) 100 mM PO4, (□) 50 mM PO4, (x) 15 mM PO4, 
(▲)10 mM PO4, (■) 5 mM PO4, (●) water; n = 3; mean ± SD. 
 The adsorption capacity of 1.50 mg/mg Al3+ determined for the ion-free 
samples (compare Table 21) decreased by 0.01 and 0.05 mg/mg Al3+ with 
phosphate concentrations of 5 and 10 mM, respectively; these decreases were 
minimal when compared to the adsorption capacities measured at higher 
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phosphate concentrations: 0.61 and 0.14 mg/mg Al3+ for the samples with 
phosphate concentrations of 50 and 100 mM, respectively. 
 The isotonic phosphate buffered saline (PBS), a common isotonic buffer 
frequently used in vaccine formulation, has pH 7.4 and final NaCl, phosphate 
and KCl concentrations of 137 mM, 10 mM and 2.7 mM, respectively. At this 
phosphate concentration and an abagovomab concentration of 2 mg/ml, less 
than 1 % abagovomab was found in the supernatant. At the IF phosphate 
concentration of 5 mM, abagovomab was almost completely adsorbed. The 
surface charge of aluminium hydroxide exposed to phosphate in these 
concentrations (more than 4 mM) goes from being a highly positive zeta 
potential to being a negative zeta potential at pH 7.4 (Rinella et al, 1995). 
Phosphate adsorbs specifically onto the surface of aluminium hydroxide by 
ligand exchange (Liu et al, 1984). The adsorption of phosphate onto aluminium 
hydroxide causes the adjuvant's surface charge to become less positive. 
Therefore, electrostatic interactions between the antigen and aluminium 
hydroxide adjuvant are weakened by increasing phosphate concentrations in 
the buffer. 
 In the case of abagovomab, the addition of phosphate causes an overall 
decrease in adsorption capacity. It could already be shown that electrostatic 
forces contribute to the adsorption of abagovomab onto the aluminium 
hydroxide adjuvant. Rinella et al. (1995), however, could show that by adding 
4 mM phosphate to ovalbumin adsorbed onto aluminium hydroxide, electrostatic 
repulsion between the negatively charged ovalbumin and the resulting 
negatively charged adjuvant were strong enough to elute 45 % of ovalbumin 
adsorbed. At this phosphate concentration and an abagovomab concentration 
of 2 mg/ml, less than 1 % of abagovomab was found in solution. It can be 
concluded that abagovomab is only slightly positively charged at pH 7.4, as the 
increasing negative charge of the adjuvant causes more free abagovomab to be 
found in solution and the resulting decrease in surface charge by the addition of 
phosphate leads to a small degree of elution through electrostatic repulsion at 
phosphate concentrations of up to 15 mM. As the adsorption of abagovomab 
onto the adjuvant is strongest when the surface charge of aluminium hydroxide 
is not changed by the addition of phosphate (see Figure 34, adsorption isotherm 
for water), electrostatic attraction does influence adsorption, but is not the 
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determining force. Hence, it can be concluded that ligand exchange, a stronger 
adsorption force than electrostatic adsorption, is the main factor determining 
adsorption between abagovomab and aluminium hydroxide. 
4.4.4.2 Citrate 
 To further investigate the influence of components of the interstitial fluid, 
citrate anion was added to the vaccine formulations. The adsorption isotherms 
for abagovomab and the aluminium hydroxide adjuvant were measured at pH 
7.4 and room temperature with citrate concentrations of 0, 2.7, 27 and 
270 mEq/l (Figure 35). 
 
Figure 35: Effect of citrate anions at pH 7.4 and room temperature on the 
adsorption of abagovomab onto the aluminium hydroxide adjuvant. 
Formulations containing different amounts of abagovomab were used. Water 
was used as the blank. Error bars indicate the standard deviation of the three 
measurements. (○) 270 mEq citrate, (□) 27 mEq citrate, (■) 2.7 mEq citrate, (●) 
water; n = 3; mean ± SD. 
 The isotherm in Figure 35 for the sample with a citrate concentration of 
2.7 mEq/l shows an adsorption capacity decrease of only 0.07 mg/mg Al3+ 
compared to that of the adsorption isotherm of the blank sample containing only 
water. It can be shown that this IF simulating citrate concentration causes 
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almost no change in the amount of abagovomab adsorbed. Seeber et al 
(1991b) determined that a citrate solution of 2.7 mEq/l did not solubilise 
aluminium hydroxide adjuvants within 12 h, whereas amorphous aluminium 
hydroxy phosphate was solubilised to 28 % / 55 % (two different dissolution 
models) in the same solution. In a 100 fold higher concentrated citrate solution 
(270 mEq/l), all of the amorphous aluminium hydroxy phosphate was solubilised 
within 12 h, but only 7.1 and 9.7 % of two different aluminium hydroxide 
samples after 132 h, with only minimal amounts of these samples being 
solubilised after 12 h. This leads to the assumption that the aluminium 
hydroxide adjuvant is basically not solubilised during the 17 h exposure to 
citrate anions carried out here. Therefore, the effect observed for the samples 
containing citrate concentrations of 27 or 270 mEq/l cannot be attributed to 
adjuvant solubilisation. Compared to the sample with 2.7 mEq/l, the sample with 
27 mEq/l shows a slight decrease in adsorption capacity to 1.23 mg/mg Al3+, 
whereas that for abagovomab in the sample containing 270 mEq/l is much 
higher: a monolayer coverage of only 0.35 mg/mg Al3+ was determined. 
4.4.4.3 Simulated interstitial fluid 
 Finally, the model abagovomab vaccines were exposed to low- and high-
concentration simulated IF solutions (Solution 1 and 2, respectively) at 37 °C 
simulating in vivo conditions after subcutaneous/intramuscular injection. These 
solutions were used to characterise how the adsorption behaviour of antigen 
and adjuvant in the vaccine changes with different compositions of simulated 
interstitial fluids: no sodium chloride and a low BSA concentration (20 mg/ml) in 
Solution 1 to a physiological salt concentration and a BSA concentration of 
25 mg/ml in Solution 2. To determine if elevated temperature up to 37°C 
resemblin in vivo conditions further contributes to the elution of abagovomab 
upon exposure to simulated IF, samples were additionally incubated at 5 °C and 
room temperature. The corresponding adsorption isotherms are shown in 
Figure 36. 
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Figure 36: Adsorption isotherms for abagovomab and the aluminium hydroxide 
adjuvant incubated in the simulated interstitial fluid Solution 1 at 5 °C, room 
temperature and 37 °C. Formulations containing different amounts of 
abagovomab were used. Error bars indicate the standard deviation of three 
measurements. (▲) 37°C, (■) RT, (●) 5°C; n = 3; mean ± SD. 
 All three isotherms for the samples incubated in Solution 1 can be 
described by the Langmuir equation; thus, the adsorption capacities were 
determined as described above. At 37 °C (body temperature) and a final total 
abagovomab concentration of 2.0 mg/ml, 16 % of the total antibody was found 
in the supernatant (data not shown). The decreased adsorption capacities 
calculated for samples incubated at 37 °C and room temperature were 
1.00 and 1.15 mg/mg Al3+, respectively; that of the sample incubated at 5 °C 
was 1.25 mg/mg Al3+. This demonstrates the influence temperature has on the 
elution of abagovomab from the aluminium hydroxide adjuvant upon exposure 
to the simulated IF, Solution 1. An elevated body temperature of 37 °C caused a 
decrease in the adsorption capacity of abagovomab onto aluminium hydroxide 
adjuvant.  
 At body temperature and a final total abagovomab concentration of 
2.0 mg/ml, 17.6 % of the total antibody was found in the supernatant of the 
sample incubated in Solution 2. The adsorption capacities determined 
accordingly were 0.83, 0.88 and 1.06 mg/mg Al3+ for samples incubated at 
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37 °C, room temperature, and 5 °C, respectively, making clear again the 
negative influence of temperature on abagovomab adsorption after exposure of 
the system to simulated interstitial fluid. A comparison of the isotherms for the 
samples incubated in simulated IFs Solutions 1 and 2 shows more abagovomab 
to be found in the supernatant the more the experimental conditions resemble in 
vivo conditions. Samples containing the simulated IF Solution 1 (Figure 36 and 
Table 21) exhibited a smaller decrease in adsorption capacity at each 
temperature than those containing the simulated IF Solution 2 (Figure 37 and 
Table 21). Based on these results, it is assumed that more adjuvant is required 
to reach a complete adsorption of abagovomab onto the adjuvant under 
conditions resembling the in vivo environment after subcutaneous or 
intramuscular administration of the vaccine. 
 
Figure 37: Adsorption isotherms for abagovomab and aluminium hydroxide 
adjuvant incubated in the simulated interstitial fluid Solution 2 at 5 °C, room 
temperature and 37 °C. Formulations containing different amounts of 
abagovomab were used. Error bars indicate the standard deviation of three 
measurements. (▲) 37°C, (■) RT, (●) 5°C; n = 3; mean ± SD. 
 Jiang et al. (2006) exposed different antigens to sheep lymph imitating IF 
showing that most of the antigens whose adsorption was based on electrostatic 
attractions were eluted completely and quickly. On the other hand, most of the 
antigens whose adsorption is driven by ligand exchange basically did not 
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desorb during exposure to IF for up to 24 hours because ligand exchange is a 
stronger adsorption force than electrostatic attraction. Abagovomab, in contrast, 
did not elute completely but only to 16 and 17.6 % in samples incubated in a 
low- and high-concentration simulated IF (Solutions 1 and 2, respectively) at 
body temperature with an abagovomab content of 2.0 mg/ml. This indicates 
again that ligand exchange plays a major role in the adsorption of abagovomab 
onto the aluminium hydroxide adjuvant.  
4.4.5 Influence of pH on the adsorption of abagovomab to aluminium 
hydroxide adjuvant 
 The influence of pH on the adsorption of abagovomab onto aluminium 
hydroxide was analysed in a pH range of 2 to 12; the results are shown in 
Figure 38. 
 
Figure 38: Abagovomab found in solution [%] after 1 h incubation at room 
temperature at different pH values. Error bars indicate the standard deviation of 
the three measurements; n = 3; mean ± SD. 
 Only a marginal change in adsorption was observed at pH values 
between 5 and 9 with 0.64 and 2.69 % of abagovomab found in the supernatant 
at these values, respectively, whereas the rate of abagovomab in solution 
reaches 52.5 % and 99.4 % at a lower and higher pH of 2.1 and 11.9, 
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respectively. Rinella et al (1998) analysed the effect of pH on the elution of 
model antigens from aluminium containing adjuvants (compare section 2.3.5.2). 
They conclude that the elution of a model antigen from an aluminium adjuvant 
at extreme pH values was attributed to the solubility of aluminium hydroxide that 
increases sharply at a pH below 5.0 or above 9.0 with a minimum of dissolution 
at pH 5. Results obtained here and the known solubilisation of aluminium 
hydroxide at a pH below 5 and above 9 support the assumption that 
abagovomab adsorption onto the aluminium hydroxide adjuvant is not primarily 
based on electrostatic attraction. Above pH 8.5, abagovomab with a pI between 
7.6 and 8.5 will be negatively charged; at pH 8.5 to 11, the surface charge of 
aluminium hydroxide is still positive, but becomes negative at a pH above 11. 
Thus, adsorption based on electrostatic attraction should reach a maximum 
between pH 8.5 and 11 when abagovomab and aluminium hydroxide are 
oppositely charged. However, an increase in free abagovomab in solution 
indicating desorption and not an increase in adsorption is observed at a pH 
above 9. This increase as well as the increase below pH 5 can most likely be 
attributed to the solubilisation of aluminium hydroxide and not a change in the 
surface charge of the adjuvant or antigen. 
4.4.6 Role of hydrophobic interactions in the adsorption of abagovomab 
to aluminium hydroxide adjuvant 
 Other possible attraction forces involved in protein-adjuvant adsorption 
could be hydrophobic interactions. The influence of hydrophobic interactions on 
the adsorption of abagovomab onto aluminium hydroxide adjuvant was studied 
by adding 10, 20 and 30 % ethylene glycol to the vaccine samples. The 
samples' adsorption isotherms (Figure 39) could be described with the 
Langmuir equation. The low abagovomab concentration in the drug substance 
solution limited its concentration in solution and prevented monolayer 
saturation. However, the isotherms all indicate a plateau in the abagovomab 
amount adsorbed and monolayer adsorption. Therefore, values do not change 
in any way that would draw questions to the conclusions drawn above. 
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Figure 39: Effect of ethylene glycol (EG) on the adsorption of abagovomab onto 
aluminium hydroxide adjuvant at an ionic strength of 0.05 M, pH 7.4 and room 
temperature. Formulations containing different amounts of abagovomab were 
used. Water was used as the blank. (■) 10 % EG, (▲) 20 % EG, (●) 30 % EG; 
n = 3; mean ± SD. 
 The shape of the isotherms changed under the addition of ethylene 
glycol but the extrapolated adsorption capacities remained constant (see Table 
21). Thus, hydrophobic interactions do not contribute to the adsorption of 
abagovomab by the aluminium hydroxide adjuvant.  
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Table 21: Summary of the adsorption capacities and coefficients of 
determination (R2) of the adsorption isotherms determined for abagovomab 
adsorbed to aluminium hydroxide adjuvant with different additives at pH 7.4. 
s IF =  simulated interstitial fluid. 
Solution 
Adsorption capacity  
[mg/mg Al3+] 
R2 
Water (blank)  1.50 >0.99 
Sodium chloride 0.05 M 1.40 >0.99 
 0.154 M 1.20 >0.99 
 0.25 M 1.16 >0.99 
 0.75 M 1.08 >0.99 
 1.0 M 1.00 >0.99 
Phosphate 5 mM 1.49 >0.99 
 10 mM 1.45 >0.99 
 15 mM 1.16 >0.99 
 50 mM 0.61 >0.99 
 100 mM 0.14 >0.89 
Citrate 2.7 mEq 1.43 >0.99 
 27.0 mEq 1.23 >0.99 
 270.0 mEq 0.35 >0.93 
s IF solution 1 5°C 1.25 >0.99 
 RT 1.15 >0.99 
 37°C 1.00 >0.99 
s IF solution 2 5°C 1.06 >0.99 
 RT 0.88 >0.99 
 37°C 0.83 >0.99 
Ethylene glycol 10 % 1.40 >0.99 
 20 % 1.40 >0.99 
 30 % 1.40 >0.99 
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4.4.7 Concluding discussion: adsorption phenomena within aluminium 
hydroxide adjuvanted vaccines 
 This study examined the force(s) involved in the adsorption of 
abagovomab onto aluminium hydroxide. The influence of the components of IF 
on the adsorption made clear that the adsorption of this system was not based 
on one single type of adsorption. Rather, ligand exchange was the dominating 
adsorption force but electrostatic forces also played a role. It could further be 
demonstrated that interstitial fluid influenced the adsorption of abagovomab 
onto aluminium hydroxide. Adsorption capacities decreased when a simulated 
interstitial fluid was added: the lowest adsorption capacity was observed at a 
simulated in vivo temperature of 37 °C when compared to those determined for 
measurements at 5 °C or room temperature. The more the adsorption 
conditions resembled in vivo conditions as is the case after subcutaneous or 
intramuscular administration of a vaccine, the less abagovomab was adsorbed. 
Therefore, it could be concluded that these conditions require more aluminium 
hydroxide adjuvant to achieve a complete adsorption of the antigen onto the 
adjuvant. Hydrophobic interactions could be excluded as a possible adsorption 
force as the addition of ethylene glycol did not yield lower adsorption capacities. 
The marginal influence of pH between 5 and 9 confirmed that ligand exchange 
was the main adsorption force. 
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5 Conclusion 
 The main focus of this work was the development of an aluminium 
hydroxide adjuvanted vaccine formulation that will be more stable than common 
vaccines that require cold chain during storage and transportation. This 
formulation should ideally not oblige storage in the refrigerator and thus would 
facilitate vaccine handling enormously. The approach was to lyophilise the vaccine 
formulations. Water reduction reduces chemical and physical degradation of the 
susceptible ingredients, especially the antigen that is usually a protein. Freezing 
and lyophilisation of an aluminium adjuvant contained within a vaccine can result 
in a loss of its potency and is the greatest hurdle when attempting to develop a 
lyophilised, aluminium adjuvanted vaccine formulation. Thus, the first step was to 
develop an innovative, stable, lyophilised aluminium hydroxide containing 
formulation in order to find a novel formulation approach capable of efficiently 
protecting an aluminium hydroxide adjuvanted vaccine during lyophilisation. 
Carbohydrates, polymers and other glass forming compounds as well as a 
surfactant were employed as excipients in order to protect the adjuvant during the 
lyophilisation process. By analysing the X-ray diffraction patterns of the obtained 
lyophilisates, conducting sedimentation studies, optical microscopy and particle 
size analysis, it could be demonstrated that formulations containing trehalose at a 
concentration of 15 or 20 %, as well as dextran, PVP K 25, HES 450 and 200, 
saccharose and sorbitol at a concentration of 10 %, promise to be good 
candidates for the protection of aluminium adjuvanted vaccines during the process 
of freezing or lyophilisation. Based on these results, vaccine formulations were 
produced containing abagovomab, an anti-idiotypic cancer immunogen, aluminium 
hydroxide adjuvant, buffer and the auspicious stabilising excipients that could best 
protect aluminium hydroxide during lyophilisation. Stability of these freeze-dried 
vaccine formulations was tested during stress testings over 6 months at elevated 
temperatures. Results obtained by this stability study demonstrated that all 
excipients successfully inhibited abagovomab from denaturation or loss in potency 
as far as could be analysed with enzyme-linked immunosorbent assay and sodium 
dodecylsulfate polyacrylamide gel electrophoresis. Formulations containing 10 % 
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dextran and HES 450/0.7 were most effectively protecting the adjuvant from 
lyophilisation stresses as physico-chemical characteristics of the adjuvant 
analysed during the stress testing could be best maintained.  
 Another focus of this work was the implementation of adsorption isotherms 
to characterise in detail the adsorption behaviour of abagovomab to Alhydrogel® 
after formulations were lyophilised, reconstituted and stress tested, as well as the 
implementation of Nile Red fluorescence microscopy to comprehend protein 
conformational changes occurring within the lyophilised and stressed vaccines. 
The methods proved to be efficient for in-depth characterisation of the 
formulations’ attributes. Nile Red fluorescence microscopy could detect 
abagovomab aggregation ‘seeds’ in the samples when exposed to accelerated 
storage conditions. Adsorption studies demonstrated that adsorption capacity of 
abagovomab adsorbed to aluminium hydroxide adjuvant could principally be 
maintained due to the use of the presented vaccine formulation excipients 
protecting the adjuvant from freezing- and drying stresses. This work’s effort could 
generate two very promising vaccine formulations that are - at least in vitro - stable 
concerning physico-chemical characteristics of the vaccine and regarding structure 
and potency of the antigen. It could further be demonstrated that lyophilisation of 
aluminium hydroxide adjuvanted vaccine formulations with the model antigen 
abagovomab containing PBS, polysorbate 80 and 10 % dextran or HES 450/0.7 is 
a promising approach for the production of stable, lyophilised vaccine formulations 
that can be handled, distributed and stored more easily and efficiently than it is 
common for current, aluminium adjuvanted vaccine pharmaceuticals. To achieve 
market maturity for given formulations, especially an in vivo proof of maintained 
immunogenicity of the vaccines will be necessary. Still, these results present 
promising formulations for less problematic and more effective vaccine delivery in 
the future.  
 Owing to the fact that adsorption behaviour of antigens onto aluminium 
adjuvants in a vaccine formulation has several physiological and technological 
effects on the vaccine's efficacy and a strong influence on its potency, another 
focus of this work was to identify the chemical force(s) involved in the adsorption 
of the antigen abagovomab onto an aluminium hydroxide adjuvant and the 
influence of the components of IF thereon. Influence of ionic strength and the 
components of IF on the adsorption of abagovomab to aluminium hydroxide 
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demonstrated that ligand exchange is the dominating adsorption force but 
electrostatic forces also play a role. The marginal influence of pH values between 
5 and 9 could verify ligand exchange to be the main adsorption force within this 
system. These results provide profound knowledge about adsorption behaviour of 
abagovomab adsorbed to aluminium hydroxide adjuvant that helps understanding 
the way the vaccine elicits an immune response. 
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